WO2001019988A1

WO2001019988A1 - Secreted proteins and polynucleotides encoding them

Info

Publication number: WO2001019988A1
Application number: PCT/US2000/025135
Authority: WO
Inventors: Kenneth Jacobs; John M. Mccoy; Edward R. Lavallie; Lisa A. Collins-Racie; Cheryl Evans; David Merberg; Maurice Treacy; Michael R. Bowman; Vikki Spaulding; Michael J. Agostino
Original assignee: Genetics Institute, Inc.
Priority date: 1999-09-17
Filing date: 2000-09-14
Publication date: 2001-03-22
Also published as: AU7379000A

Abstract

Novel polynucleotides and the proteins encoded thereby are disclosed.

Description

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

BACKGROUND OF THE INVENTION Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well- recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 from nucleotide 282 to nucleotide 565;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 from nucleotide 342 to nucleotide 565; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AX65_22 deposited with the ATCC under accession number 98196;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AX65 22 deposited with the ATCC under accession number 98196; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AX65 22 deposited with the ATCC under accession number 98196;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AX65_22 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 1. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1 from nucleotide 282 to nucleotide 565; the nucleotide sequence of SEQ ID NO: 1 from nucleotide 342 to nucleotide 565; the nucleotide sequence of the full-length protein coding sequence of clone

AX65 22 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone AX65_22 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AX65 22 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 42 to amino acid 51 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:l and SEQ ID NO:3. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO: 1;

(ab) SEQ ID NO:3, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:3; and (ac) the nucleotide sequence of the cDNA insert of clone

AX65 22 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO: 1;

(bb) SEQ ID NO: 3, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:3; and

(be) the nucleotide sequence of the cDNA insert of clone AX65 22 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:l and SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO : 1 , and extending contiguously from a nucleotide sequence corresponding to the 5 ' end of SEQ ID NO: 1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 1 from nucleotide 282 to nucleotide 565, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 1 from nucleotide 282 to nucleotide 565, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: l from nucleotide 282 to nucleotide 565. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: l from nucleotide 342 to nucleotide 565, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:l from nucleotide 342 to nucleotide 565, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:l from nucleotide 342 to nucleotide 565.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:2;

(b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and

(c) the amino acid sequence encoded by the cDNA insert of clone AX65_22 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 42 to amino acid 51 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4 from nucleotide 192 to nucleotide 2318;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4 from nucleotide 653 to nucleotide 825; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD335_14 deposited with the ATCC under accession number 98196;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD335 14 deposited with the ATCC under accession number 98196;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD335_14 deposited with the ATCC under accession number 98196;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD335 14 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:5;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO : 5 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:5;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:4. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ H)NO:4 from nucleotide 192 to nucleotide 2318; the nucleotide sequence of SEQ ID NO:4 from nucleotide 653 to nucleotide 825; the nucleotide sequence of the full-length protein coding sequence of clone BD335_14 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BD335_14 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BD335_ 14 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:5 from amino acid 148 to amino acid 240. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 5 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:5, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment comprising the amino acid sequence from amino acid 349 to amino acid 358 of SEQ ID NO:5.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:4.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:4, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:4; and

(ab) the nucleotide sequence of the cDNA insert of clone BD335_14 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:4, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:4; and

(bb) the nucleotide sequence of the cDNA insert of clone BD335 14 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:4, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:4 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:4 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:4. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:4 from nucleotide 192 to nucleotide 2318, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:4 from nucleotide 192 to nucleotide 2318, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:4 from nucleotide 192 to nucleotide 2318. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:4 from nucleotide 653 to nucleotide 825, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:4 from nucleotide 653 to nucleotide 825, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:4 from nucleotide 653 to nucleotide 825.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ED NO:5;

(b) the amino acid sequence of SEQ ID NO: 5 from amino acid 148 to amino acid 240;

(c) a fragment of the amino acid sequence of SEQ ID NO:5, the fragment comprising eight contiguous amino acids of SEQ ID NO:5; and

(d) the amino acid sequence encoded by the cDNA insert of clone BD335_ 14 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:5 or the amino acid sequence of SEQ ID NO:5 from amino acid 148 to amino acid 240. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:5, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 5 having biological activity, the fragment comprising the amino acid sequence from amino acid 349 to amino acid 358 of SEQ ID NO:5.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 206 to nucleotide 391; (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG241 1 deposited with the ATCC under accession number 98196;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG241_1 deposited with the ATCC under accession number 98196;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG241 1 deposited with the ATCC under accession number 98196;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG241 1 deposited with the ATCC under accession number 98196;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 8;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:7. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 206 to nucleotide 391; the nucleotide sequence of the full-length protein coding sequence of clone BG241 1 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BG241 1 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG241_1 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 8 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7, SEQ ID NO:6, and SEQ ID NO:9 . Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(aa) SEQ ID NO:6;

(ab) SEQ ID NO:7;

(ac) SEQ ID NO:9, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:9; and (ad) the nucleotide sequence of the cDNA insert of clone

BG241 1 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:6;

(bb) SEQ ID NO:7;

(be) SEQ ID NO:9, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:9; and

(bd) the nucleotide sequence of the cDNA insert of clone BG241_1 deposited with the ATCC under accession number 98196;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:6 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 206 to nucleotide 391, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 206 to nucleotide 391, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 7 from nucleotide 206 to nucleotide 391. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 8;

(b) a fragment of the amino acid sequence of SEQ ID NO: 8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and (c) the amino acid sequence encoded by the cDNA insert of clone BG241 _ 1 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 8 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:8.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 10;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 10 from nucleotide 302 to nucleotide 1762;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 10 from nucleotide 389 to nucleotide 1762; (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 10 from nucleotide 1723 to nucleotide 2050;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL187 4 deposited with the ATCC under accession number 98196;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL187_4 deposited with the ATCC under accession number 98196;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BL187 4 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BL187 4 deposited with the ATCC under accession number 98196;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:l l; (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 11 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:l 1;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 10.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 10 from nucleotide 302 to nucleotide 1762; the nucleotide sequence of SEQ ID NO: 10 from nucleotide 389 to nucleotide 1762; the nucleotide sequence of SEQ ID NO: 10 from nucleotide 1723 to nucleotide 2050; the nucleotide sequence of the full-length protein coding sequence of clone BL187_4 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BLl 87 4 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BL187 4 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 11 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 11, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 11 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO: 11.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:10.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 10, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 10; and

(ab) the nucleotide sequence of the cDNA insert of clone BL187_4 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 10, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:10; and

(bb) the nucleotide sequence of the cDNA insert of clone BL 187 4 deposited with the ATCC under accession number 98196;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 10, and extending contiguously from a nucleotide sequence corresponding to the 5 ' end of SEQ ID NO : 10 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 10 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 10. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 10 from nucleotide 302 to nucleotide 1762, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 10 from nucleotide 302 to nucleotide 1762, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 10 from nucleotide 302 to nucleotide 1762. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:10 from nucleotide 389 to nucleotide 1762, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 10 from nucleotide 389 to nucleotide 1762, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 10 from nucleotide 389 to nucleotide 1762. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 10 from nucleotide 1723 to nucleotide 2050, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 10 from nucleotide 1723 to nucleotide 2050, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 10 from nucleotide 1723 to nucleotide 2050.

(a) the amino acid sequence of SEQ ID NO: 11 ;

(b) a fragment of the amino acid sequence of SEQ ID NO: 11 , the fragment comprising eight contiguous amino acids of SEQ ID NO: 11 ; and

(c) the amino acid sequence encoded by the cDNA insert of clone BLl 87_4 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 11. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ

ID NO: 11 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 11 , or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 11 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO: 11. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 12;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 12 from nucleotide 2 to nucleotide 2290;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 12 from nucleotide 134 to nucleotide 2290;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 12 from nucleotide 1 to nucleotide 309; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL249_18 deposited with the ATCC under accession number 98196;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL249_18 deposited with the ATCC under accession number 98196; (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BL249 18 deposited with the ATCC under accession number

98196;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BL249_18 deposited with the ATCC under accession number 98196; (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:13;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 13 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 13; (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 12.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 12 from nucleotide 2 to nucleotide 2290; the nucleotide sequence of SEQ ID NO: 12 from nucleotide 134 to nucleotide 2290; the nucleotide sequence of SEQ ID NO: 12 from nucleotide 1 to nucleotide 309; the nucleotide sequence of the full-length protein coding sequence of clone BL249 18 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BL249 18 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BL249 18 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 13 from amino acid 3 to amino acid 102. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 13 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 13, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 13 having biological activity, the fragment comprising the amino acid sequence from amino acid 376 to amino acid 385 of SEQ ID NO: 13.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:12.

(aa) SEQ ID NO: 12, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 12; and

(ab) the nucleotide sequence of the cDNA insert of clone BL249 18 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO: 12, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 12; and

(bb) the nucleotide sequence of the cDNA insert of clone BL249_18 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 12, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 12 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 12 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 12. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 12 from nucleotide 2 to nucleotide 2290, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 12 from nucleotide 2 to nucleotide 2290, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 12 from nucleotide 2 to nucleotide 2290. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 12 from nucleotide 134 to nucleotide 2290, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 12 from nucleotide 134 to nucleotide 2290, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 12 from nucleotide 134 to nucleotide 2290. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 12 fromnucleotide 1 to nucleotide 309, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 12 from nucleotide 1 to nucleotide 309, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 12 from nucleotide 1 to nucleotide 309.

(a) the amino acid sequence of SEQ ID NO: 13;

(b) the amino acid sequence of SEQ ID NO: 13 from amino acid 3 to amino acid 102;

(c) a fragment of the amino acid sequence of SEQ ID NO : 13 , the fragment comprising eight contiguous amino acids of SEQ ID NO: 13; and (d) the amino acid sequence encoded by the cDNA insert of clone BL249_18 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 13 or the amino acid sequence of SEQ ID NO: 13 from amino acid 3 to amino acid 102. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 13 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 13, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 13 having biological activity, the fragment comprising the amino acid sequence from amino acid 376 to amino acid 385 of SEQ ID NO: 13.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 15;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 15 from nucleotide 459 to nucleotide 539;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone B071 1 deposited with the ATCC under accession number 98196;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone B071 1 deposited with the ATCC under accession number 98196;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone B071 1 deposited with the ATCC under accession number 98196;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone B071 1 deposited with the ATCC under accession number 98196;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 16;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO: 15.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 15 from nucleotide 459 to nucleotide 539; the nucleotide sequence of the full-length protein coding sequence of clone B071 1 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone B071 1 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone B071 1 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 8 to amino acid 17 of SEQ ID NO: 16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15, SEQ ID NO: 14, and SEQ ID NO:17 .

(aa) SEQ ID NO: 14;

(ab) SEQ ID NO: 15;

(ac) SEQ ID NO: 17, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 17; and

(ad) the nucleotide sequence of the cDNA insert of clone B071_l deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 14;

(bb) SEQ ID NO: 15;

(be) SEQ ID NO: 17, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:17; and (bd) the nucleotide sequence of the cDNA insert of clone

B071 1 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 14 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 17, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 15 from nucleotide 459 to nucleotide 539, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 15 from nucleotide 459 to nucleotide 539, to a nucleotide sequence corresponding to the 3 ' end of said sequence of SEQ ID NO : 15 from nucleotide 459 to nucleotide 539. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 16;

(b) a fragment of the amino acid sequence of SEQ ID NO: 16, the fragment comprising eight contiguous amino acids of SEQ ID NO: 16; and (c) the amino acid sequence encoded by the cDNA insert of clone B071 1 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 8 to amino acid 17 of SEQ ID NO: 16. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 18;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 18 from nucleotide 1237 to nucleotide 1944; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 18 from nucleotide 737 to nucleotide 1072;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone B0365_2 deposited with the ATCC under accession number 98196; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone B0365 2 deposited with the ATCC under accession number 98196;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone B0365 2 deposited with the ATCC under accession number 98196; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone B0365 2 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:19;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 19 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 19;

(j ) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 18.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 18 from nucleotide 1237 to nucleotide 1944; the nucleotide sequence of SEQ ID NO: 18 from nucleotide 737 to nucleotide 1072; the nucleotide sequence of the full-length protein coding sequence of clone B0365 2 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone B0365_2 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone B0365_2 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 19 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 19, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 19 having biological activity, the fragment comprising the amino acid sequence from amino acid 113 to amino acid 122 of SEQ ID NO: 19. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID

NO: 18.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO: 18, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 18; and (ab) the nucleotide sequence of the cDNA insert of clone

B0365 2 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO: 18, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 18; and

(bb) the nucleotide sequence of the cDNA insert of clone B0365 2 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 18, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 18 to a nucleotide sequence corresponding to the 3 ' end of SEQ ID NO : 18 , but excluding the poly( A) tail at the 3 ' end of SEQ

ID NO: 18. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 18 from nucleotide

1237 to nucleotide 1944, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 18 from nucleotide 1237 to nucleotide 1944, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO: 18 from nucleotide 1237 to nucleotide 1944. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED

NO: 18 from nucleotide 737 to nucleotide 1072, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO: 18 from nucleotide 737 to nucleotide 1072, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 18 from nucleotide 737 to nucleotide 1072.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 19;

(b) a fragment of the amino acid sequence of SEQ ID NO: 19, the fragment comprising eight contiguous amino acids of SEQ ED NO: 19; and

(c) the amino acid sequence encoded by the cDNA insert of clone B0365 2 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 19. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ

ID NO: 19 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 19, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 19 having biological activity, the fragment comprising the amino acid sequence from amino acid 113 to amino acid 122 of SEQ ID NO: 19.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:20;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 68 to nucleotide 328;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV51_1 deposited with the ATCC under accession number 98196;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV51_1 deposited with the ATCC under accession number 98196;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV51 1 deposited with the ATCC under accession number 98196;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV51 1 deposited with the ATCC under accession number 98196;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:21; (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:21 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ED NO:21;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ED NO:20.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ED NO:20 from nucleotide 68 to nucleotide 328; the nucleotide sequence of the full-length protein coding sequence of clone BV51_1 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BV51 1 deposited with the

ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV51_1 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:21 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ

ID NO:21, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:21.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:20 and SEQ ID NO:22.

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:20;

(ab) SEQ ID NO:22, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:22; and

(ac) the nucleotide sequence of the cDNA insert of clone BV51 1 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of: (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:20; (bb) SEQ ID NO:22, but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:22; and

(be) the nucleotide sequence of the cDNA insert of clone BV51 1 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ED NO:20 and SEQ ID NO:22, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO:20 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 22, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:22. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

NO:20, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO:20 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO:20. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:20 from nucleotide 68 to nucleotide 328, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:20 from nucleotide 68 to nucleotide 328, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:20 from nucleotide 68 to nucleotide 328.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ED NO:21 ; (b) a fragment of the amino acid sequence of SEQ ID NO: 21 , the fragment comprising eight contiguous amino acids of SEQ ID NO:21; and

(c) the amino acid sequence encoded by the cDNA insert of clone BV51_1 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:21. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:21 , or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 21 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:21. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:24;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:24 from nucleotide 57 to nucleotide 396;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV140_3 deposited with the ATCC under accession number 98196;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV 140_3 deposited with the ATCC under accession number 98196;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV140 3 deposited with the ATCC under accession number 98196;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV 140 3 deposited with the ATCC under accession number 98196;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:25;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:25 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:25;

(j ) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:24. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ED NO:24 from nucleotide 57 to nucleotide 396; the nucleotide sequence of the full-length protein coding sequence of clone BV140 3 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BV140 3 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV140_3 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:25 from amino acid 29 to amino acid 57. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 25 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:25, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:25 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO: 25.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:24, SEQ ID NO:23, and SEQ ID NO:26 .

(aa) SEQ ED NO:23; (ab) SEQ ID NO:24;

(ac) SEQ ID NO:26, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:26; and

(ad) the nucleotide sequence of the cDNA insert of clone BV140 3 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(ba) SEQ ID NO:23; (bb) SEQ ID NO:24;

(be) SEQ EO NO:26, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:26; and

(bd) the nucleotide sequence of the cDNA insert of clone BV140 3 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:23, SEQ ED NO:24, and SEQ ED

NO:26, and extending contiguously from a nucleotide sequence corresponding to the 5' end of

SEQ ID NO:23 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO:26, but excluding the poly(A) tail at the 3' end of SEQ ED NO:26. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 24, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:24 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:24. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 24 from nucleotide 57 to nucleotide 396, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:24 from nucleotide 57 to nucleotide

396, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:24 from nucleotide 57 to nucleotide 396.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:25;

(b) the amino acid sequence of SEQ ID NO:25 from amino acid 29 to amino acid 57;

(c) a fragment of the amino acid sequence of SEQ ID NO:25, the fragment comprising eight contiguous amino acids of SEQ ED NO:25; and (d) the amino acid sequence encoded by the cDNA insert of clone B V 140_3 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:25 or the amino acid sequence of SEQ ID NO:25 from amino acid 29 to amino acid 57. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:25 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:25, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:25 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:25. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 328;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 1 to nucleotide 197;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV141_2 deposited with the ATCC under accession number 98196;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV141_2 deposited with the ATCC under accession number 98196;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV141 2 deposited with the ATCC under accession number 98196;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV141 2 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:28 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:27.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ED NO:27 from nucleotide 101 to nucleotide 328; the nucleotide sequence of SEQ ID NO:27 from nucleotide 1 to nucleotide 197; the nucleotide sequence of the full-length protein coding sequence of clone BV141_2 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BV141_2 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BV141_2 deposited with the ATCCunder accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28 from amino acid 1 to amino acid 37. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO:28.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:27.

(aa) SEQ ID NO:27, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:27; and

(ab) the nucleotide sequence of the cDNA insert of clone BV141 2 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(i) preparing one or more polynucleotide primers that hybridize in

6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:27, but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:27; and

(bb) the nucleotide sequence of the cDNA insert of clone BV141 2 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:27 , but excluding the poly(A) tail at the 3 ' end of SEQ

ED NO:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 328, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 328, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 328. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:27 from nucleotide 1 to nucleotide 197, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 1 to nucleotide 197, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED

NO:27 from nucleotide 1 to nucleotide 197.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:28; (b) the amino acid sequence of SEQ ID NO:28 from amino acid 1 to amino acid 37;

(c) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and (d) the amino acid sequence encoded by the cDNA insert of clone BV141 2 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:28 or the amino acid sequence of SEQ ED

NO:28 from amino acid 1 to amino acid 37. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ED NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ED NO:28. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ED NO : 29 from nucleotide 28 to nucleotide 351; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 328 to nucleotide 351;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC194_4 deposited with the ATCC under accession number 98196; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC194 4 deposited with the ATCC under accession number 98196;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CC194_4 deposited with the ATCC under accession number 98196; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CC194 4 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:29.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 28 to nucleotide 351 ; the nucleotide sequence of SEQ ID NO:29 from nucleotide 328 to nucleotide 351 ; the nucleotide sequence of the full-length protein coding sequence of clone CC194 4 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone CC 194_4 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CC194 4 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30 from amino acid 56 to amino acid 108. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:30.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:29 and SEQ ID NO:31.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:29; (ab) SEQ ID NO:31 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:31; and

(ac) the nucleotide sequence of the cDNA insert of clone CC194_4 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:29;

(bb) SEQ ID NO:31 , but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:31; and (be) the nucleotide sequence of the cDNA insert of clone

CC194 4 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:29 and SEQ ID NO:31, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:31 , but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:31. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5¹ end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:29 from nucleotide 28 to nucleotide 351, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 28 to nucleotide 351, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 28 to nucleotide 351. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 328 to nucleotide 351, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO:29 from nucleotide 328 to nucleotide 351 , to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:29 from nucleotide 328 to nucleotide 351. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:30;

(b) the amino acid sequence of SEQ ED NO : 30 from amino acid 56 to amino acid 108; (c) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and

(d) the amino acid sequence encoded by the cDNA insert of clone CC 194 4 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:30 or the amino acid sequence of SEQ ID NO:30 from amino acid 56 to amino acid 108. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:30.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 32 ; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 338 to nucleotide 1198;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:32 from nucleotide 467 to nucleotide 1058; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone DA 136 11 deposited with the ATCC under accession number 98196;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone DA136 11 deposited with the ATCC under accession number 98196;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone DA136_11 deposited with the ATCC under accession number 98196;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone DAI 36 11 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 33 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:33;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:32. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:32 from nucleotide 338 to nucleotide 1198; the nucleotide sequence of SEQ ID NO:32 from nucleotide 467 to nucleotide 1058; the nucleotide sequence of the full-length protein coding sequence of clone DA136 11 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone DA136 11 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone DA136_11 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33 from amino acid 124 to amino acid 182. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:33 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:33, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO: 33 having biological activity, the fragment comprising the amino acid sequence from amino acid 138 to amino acid 147 of SEQ ED NO: 33.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:32.

(aa) SEQ ID NO:32, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:32; and

(ab) the nucleotide sequence of the cDNA insert of clone DA136_11 deposited with the ATCC under accession number 98196; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:32, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:32; and

(bb) the nucleotide sequence of the cDNA insert of clone DA136 11 deposited with the ATCC under accession number 98196; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:32, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:32 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:32 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:32. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO: 32 from nucleotide 338 to nucleotide 1198, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO:32 from nucleotide 338 to nucleotide 1198, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:32 from nucleotide 338 to nucleotide 1198. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:32 from nucleotide 467 to nucleotide 1058, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:32 from nucleotide 467 to nucleotide 1058, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:32 from nucleotide 467 to nucleotide 1058.

(a) the amino acid sequence of SEQ ED NO: 33;

(b) the amino acid sequence of SEQ ID NO:33 from amino acid 124 to amino acid 182;

(c) a fragment of the amino acid sequence of SEQ ID NO:33, the fragment comprising eight contiguous amino acids of SEQ ID NO:33; and

(d) the amino acid sequence encoded by the cDNA insert of clone DAI 36 11 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ED NO:33 or the amino acid sequence of SEQ ED NO: 33 from amino acid 124 to amino acid 182. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:33 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:33, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 33 having biological activity, the fragment comprising the amino acid sequence from amino acid 138 to amino acid 147 of SEQ ID NO:33.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 34; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:34 from nucleotide 437 to nucleotide 1159;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:34 from nucleotide 515 to nucleotide 1159; (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:34 from nucleotide 539 to nucleotide 1099;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AR415 4 deposited with the ATCC under accession number 98232; (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AR415_4 deposited with the ATCC under accession number 98232;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AR415_4 deposited with the ATCC under accession number 98232; (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AR415_4 deposited with the ATCC under accession number 98232;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:35;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 35 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:35;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:34.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:34 from nucleotide 437 to nucleotide 1159; the nucleotide sequence of SEQ ID NO:34 from nucleotide 515 to nucleotide 1159; the nucleotide sequence of SEQ ED NO:34 from nucleotide

539 to nucleotide 1099; the nucleotide sequence of the full-length protein coding sequence of clone AR415 4 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone AR415_4 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone AR415_4 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:35 from amino acid 51 to amino acid 221. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NO:35 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:35, or a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NO- 35 having biological activity, the fragment compπsing the ammo acid sequence from amino acid 115 to amino acid 124 of SEQ ID NO:35.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:34. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process compπsing the steps of:

(l) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:34, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:34, and

(ab) the nucleotide sequence of the cDNA insert of clone AR415 4 deposited with the ATCC under accession number 98232; (n) hybπdizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process compπsing the steps of: (l) preparing one or more polynucleotide pπmers that hybπdize in

(ba) SEQ ID NO:34, but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:34; and (bb) the nucleotide sequence of the cDNA insert of clone AR415 4 deposited with the ATCC under accession number 98232; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:34, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:34 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:34 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:34. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:34 from nucleotide 437 to nucleotide 1159, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:34 from nucleotide 437 to nucleotide 1159, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:34 from nucleotide 437 to nucleotide 1159. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:34 from nucleotide 515 to nucleotide 1159, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:34 from nucleotide 515 to nucleotide 1159, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:34 from nucleotide 515 to nucleotide 1159. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:34 from nucleotide 539 to nucleotide 1099, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 34 from nucleotide 539 to nucleotide 1099, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:34 from nucleotide 539 to nucleotide 1099.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ED NO:35; (b) the amino acid sequence of SEQ ED NO:35 from amino acid 51 to amino acid 221;

(c) a fragment of the amino acid sequence of SEQ ID NO: 35, the fragment comprising eight contiguous amino acids of SEQ ID NO:35; and

(d) the amino acid sequence encoded by the cDNA insert of clone AR415 4 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 35 or the amino acid sequence of SEQ ED

NO:35 from amino acid 51 to amino acid 221. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:35 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:35, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:35 having biological activity, the fragment comprising the amino acid sequence from amino acid 115 to amino acid 124 of SEQ ID NO:35.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO : 36;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:36 from nucleotide 59 to nucleotide 376;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:36 from nucleotide 179 to nucleotide 376;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AS63 29 deposited with the ATCC under accession number 98232;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AS63_29 deposited with the ATCC under accession number 98232;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AS63_29 deposited with the ATCC under accession number 98232;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AS63_29 deposited with the ATCC under accession number 98232;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:37;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:37 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ED NO:37;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:36.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:36 from nucleotide 59 to nucleotide 376; the nucleotide sequence of SEQ ID NO:36 from nucleotide 179 to nucleotide 376; the nucleotide sequence of the full-length protein coding sequence of clone AS63 29 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone AS63_29 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AS63 29 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:37 from amino acid 1 to amino acid 91. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:37 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:37, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:37 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ED NO:37.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ED NO:36 and SEQ ID NO:38.

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:36;

(ab) SEQ ID NO:38, but excluding the poly(A) tail at the 3' end of SEQ ID NO:38; and

(ac) the nucleotide sequence of the cDNA insert of clone AS63_29 deposited with the ATCC under accession number 98232; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO:36; (bb) SEQ ID NO:38, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:38; and

(be) the nucleotide sequence of the cDNA insert of clone AS63 29 deposited with the ATCC under accession number 98232; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO: 36 and SEQ ID NO: 38, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO:36 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO: 38, but excluding the poly(A) tail at the 3' end of SEQ ID NO:38. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:36, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:36 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:36. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO: 36 from nucleotide 59 to nucleotide 376, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:36 from nucleotide 59 to nucleotide 376, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO: 36 from nucleotide 59 to nucleotide 376. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:36 from nucleotide 179 to nucleotide 376, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:36 from nucleotide 179 to nucleotide 376, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:36 from nucleotide 179 to nucleotide 376.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:37;

(b) the amino acid sequence of SEQ ID NO: 37 from amino acid 1 to amino acid 91;

(c) a fragment of the amino acid sequence of SEQ ID NO:37, the fragment comprising eight contiguous amino acids of SEQ ED NO:37; and (d) the amino acid sequence encoded by the cDNA insert of clone AS63_29 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:37 or the amino acid sequence of SEQ ID

NO: 37 from amino acid 1 to amino acid 91. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:37 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:37, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:37 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO: 37. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 39 from nucleotide 198 to nucleotide 2039; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 490 to nucleotide 809;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AY304 14 deposited with the ATCC under accession number 98561; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AY304 14 deposited with the ATCC under accession number 98561;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AY304 14 deposited with the ATCC under accession number 98561; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AY304_14 deposited with the ATCC under accession number 98561;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:40; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 40;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:39.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:39 from nucleotide 198 to nucleotide 2039; the nucleotide sequence of SEQ ID NO:39 from nucleotide 490 to nucleotide 809; the nucleotide sequence of the full-length protein coding sequence of clone AY304 14 deposited with the ATCC under accession number 98561; or the nucleotide sequence of a mature protein coding sequence of clone AY304 14 deposited with the ATCC under accession number 98561. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AY304 14 deposited with the ATCC under accession number 98561. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:40 from amino acid 106 to amino acid 204. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 302 to amino acid 311 of SEQ ID NO:40.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:39. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:39, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:39; and

(ab) the nucleotide sequence of the cDNA insert of clone AY304 14 deposited with the ATCC under accession number 98561 ;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO:39, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:39; and

(bb) the nucleotide sequence of the cDNA insert of clone AY304 14 deposited with the ATCC under accession number 98561; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:39, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:39 , but excluding the poly(A) tail at the 3 ' end of SEQ

ID NO:39. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 198 to nucleotide 2039, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 198 to nucleotide 2039, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 198 to nucleotide 2039. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 490 to nucleotide 809, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 490 to nucleotide 809, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 490 to nucleotide 809.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:40; (b) the amino acid sequence of SEQ ID NO:40 from amino acid 106 to amino acid 204;

(c) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ED NO:40; and

(d) the amino acid sequence encoded by the cDNA insert of clone A Y304_ 14 deposited with the ATCC under accession number 98561 ; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:40 or the amino acid sequence of SEQ ID NO:40 from amino acid 106 to amino acid 204. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ ED NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 302 to amino acid 311 of SEQ ID NO:40.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 ;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431 ; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG160 1 deposited with the ATCC under accession number 98232;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG160 1 deposited with the ATCC under accession number 98232;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG160_1 deposited with the ATCC under accession number 98232;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG160 1 deposited with the ATCC under accession number 98232;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQEDNO:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;

(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:41. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027; the nucleotide sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027; the nucleotide sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431; the nucleotide sequence of the full-length protein coding sequence of clone BG160 1 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone BGl 60 1 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 110. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ED NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment compnsing the amino acid sequence from amino acid 316 to amino acid 325 of SEQ ED NO:42.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:41.

(a) a process compπsing the steps of:

(l) prepaπng one or more polynucleotide probes that hybπdize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:41 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:41; and

(ab) the nucleotide sequence of the cDNA insert of clone BG160 1 deposited with the ATCC under accession number 98232; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(1) prepaπng one or more polynucleotide pπmers that hybπdize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:41 , but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:41; and

(bb) the nucleotide sequence of the cDNA insert of clone BGl 60 1 deposited with the ATCC under accession number 98232;

(n) hybπdizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(ιn). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:41 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO:41 from nucleotide 1902 to nucleotide 2027, to a nucleotide sequence corresponding to the 3 ' end of said sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 fromnucleotide 1 to nucleotide 431 , and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431.

(a) the amino acid sequence of SEQ ID NO:42;

(b) the amino acid sequence of SEQ ED NO:42 from amino acid 1 to amino acid 110;

(c) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ED NO:42; and

(d) the amino acid sequence encoded by the cDNA insert of clone BG160 1 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42 or the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 110. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 316 to amino acid 325 of SEQ ID NO:42.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:44;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:44 from nucleotide 566 to nucleotide 631;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone B0432_4 deposited with the ATCC under accession number 98232;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone B0432 4 deposited with the ATCC under accession number 98232;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone B0432 4 deposited with the ATCC under accession number 98232;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone B0432_4 deposited with the ATCC under accession number 98232;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:45; (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:45 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:45;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:44.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:44 from nucleotide 566 to nucleotide 631 ; the nucleotide sequence of the full-length protein coding sequence of clone B0432_4 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone B0432 4 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone B0432 4 deposited with the ATCC under accession number 98232. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO: 45 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:45, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:45 having biological activity, the fragment comprising the amino acid sequence from amino acid 6 to amino acid 15 of SEQ ID NO:45. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID

NO:44, SEQ ID NO:43, and SEQ ID NO:46 .

(a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ E NO:43;

(ab) SEQ ID NO:44; (ac) SEQ ED NO:46, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:46; and

(ad) the nucleotide sequence of the cDNA insert of clone B0432 4 deposited with the ATCC under accession number 98232; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:43;

(bb) SEQ ID NO:44;

(be) SEQ ID NO:46, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:46; and (bd) the nucleotide sequence of the cDNA insert of clone B0432_4 deposited with the ATCC under accession number 98232; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:43, SEQ ID NO:44, and SEQ ED

NO:46, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:46, but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:46. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:44, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO:44 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:44. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:44 from nucleotide 566 to nucleotide 631, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO:44 from nucleotide 566 to nucleotide

631 , to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:44 from nucleotide 566 to nucleotide 631.

(a) the amino acid sequence of SEQ ED NO:45;

(b) a fragment of the amino acid sequence of SEQ ED NO:45, the fragment comprising eight contiguous amino acids of SEQ ED NO:45; and

(c) the amino acid sequence encoded by the cDNA insert of clone B0432_4 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:45. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ

ED NO:45 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:45, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:45 having biological activity, the fragment comprising the amino acid sequence from amino acid 6 to amino acid 15 of SEQ ID NO:45. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:47;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 45 to nucleotide 428;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone B0538 2 deposited with the ATCC under accession number 98232;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone B0538_2 deposited with the ATCC under accession number 98232;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone B0538_2 deposited with the ATCC under accession number 98232;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone B0538_2 deposited with the ATCC under accession number 98232;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:47. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 45 to nucleotide 428; the nucleotide sequence of the full-length protein coding sequence of clone B0538 2 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone B0538_2 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone B0538 2 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48 from amino acid 52 to amino acid 128. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 59 to amino acid 68 of SEQ ID NO:48. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID

NO:47 and SEQ ED NO:49.

(aa) SEQ ID NO:47;

(ab) SEQ ID NO:49, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:49; and

(ac) the nucleotide sequence of the cDNA insert of clone B0538 2 deposited with the ATCC under accession number 98232; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ED NO:47;

(bb) SEQ ED NO:49, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:49; and

(be) the nucleotide sequence of the cDNA insert of clone B0538_2 deposited with the ATCC under accession number 98232; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:47 and SEQ ID NO:49, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:49, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:49. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

NO:47, and extending contiguously from a nucleotide sequence corresponding to the 5' end of

SEQ ID NO:47 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO:47. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 45 to nucleotide 428, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 45 to nucleotide 428, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:47 from nucleotide 45 to nucleotide 428.

(a) the amino acid sequence of SEQ ID NO:48;

(b) the amino acid sequence of SEQ ID NO:48 from amino acid 52 to amino acid 128;

(c) a fragment of the amino acid sequence of SEQ ED NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and

(d) the amino acid sequence encoded by the cDNA insert of clone B0538 2 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:48 or the amino acid sequence of SEQ ED NO:48 from amino acid 52 to amino acid 128. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 59 to amino acid 68 of SEQ ID NO:48. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:50;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:50 from nucleotide 144 to nucleotide 566;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BR595 4 deposited with the ATCC under accession number 98232;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BR595 4 deposited with the ATCC under accession number 98232;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BR595 4 deposited with the ATCC under accession number 98232;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BR595_4 deposited with the ATCC under accession number 98232;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:51;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO: 51 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 51 ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:50. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 50 from nucleotide 144 to nucleotide 566; the nucleotide sequence of the full-length protein coding sequence of clone BR595 4 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone BR595 4 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BR595_4 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:51 from amino acid 39 to amino acid 141. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:51 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:51, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 51 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:51. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID

NO:50 and SEQ ID NO:52.

(aa) SEQ ED NO:50;

(ab) SEQ ID NO:52, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:52; and

(ac) the nucleotide sequence of the cDNA insert of clone BR595 4 deposited with the ATCC under accession number 98232; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:50;

(bb) SEQ ID NO:52, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:52; and

(be) the nucleotide sequence of the cDNA insert of clone BR595 4 deposited with the ATCC under accession number 98232; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:50 and SEQ ED NO:52, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 50 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:52, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:52. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED

NO:50, and extending contiguously from a nucleotide sequence corresponding to the 5' end of

SEQ ID NO:50 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:50. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:50 from nucleotide 144 to nucleotide 566, and extending contiguously from a nucleotide sequence corresponding to the 5¹ end of said sequence of SEQ ID NO:50 from nucleotide 144 to nucleotide 566, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO: 50 from nucleotide 144 to nucleotide 566.

(a) the amino acid sequence of SEQ ID NO: 51 ;

(b) the amino acid sequence of SEQ ID NO: 51 from amino acid 39 to amino acid 141;

(c) a fragment of the amino acid sequence of SEQ ED NO : 51 , the fragment comprising eight contiguous amino acids of SEQ ID NO: 51 ; and

(d) the amino acid sequence encoded by the cDNA insert of clone BR595_4 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 51 or the amino acid sequence of SEQ ED NO:51 from amino acid 39 to amino acid 141. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:51 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:51, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 51 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:51. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:53;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:53 from nucleotide 232 to nucleotide 1041;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 460 to nucleotide 1041;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 590 to nucleotide 1163; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CI490_2 deposited with the ATCC under accession number 98232;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CI490 2 deposited with the ATCC under accession number 98232; (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CI490 2 deposited with the ATCC under accession number

98232;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CI490 2 deposited with the ATCC under accession number 98232; (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:54;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ED NO:54; (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:53.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ED NO:53 from nucleotide 232 to nucleotide 1041; the nucleotide sequence of SEQ ID NO:53 from nucleotide 460 to nucleotide 1041; the nucleotide sequence of SEQ ED NO:53 from nucleotide 590 to nucleotide 1163; the nucleotide sequence of the full-length protein coding sequence of clone CI490 2 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone CI490_2 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone CI490 2 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:54 from amino acid 133 to amino acid 270. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 130 to amino acid 139 of SEQ ID NO:54.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ED NO:53.

(i) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO:53, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:53; and

(ab) the nucleotide sequence of the cDNA insert of clone CI490 2 deposited with the ATCC under accession number 98232; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:53, but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:53; and

(bb) the nucleotide sequence of the cDNA insert of clone CI490 2 deposited with the ATCC under accession number 98232; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO: 53 to a nucleotide sequence corresponding to the 3 ' end of SEQ ED NO : 53 , but excluding the poly( A) tail at the 3 ' end of SEQ ID NO: 53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 232 to nucleotide 1041, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO:53 from nucleotide 232 to nucleotide 1041, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:53 from nucleotide 232 to nucleotide 1041. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:53 from nucleotide 460 to nucleotide 1041, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO: 53 from nucleotide 460 to nucleotide 1041, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 460 to nucleotide 1041. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 590 to nucleotide 1163, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 590 to nucleotide 1163, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 590 to nucleotide 1163.

(a) the amino acid sequence of SEQ ID NO:54;

(b) the aminoacidsequenceofSEQIDNO:54 fromaminoacid 133 to amino acid 270;

(c) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and (d) the amino acid sequence encoded by the cDNA insert of clone CI490 2 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:54 or the amino acid sequence of SEQ ID NO:54 from amino acid 133 to amino acid 270. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 130 to amino acid 139 of SEQ ID NO:54.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO: 55;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ED NO : 55 from nucleotide 268 to nucleotide 624;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 55 from nucleotide 325 to nucleotide 624;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CI522_1 deposited with the ATCC under accession number 98232;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CI522_1 deposited with the ATCC under accession number 98232;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CI522_1 deposited with the ATCC under accession number 98232;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CI522 1 deposited with the ATCC under accession number 98232;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:56; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 268 to nucleotide 624; the nucleotide sequence of SEQ ED NO: 55 from nucleotide 325 to nucleotide 624; the nucleotide sequence of the full-length protein coding sequence of clone

CI522_1 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone CI522_1 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CI522 1 deposited with the ATCC under accession number 98232. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID

NO: 56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 54 to amino acid 63 of SEQ ID NO:56.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:55 and SEQ ID NO:57.

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ED NO:55;

(ab) SEQ ID NO:57, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:57; and

(ac) the nucleotide sequence of the cDNA insert of clone CI522_1 deposited with the ATCC under accession number 98232; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(ba) SEQ ID NO:55; (bb) SEQ ED NO:57, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:57; and

(be) the nucleotide sequence of the cDNA insert of clone CI522_1 deposited with the ATCC under accession number 98232; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ED NO:55 and SEQ ED NO:57, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 57, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:57. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:55 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO:55. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 268 to nucleotide 624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO:55 from nucleotide 268 to nucleotide 624, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 268 to nucleotide 624. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 624, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 624.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:56;

(b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and

(c) the amino acid sequence encoded by the cDNA insert of clone CI522_1 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:56. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ IDNO:56, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 54 to amino acid 63 of SEQ ID NO:56.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 58 ; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:58 from nucleotide 288 to nucleotide 710;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 58 from nucleotide 868 to nucleotide 1887;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CN238 1 deposited with the ATCC under accession number 98232;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CN238 1 deposited with the ATCC under accession number 98232;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CN238 1 deposited with the ATCC under accession number

98232;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CN238 1 deposited with the ATCC under accession number 98232;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:59; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:59 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:59;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:58.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:58 from nucleotide 288 to nucleotide 710; the nucleotide sequence of SEQ ID NO:58 from nucleotide 868 to nucleotide 1887; the nucleotide sequence of the full-length protein coding sequence of clone CN238 1 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone CN238_1 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CN238 1 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:59 from amino acid 1 to amino acid 109. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:59 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:59, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:59 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:59.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:58.

(aa) SEQ ID NO:58, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:58; and

(ab) the nucleotide sequence of the cDNA insert of clone CN238_1 deposited with the ATCC under accession number 98232; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:58, but excluding the poly(A) tail at the 3 ^* end of SEQ ED NO:58; and

(bb) the nucleotide sequence of the cDNA insert of clone CN238_1 deposited with the ATCC under accession number 98232; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:58, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ IDNO:58 to a nucleotide sequence corresponding to the 3 ' end of SEQ ED NO : 58 , but excluding the poly( A) tail at the 3 ' end of SEQ ID NO:58. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:58 from nucleotide 288 to nucleotide 710, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 58 from nucleotide 288 to nucleotide 710, to a nucleotide sequence corresponding to the 3¹ end of said sequence of SEQ ID NO:58 from nucleotide 288 to nucleotide 710. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:58 from nucleotide 868 to nucleotide 1887, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:58 from nucleotide 868 to nucleotide 1887, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:58 from nucleotide 868 to nucleotide 1887.

(a) the amino acid sequence of SEQ ED NO:59;

(b) the amino acid sequence of SEQ ED NO:59 from amino acid 1 to amino acid 109;

(c) a fragment of the amino acid sequence of SEQ ID NO:59, the fragment comprising eight contiguous amino acids of SEQ ID NO:59; and

(d) the amino acid sequence encoded by the cDNA insert of clone CN238_1 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:59 or the amino acid sequence of SEQ ED NO:59 from amino acid 1 to amino acid 109. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:59 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:59, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 59 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO: 59. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:60;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:60 from nucleotide 87 to nucleotide 1871;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:60 from nucleotide 628 to nucleotide 1882;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CO390 1 deposited with the ATCC under accession number 98232;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CO390 1 deposited with the ATCC under accession number 98232;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CO390_l deposited with the ATCC under accession number 98232; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CO390 1 deposited with the ATCC under accession number 98232;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:61; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ IDNO:61 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:61;

(j ) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:60.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:60 from nucleotide 87 to nucleotide 1871; the nucleotide sequence of SEQ ED NO:60 from nucleotide 628 to nucleotide 1882; the nucleotide sequence of the full-length protein coding sequence of clone CO390_l deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone CO390 1 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CO390_l deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:61 from amino acid 182 to amino acid 248. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 61 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:61, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:61 having biological activity, the fragment comprising the amino acid sequence from amino acid 292 to amino acid 301 of SEQ ED NO:61.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:60. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:60, but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:60; and

(ab) the nucleotide sequence of the cDNA insert of clone CO390_l deposited with the ATCC under accession number 98232;

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO:60, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:60; and

(bb) the nucleotide sequence of the cDNA insert of clone CO390 1 deposited with the ATCC under accession number 98232; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:60, and extending contiguously from a nucleotide sequence corresponding to the 5 ' end of SEQ ID NO : 60 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:60 , but excluding the poly(A) tail at the 3 ' end of SEQ

ID NO:60. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO: 60 from nucleotide 87 to nucleotide 1871, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO:60 from nucleotide 87 to nucleotide 1871, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 60 from nucleotide 87 to nucleotide 1871. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:60 from nucleotide 628 to nucleotide 1882, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 60 from nucleotide 628 to nucleotide 1882, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:60 from nucleotide 628 to nucleotide 1882.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:61; (b) the amino acid sequence of SEQ ID NO: 61 from amino acid 182 to amino acid 248;

(c) a fragment of the amino acid sequence of SEQ ID NO : 61 , the fragment comprising eight contiguous amino acids of SEQ ID NO:61; and

(d) the amino acid sequence encoded by the cDNA insert of clone CO390 1 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:61 or the amino acid sequence of SEQ ED NO:61 from amino acid 182 to amino acid 248. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:61 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:61, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:61 having biological activity, the fragment comprising the amino acid sequence from amino acid 292 to amino acid 301 of SEQ ID NO:61.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:62;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:62 from nucleotide 68 to nucleotide 430; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:62 from nucleotide 128 to nucleotide 430;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ20 2 deposited with the ATCC under accession number 98261; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ20 2 deposited with the ATCC under accession number 98261;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AJ20 2 deposited with the ATCC under accession number 98261;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AJ20_2 deposited with the ATCC under accession number 98261;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:63; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:63 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ED NO:63;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:62.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 62 from nucleotide 68 to nucleotide 430; the nucleotide sequence of SEQ ID NO:62 from nucleotide 128 to nucleotide 430; the nucleotide sequence of the full-length protein coding sequence of clone AJ20 2 deposited with the ATCC under accession number 98261 ; or the nucleotide sequence of a mature protein coding sequence of clone AJ20 2 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AJ20_2 deposited with the ATCC under accession number 98261. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID

NO:63 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO: 63, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:63 having biological activity, the fragment comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ ID NO:63. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:62 and SEQ ID NO:64.

(aa) SEQ ID NO:62; (ab) SEQ ID NO:64, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:64; and

(ac) the nucleotide sequence of the cDNA insert of clone AJ20_2 deposited with the ATCC under accession number 98261; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:62;

(bb) SEQ ID NO:64, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:64; and (be) the nucleotide sequence of the cDNA insert of clone

AJ20_2 deposited with the ATCC under accession number 98261; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:62 and SEQ ID NO:64, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO: 62 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO: 64, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:64. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:62, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:62 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:62. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:62 from nucleotide 68 to nucleotide 430, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:62 from nucleotide 68 to nucleotide 430, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:62 from nucleotide 68 to nucleotide 430. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 62 from nucleotide 128 to nucleotide 430, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:62 from nucleotide 128 to nucleotide 430, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:62 from nucleotide 128 to nucleotide 430. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:63;

(b) a fragment of the amino acid sequence of SEQ ID NO: 63, the fragment comprising eight contiguous amino acids of SEQ ED NO:63; and (c) the amino acid sequence encoded by the cDNA insert of clone AJ20 2 deposited with the ATCC under accession number 98261; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 63. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO: 63 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO : 63 , or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 63 having biological activity, the fragment comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ ED NO:63.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:66;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 66 from nucleotide 289 to nucleotide 780; (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AR440 1 deposited with the ATCC under accession number 98261;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AR440 1 deposited with the ATCC under accession number 98261 ;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AR440_1 deposited with the ATCC under accession number 98261;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AR440 1 deposited with the ATCC under accession number 98261 ;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:67;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:67 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:67;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:66. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:66 from nucleotide 289 to nucleotide 780; the nucleotide sequence of the full-length protein coding sequence of clone AR440_1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone AR440_1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:67 from amino acid 1 to amino acid 160. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:67 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:67, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:67 having biological activity, the fragment comprising the amino acid sequence from amino acid 77 to amino acid 86 of SEQ ID NO:67. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID

NO:66 and SEQ ID NO:65.

(aa) SEQ ID NO:65;

(ab) SEQ ID NO:66, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:66; and

(ac) the nucleotide sequence of the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:65;

(bb) SEQ ID NO:66, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:66; and

(be) the nucleotide sequence of the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261 ;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ED NO: 65 and SEQ ID NO: 66, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO:65 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO:66, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:66. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 66, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:66 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:66, but excluding the poly(A) tail at the 3' end of SEQ ID NO:66. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:66 from nucleotide 289 to nucleotide 780, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:66 from nucleotide 289 to nucleotide 780, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:66 from nucleotide 289 to nucleotide 780. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 67;

(b) the amino acid sequence of SEQ ID NO: 67 from amino acid 1 to amino acid 160; (c) a fragment of the amino acid sequence of SEQ ID NO:67, the fragment comprising eight contiguous amino acids of SEQ ID NO:67; and

(d) the amino acid sequence encoded by the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 67 or the amino acid sequence of SEQ ED

NO: 67 from amino acid 1 to amino acid 160. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:67 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:67, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 67 having biological activity, the fragment comprising the amino acid sequence from amino acid 77 to amino acid 86 of SEQ ID NO:67.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:68; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:68 from nucleotide 76 to nucleotide 1050;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:68 from nucleotide 331 to nucleotide 567; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AS164 1 deposited with the ATCC under accession number 98261;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AS164 1 deposited with the ATCC under accession number 98261; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AS164 1 deposited with the ATCC under accession number 98261;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AS164 1 deposited with the ATCC under accession number 98261; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:69;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 69 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:69; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ED NO:68. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ED NO:68 from nucleotide 76 to nucleotide 1050; the nucleotide sequence of SEQ ID NO:68 from nucleotide 331 to nucleotide 567; the nucleotide sequence of the full-length protein coding sequence of clone AS164 1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone AS164_ 1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AS164_1 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:69 from amino acid 87 to amino acid 164. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:69 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:69, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 69 having biological activity, the fragment comprising the amino acid sequence from amino acid 157 to amino acid 166 of SEQ ID NO: 69. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID

NO:68.

(aa) SEQ ID NO:68, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:68; and (ab) the nucleotide sequence of the cDNA insert of clone

AS164 1 deposited with the ATCC under accession number 98261; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ED NO:68, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:68; and

(bb) the nucleotide sequence of the cDNA insert of clone AS164_1 deposited with the ATCC under accession number 98261; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 68, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:68 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:68 , but excluding the poly(A) tail at the 3 ' end of SEQ

ID NO:68. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 68 from nucleotide

76 to nucleotide 1050, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:68 from nucleotide 76 to nucleotide 1050, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:68 from nucleotide 76 to nucleotide 1050. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

NO:68 from nucleotide 331 to nucleotide 567, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:68 from nucleotide 331 to nucleotide 567, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED

NO:68 from nucleotide 331 to nucleotide 567.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ED NO: 69;

(b) the amino acid sequence of SEQ ID NO : 69 from amino acid 87 to amino acid 164;

(c) a fragment of the amino acid sequence of SEQ ID NO:69, the fragment comprising eight contiguous amino acids of SEQ ID NO:69; and (d) the amino acid sequence encoded by the cDNA insert of clone AS164_1 deposited with the ATCC under accession number 98261; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:69 or the amino acid sequence of SEQ ED

NO:69 from amino acid 87 to amino acid 164. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:69 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:69, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:69 having biological activity, the fragment comprising the amino acid sequence from amino acid 157 to amino acid 166 of SEQ ED NO:69. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:70;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 70 from nucleotide 242 to nucleotide 1060;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:70 from nucleotide 596 to nucleotide 1060;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:70 from nucleotide 10 to nucleotide 373; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AX8_1 deposited with the ATCC under accession number 98261;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AX8 1 deposited with the ATCC under accession number 98261; (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AX8 1 deposited with the ATCC under accession number

98261;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AX8 1 deposited with the ATCC under accession number 98261; (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:71;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:71 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:71; (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:70.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 70 from nucleotide 242 to nucleotide 1060; the nucleotide sequence of SEQ ID NO:70 from nucleotide 596 to nucleotide 1060; the nucleotide sequence of SEQ ED NO:70 from nucleotide 10 to nucleotide 373; the nucleotide sequence of the full-length protein coding sequence of clone AX8_1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone AX8 1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AX8_1 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:71 from amino acid 1 to amino acid 44. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:71 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:71, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:71 having biological activity, the fragment comprising the amino acid sequence from amino acid 131 to amino acid 140 of SEQ ED NO:71.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ED NO:70.

(aa) SEQ ID NO:70, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:70; and

(ab) the nucleotide sequence of the cDNA insert of clone AX8 1 deposited with the ATCC under accession number 98261;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:70, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:70; and

(bb) the nucleotide sequence of the cDNA insert of clone AX8_1 deposited with the ATCC under accession number 98261; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:70, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 70 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO: 70 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:70. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO: 70 from nucleotide 242 to nucleotide 1060, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 70 from nucleotide 242 to nucleotide 1060, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:70 from nucleotide 242 to nucleotide 1060. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:70 from nucleotide 596 to nucleotide 1060, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO:70 from nucleotide 596 to nucleotide 1060, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:70 from nucleotide 596 to nucleotide 1060. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:70 from nucleotide 10 to nucleotide 373, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO: 70 from nucleotide 10 to nucleotide 373, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:70 from nucleotide 10 to nucleotide 373.

(a) the amino acid sequence of SEQ ID NO: 71 ;

(b) the amino acid sequence of SEQ ID NO: 71 from amino acid 1 to amino acid 44;

(c) a fragment of the amino acid sequence of SEQ ID NO:71, the fragment comprising eight contiguous amino acids of SEQ ID NO: 71 ; and (d) the amino acid sequence encoded by the cDNA insert of clone AX8_1 deposited with the ATCC under accession number 98261; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 71 or the amino acid sequence of SEQ ID NO:71 from amino acid 1 to amino acid 44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 71 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:71, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 71 having biological activity, the fragment comprising the amino acid sequence from amino acid 131 to amino acid 140 of SEQ ID NO : 71.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:72;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:72 from nucleotide 773 to nucleotide 928;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:72 from nucleotide 815 to nucleotide 928;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD176 3 deposited with the ATCC under accession number 98261;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD176_3 deposited with the ATCC under accession number 98261;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD176 3 deposited with the ATCC under accession number 98261;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD176_3 deposited with the ATCC under accession number 98261;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:73; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 73 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:73;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:72.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:72 from nucleotide 773 to nucleotide 928 ; the nucleotide sequence of SEQ ID NO:72 from nucleotide 815 to nucleotide 928; the nucleotide sequence of the full-length protein coding sequence of clone

BD176 3 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone BD 176_3 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BD176_3 deposited with the ATCC under accession number 98261. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED

NO: 73 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:73, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:73 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:73.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ED NO:72 and SEQ ID NO:74.

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:72;

(ab) SEQ ID NO:74, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:74; and

(ac) the nucleotide sequence of the cDNA insert of clone BD176 3 deposited with the ATCC under accession number 98261; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO:72; (bb) SEQ ID NO:74, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:74; and

(be) the nucleotide sequence of the cDNA insert of clone BD176 3 deposited with the ATCC under accession number 98261; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:72 and SEQ ED NO:74, and extending contiguously from a nucleotide sequence corresponding to the 5 ' end of SEQ ID NO : 72 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO:74, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:74. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:72, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 72 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 72. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:72 from nucleotide 773 to nucleotide 928, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:72 from nucleotide 773 to nucleotide 928, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:72 from nucleotide 773 to nucleotide 928. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 72 from nucleotide 815 to nucleotide 928, and extending contiguously from a nucleotide sequence corresponding to the 5 ' end of said sequence of SEQ ID NO : 72 from nucleotide 815 to nucleotide 928, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:72 from nucleotide 815 to nucleotide 928.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:73;

(b) a fragment of the amino acid sequence of SEQ ID NO: 73, the fragment comprising eight contiguous amino acids of SEQ ID NO:73; and

(c) the amino acid sequence encoded by the cDNA insert of clone BD 176 3 deposited with the ATCC under accession number 98261 ; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:73. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:73 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:73, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:73 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:73.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 174 to nucleotide 440;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 1 to nucleotide 313;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD339 1 deposited with the ATCC under accession number 98261;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD339 1 deposited with the ATCC under accession number 98261;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD339 1 deposited with the ATCC under accession number

98261;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD339_1 deposited with the ATCC under accession number 98261;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:76; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:76;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ED NO:75.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:75 from nucleotide 174 to nucleotide 440; the nucleotide sequence of SEQ ID NO:75 from nucleotide 1 to nucleotide 313 ; the nucleotide sequence of the full-length protein coding sequence of clone BD339 1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone BD339 1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BD339_1 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:76 from amino acid 1 to amino acid 46. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:76.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:75.

(aa) SEQ ID NO:75, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:75; and

(ab) the nucleotide sequence of the cDNA insert of clone BD339_1 deposited with the ATCC under accession number 98261; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO:75, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:75; and

(bb) the nucleotide sequence of the cDNA insert of clone BD339 1 deposited with the ATCC under accession number 98261; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 75 to a nucleotide sequence corresponding to the 3 ' end of SEQ ID NO : 75 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:75. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 174 to nucleotide 440, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:75 from nucleotide 174 to nucleotide 440, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:75 from nucleotide 174 to nucleotide 440. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 1 to nucleotide 313, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:75 from nucleotide 1 to nucleotide 313, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:75 from nucleotide 1 to nucleotide 313.

(a) the amino acid sequence of SEQ ID NO:76;

(b) the amino acid sequence of SEQ ED NO: 76 from amino acid 1 to amino acid 46;

(c) a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76; and

(d) the amino acid sequence encoded by the cDNA insert of clone BD339 1 deposited with the ATCC under accession number 98261; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:76 or the amino acid sequence of SEQ ID NO:76 from amino acid 1 to amino acid 46. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:76, or a protein comprising a fragment of the amino acid sequence of SEQ ED NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:76. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 509 to nucleotide 619;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:77 from nucleotide 1 to nucleotide 580;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD427 1 deposited with the ATCC under accession number 98261;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD427 1 deposited with the ATCC under accession number 98261;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD427_1 deposited with the ATCC under accession number 98261; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD427_1 deposited with the ATCC under accession number 98261;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:78; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 78 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 78;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:77.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:77 from nucleotide 509 to nucleotide 619; the nucleotide sequence of SEQ ED NO:77 from nucleotide 1 to nucleotide 580; the nucleotide sequence of the full-length protein coding sequence of clone BD427 1 deposited with the ATCC under accession number 98261 ; or the nucleotide sequence of a mature protein coding sequence of clone BD427 1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BD427_1 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID

NO:78 from amino acid 1 to amino acid 24. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:78, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID

NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 13 to amino acid 22 of SEQ ID NO:78.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:77. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO:77, but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:77; and

(ab) the nucleotide sequence of the cDNA insert of clone BD427 1 deposited with the ATCC under accession number 98261 ;

(ba) SEQ ID NO:77, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:77; and

(bb) the nucleotide sequence of the cDNA insert of clone BD427_1 deposited with the ATCC under accession number 98261; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 77, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 77 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:77 , but excluding the poly(A) tail at the 3 ' end of SEQ

ID NO:77. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 509 to nucleotide 619, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 509 to nucleotide 619, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:77 from nucleotide 509 to nucleotide 619. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 1 to nucleotide 580, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 1 to nucleotide 580, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:77 from nucleotide 1 to nucleotide 580.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ED NO:78; (b) the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 24;

(c) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ED NO:78; and

(d) the amino acid sequence encoded by the cDNA insert of clone BD427 1 deposited with the ATCC under accession number 98261 ; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:78 or the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 24. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:78, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 13 to amino acid 22 of SEQ ID NO:78. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL229 22 deposited with the ATCC under accession number 98261;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL229_22 deposited with the ATCC under accession number 98261; (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BL229 22 deposited with the ATCC under accession number 98261;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BL229_22 deposited with the ATCC under accession number 98261 ;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO: 80;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:80;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:79. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360; the nucleotide sequence of the full-length protein coding sequence of clone BL229 22 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone BL229 22 deposited with the

ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BL229 22 deposited with the ATCC under accession number 98261. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO: 80, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 80 having biological activity, the fragment comprising the amino acid sequence from amino acid 5 to amino acid 14 of SEQ ED NO: 80.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:79 and SEQ ID NO:81. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(aa) SEQ ID NO:79;

(ab) SEQ ID NO:81 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:81; and (ac) the nucleotide sequence of the cDNA insert of clone

BL229 22 deposited with the ATCC under accession number 98261; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:79;

(bb) SEQ ID NO : 81 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:81; and

(be) the nucleotide sequence of the cDNA insert of clone BL229_22 deposited with the ATCC under accession number 98261; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO: 79 and SEQ ED NO:81, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 79 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 81 , but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:81. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:79 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:79. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ED NO: 80;

(b) a fragment of the amino acid sequence of SEQ ID NO: 80, the fragment comprising eight contiguous amino acids of SEQ ID NO: 80; and

(c) the amino acid sequence encoded by the cDNA insert of clone BL229 22 deposited with the ATCC under accession number 98261; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:80. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 80, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 5 to amino acid 14 of SEQ ID NO:80.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO: 82; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 82 from nucleotide 604 to nucleotide 771;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 82 from nucleotide 1 to nucleotide 684;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV123_16 deposited with the ATCC under accession number 98261;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV123 16 deposited with the ATCC under accession number 98261; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV123_16 deposited with the ATCC under accession number 98261;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV123 16 deposited with the ATCC under accession number 98261;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:83;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 83 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 83 ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:82. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:82 from nucleotide 604 to nucleotide 771; the nucleotide sequence of SEQ ID NO: 82 from nucleotide 1 to nucleotide 684; the nucleotide sequence of the full-length protein coding sequence of clone BV123 16 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone B V 123_16 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BV123_16 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 83 from amino acid 1 to amino acid 27. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:83 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:83, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 83 having biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID NO:83. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:82.

(i) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO:82, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 82; and

(ab) the nucleotide sequence of the cDNA insert of clone BV123 16 deposited with the ATCC under accession number 98261; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO: 82, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:82; and

(bb) the nucleotide sequence of the cDNA insert of clone BV123_16 deposited with the ATCC under accession number 98261; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 82, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 82 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 82 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 82. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 82 from nucleotide 604 to nucleotide 771 , and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:82 from nucleotide 604 to nucleotide 771, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 82 from nucleotide 604 to nucleotide 771. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 82 from nucleotide 1 to nucleotide 684, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 82 from nucleotide 1 to nucleotide 684, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:82 from nucleotide 1 to nucleotide 684.

(a) the amino acid sequence of SEQ ED NO: 83 ;

(b) the amino acid sequence of SEQ ED NO:83 from amino acid 1 to amino acid 27;

(c) a fragment of the amino acid sequence of SEQ ED NO:83, the fragment comprising eight contiguous amino acids of SEQ ID NO:83; and

(d) the amino acid sequence encoded by the cDNA insert of clone BV 123 16 deposited with the ATCC under accession number 98261; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:83 or the amino acid sequence of SEQ ID NO: 83 from amino acid 1 to amino acid 27. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 83 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 83, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:83 having biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID NO: 83.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:84;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:84 from nucleotide 43 to nucleotide 297;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 84 from nucleotide 94 to nucleotide 297;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:84 from nucleotide 1 to nucleotide 379; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CH377 1 deposited with the ATCC under accession number 98261;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CH377_1 deposited with the ATCC under accession number 98261;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CH377_1 deposited with the ATCC under accession number 98261;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CH377 1 deposited with the ATCC under accession number 98261;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:85;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 85 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:85;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:84. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 84 from nucleotide 43 to nucleotide 297; the nucleotide sequence of SEQ ID NO:84 from nucleotide 94 to nucleotide 297; the nucleotide sequence of SEQ ED NO: 84 from nucleotide 1 to nucleotide 379; the nucleotide sequence of the full-length protein coding sequence of clone CH377_1 deposited with the ATCC under accession number 98261 ; or the nucleotide sequence of a mature protein coding sequence of clone CH377_1 deposited with the ATCC under accession number

98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CH377 1 deposited with the ATCC under accession number 98261. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:85 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:85, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:85 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:85. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ED

NO: 84.

(aa) SEQ ID NO:84, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:84; and (ab) the nucleotide sequence of the cDNA insert of clone

CH377_1 deposited with the ATCC under accession number 98261; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO:84, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 84; and

(bb) the nucleotide sequence of the cDNA insert of clone CH377_1 deposited with the ATCC under accession number 98261; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO: 84, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 84 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:84 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 84. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 84 from nucleotide 43 to nucleotide 297, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 84 from nucleotide 43 to nucleotide 297, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 84 from nucleotide 43 to nucleotide 297. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:84 from nucleotide 94 to nucleotide 297, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 84 from nucleotide 94 to nucleotide 297, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO: 84 from nucleotide 94 to nucleotide 297. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 84 from nucleotide 1 to nucleotide 379, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO: 84 from nucleotide 1 to nucleotide 379, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 84 from nucleotide 1 to nucleotide 379.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ED NO:85;

(b) a fragment of the amino acid sequence of SEQ ID NO:85, the fragment comprising eight contiguous amino acids of SEQ ED NO:85; and

(c) the amino acid sequence encoded by the cDNA insert of clone CH377 1 deposited with the ATCC under accession number 98261 ; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 85. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 85 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 85, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 85 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:85.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 87 from nucleotide 390 to nucleotide 563;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD441 1 deposited with the ATCC under accession number 98264;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD441_1 deposited with the ATCC under accession number 98264;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:88; (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 88 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 88;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:87.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ED NO: 87 from nucleotide 390 to nucleotide 563; the nucleotide sequence of the full-length protein coding sequence of clone BD441 1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BD441 1 deposited with the

ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 88, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:88. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ED

NO: 87, SEQ ID NO: 86, and SEQ ED NO: 89 .

(aa) SEQ ID NO:86;

(ab) SEQ ID NO: 87; (ac) SEQ ID NO: 89, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:89; and

(ad) the nucleotide sequence of the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:86;

(bb) SEQ ID NO:87;

(be) SEQ ID NO: 89, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:89; and

(bd) the nucleotide sequence of the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:86, SEQ ID NO:87, and SEQ ED NO:89, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:86 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:89, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 89. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 87, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:87 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:87. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 87 from nucleotide 390 to nucleotide 563, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 87 from nucleotide 390 to nucleotide 563, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:87 from nucleotide 390 to nucleotide 563.

(a) the amino acid sequence of SEQ ED NO: 88;

(b) a fragment of the amino acid sequence of SEQ ID NO:88, the fragment comprising eight contiguous amino acids of SEQ ED NO:88; and

(c) the amino acid sequence encoded by the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 88. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:88, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:88. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO : 90 ;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ED NO: 90 from nucleotide 583 to nucleotide 756; (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD441_2 deposited with the ATCC under accession number 98264;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD441 2 deposited with the ATCC under accession number 98264;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD441 2 deposited with the ATCC under accession number 98264;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD441 2 deposited with the ATCC under accession number 98264;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:91;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:91 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 91 ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ED NO:90. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:90 from nucleotide 583 to nucleotide 756; the nucleotide sequence of the full-length protein coding sequence of clone BD441 2 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BD441 2 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BD441_2 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:91 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:91, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:91 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:91.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:90 and SEQ ID NO:92. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO:90;

(ab) SEQ ID NO:92, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:92; and

(ac) the nucleotide sequence of the cDNA insert of clone BD441_2 deposited with the ATCC under accession number 98264;

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO:90; (bb) SEQ ID NO:92, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:92; and

(be) the nucleotide sequence of the cDNA insert of clone BD441_2 deposited with the ATCC under accession number 98264; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:90 and SEQ ID NO:92, and extending contiguously from a nucleotide sequence corresponding to the 5 ' end of SEQ ID NO : 90 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:92, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:92. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:90, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:90 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO:90. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:90 from nucleotide 583 to nucleotide 756, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:90 from nucleotide 583 to nucleotide 756, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:90 from nucleotide 583 to nucleotide 756.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 91 ; (b) a fragment of the amino acid sequence of SEQ ID NO: 91 , the fragment comprising eight contiguous amino acids of SEQ ED NO:91; and

(c) the amino acid sequence encoded by the cDNA insert of clone BD441 _2 deposited with the ATCC under accession number 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:91. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO:91 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:91 , or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 91 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO: 91.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93 from nucleotide 426 to nucleotide 581;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93 from nucleotide 495 to nucleotide 581;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93 from nucleotide 354 to nucleotide 503; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG102 3 deposited with the ATCC under accession number 98264;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG102 3 deposited with the ATCC under accession number 98264;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG102 3 deposited with the ATCC under accession number 98264;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG102 3 deposited with the ATCC under accession number 98264;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:94;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO: 94 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 94;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-Q and that has a length that is at least 25% of the length of SEQ ID NO:93. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:93 from nucleotide 426 to nucleotide 581 ; the nucleotide sequence of SEQ ID NO:93 from nucleotide 495 to nucleotide 581; the nucleotide sequence of SEQ ED NO:93 from nucleotide 354 to nucleotide 503; the nucleotide sequence of the full-length protein coding sequence of clone BG102 3 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BGl 02_3 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG102 3 deposited with the ATCC under accession number 98264. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 94 from amino acid 1 to amino acid 26. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 94, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:94 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:94.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:93.

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO:93, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:93; and

(ab) the nucleotide sequence of the cDNA insert of clone BG102 3 deposited with the ATCC under accession number 98264; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:93, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:93; and

(bb) the nucleotide sequence of the cDNA insert of clone BG102_3 deposited with the ATCC under accession number 98264;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:93 to a nucleotide sequence corresponding to the 3* end of SEQ ED NO:93 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:93. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 426 to nucleotide 581, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:93 from nucleotide 426 to nucleotide 581, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 93 from nucleotide 426 to nucleotide 581. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 495 to nucleotide 581, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO: 93 from nucleotide 495 to nucleotide 581, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO:93 from nucleotide 495 to nucleotide 581. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 354 to nucleotide 503, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:93 from nucleotide 354 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:93 from nucleotide 354 to nucleotide 503.

(a) the amino acid sequence of SEQ ID NO:94;

(b) the amino acid sequence of SEQ ED NO: 94 from amino acid 1 to amino acid 26;

(c) a fragment of the amino acid sequence of SEQ ID NO:94, the fragment comprising eight contiguous amino acids of SEQ ID NO:94; and

(d) the amino acid sequence encoded by the cDNA insert of clone BGl 02_3 deposited with the ATCC under accession number 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ED NO: 94 or the amino acid sequence of SEQ ID NO:94 from amino acid 1 to amino acid 26. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:94, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 94 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:94.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 95 from nucleotide 112 to nucleotide 978;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95 from nucleotide 436 to nucleotide 1048; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BK158_1 deposited with the ATCC under accession number 98264;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BK158 1 deposited with the ATCC under accession number 98264; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BK158 1 deposited with the ATCC under accession number 98264;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BK158_1 deposited with the ATCC under accession number 98264; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:96;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 96 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 96; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:95.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:95 from nucleotide 112 to nucleotide 978; the nucleotide sequence of SEQ ID NO:95 from nucleotide 436 to nucleotide 1048; the nucleotide sequence of the full-length protein coding sequence of clone BK158 1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BK158_1 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BK158_1 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 96, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 139 to amino acid 148 of SEQ ID NO:96.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:95. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(aa) SEQ ID NO:95, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:95; and

(ab) the nucleotide sequence of the cDNA insert of clone BK158 1 deposited with the ATCC under accession number 98264; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of: (i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO:95, but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:95; and (bb) the nucleotide sequence of the cDNA insert of clone BK158_1 deposited with the ATCC under accession number 98264; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO: 95 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:95 , but excluding the poly( A) tail at the 3 ' endofSEQ ID NO:95. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:95 from nucleotide 112 to nucleotide 978, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:95 from nucleotide 112 to nucleotide 978, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:95 from nucleotide 112 to nucleotide 978. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO:95 from nucleotide 436 to nucleotide 1048, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 95 from nucleotide 436 to nucleotide 1048, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ED NO:95 from nucleotide 436 to nucleotide 1048.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:96; (b) a fragment of the amino acid sequence of SEQ ED NO:96, the fragment comprising eight contiguous amino acids of SEQ ID NO:96; and

(c) the amino acid sequence encoded by the cDNA insert of clone BK158 1 deposited with the ATCC under accession number 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:96. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 96 having biological activity, the fragment comprising the amino acid sequence from amino acid 139 to amino acid 148 of SEQ ID NO:96. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:97;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ED NO:97 from nucleotide 16 to nucleotide 492;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BP163 1 deposited with the ATCC under accession number 98264;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BP163_1 deposited with the ATCC under accession number 98264;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BP163 1 deposited with the ATCC under accession number 98264;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BP 163_1 deposited with the ATCC under accession number 98264;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ED NO:98;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 98 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:98;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:97. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ED NO:97 from nucleotide 16 to nucleotide 492; the nucleotide sequence of the full-length protein coding sequence of clone BP163 1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BP163_1 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BP163 1 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:98.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ED NO:97 and SEQ ID NO:99. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO:97;

(ab) SEQ ID NO:99, but excluding the poly(A) tail at the 3 ' end of SEQ ED NO:99; and

(ac) the nucleotide sequence of the cDNA insert of clone BP163 1 deposited with the ATCC under accession number 98264;

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO:97; (bb) SEQ ID NO:99, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:99; and

(be) the nucleotide sequence of the cDNA insert of clone BP163 1 deposited with the ATCC under accession number 98264; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:97 and SEQ ID NO:99, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:97 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:99, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:99. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

NO:97, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:97 to a nucleotide sequence corresponding to the 3' end of SEQ ED NO:97. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 97 from nucleotide 16 to nucleotide 492, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:97 from nucleotide 16 to nucleotide 492, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:97 from nucleotide 16 to nucleotide 492.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ED NO:98; (b) a fragment of the amino acid sequence of SEQ ID NO:98, the fragment comprising eight contiguous amino acids of SEQ ED NO:98; and

(c) the amino acid sequence encoded by the cDNA insert of clone BP 163_ 1 deposited with the ATCC under accession number 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:98. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO:98, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:98.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 101;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 101 from nucleotide 72 to nucleotide 569; (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BZ16 3 deposited with the ATCC under accession number 98264;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BZ16 3 deposited with the ATCC under accession number 98264;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BZ16 3 deposited with the ATCC under accession number 98264;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BZ16_3 deposited with the ATCC under accession number 98264;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:102;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 102 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 102;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO: 101. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 101 from nucleotide 72 to nucleotide 569; the nucleotide sequence of the full-length protein coding sequence of clone BZ16 3 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BZ16_3 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BZ16 3 deposited with the ATCC under accession number 98264. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 102 from amino acid 1 to amino acid 124. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 102, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 102 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO: 102. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID

NO: 101 and SEQ ID NO: 100.

(aa) SEQ ID NO: 100;

(ab) SEQ ID NO : 101 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 101; and

(ac) the nucleotide sequence of the cDNA insert of clone BZ16 3 deposited with the ATCC under accession number 98264; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO: 100;

(bb) SEQ ID NO: 101 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:101; and

(be) the nucleotide sequence of the cDNA insert of clone BZ16_3 deposited with the ATCC under accession number 98264;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ED NO: 100 and SEQ ID NO: 101, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ED NO:100 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:101, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 101. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 101, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 101 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 101 , but excluding the poly( A) tail at the 3 ' end of SEQ ID NO: 101. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 101 from nucleotide 72 to nucleotide 569, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 101 from nucleotide 72 to nucleotide 569, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 101 from nucleotide 72 to nucleotide 569.

(a) the amino acid sequence of SEQ ED NO: 102;

(b) the amino acid sequence of SEQ ID NO: 102 from amino acid 1 to amino acid 124;

(c) a fragment of the amino acid sequence of SEQ ID NO: 102, the fragment comprising eight contiguous amino acids of SEQ ID NO: 102; and

(d) the amino acid sequence encoded by the cDNA insert of clone BZ16 3 deposited with the ATCC under accession number 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 102 or the amino acid sequence of SEQ ID NO: 102 from amino acid 1 to amino acid 124. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 102, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 102 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO: 102.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 103;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 103 from nucleotide 405 to nucleotide 662;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 103 from nucleotide 519 to nucleotide 662;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 103 from nucleotide 1 to nucleotide 584;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC182_1 deposited with the ATCC under accession number 98264;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC182 1 deposited with the ATCC under accession number 98264;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CC182 1 deposited with the ATCC under accession number 98264;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CC182 1 deposited with the ATCC under accession number 98264;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:104; (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 104 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ED NO: 104;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 103.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 103 from nucleotide 405 to nucleotide 662; the nucleotide sequence of SEQ ED NO: 103 from nucleotide 519 to nucleotide 662; the nucleotide sequence of SEQ ID NO: 103 from nucleotide 1 to nucleotide 584; the nucleotide sequence of the full-length protein coding sequence of clone CC182_1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone CC 182 1 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CC182_1 deposited with the ATCC under accession number 98264. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 104 from amino acid 1 to amino acid 60. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 104, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO: 104 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:104.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO: 103.

(aa) SEQ ID NO: 103 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:103; and

(ab) the nucleotide sequence of the cDNA insert of clone CC182_1 deposited with the ATCC under accession number 98264;

(ba) SEQ ID NO: 103, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:103; and (bb) the nucleotide sequence of the cDNA insert of clone CC182_1 deposited with the ATCC under accession number 98264; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 103, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 103 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 103 , but excluding the poly (A) tail at the 3 ' end of SEQ ED NO: 103. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO: 103 from nucleotide 405 to nucleotide 662, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 103 from nucleotide 405 to nucleotide 662, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 103 from nucleotide 405 to nucleotide 662. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 103 from nucleotide 519 to nucleotide 662, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 103 from nucleotide 519 to nucleotide 662, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ

ED NO: 103 from nucleotide 519 to nucleotide 662. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 103 from nucleotide 1 to nucleotide 584, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO: 103 from nucleotide 1 to nucleotide 584, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 103 from nucleotide 1 to nucleotide 584.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 104; (b) the amino acid sequence of SEQ ID NO: 104 from amino acid 1 to amino acid 60;

(c) a fragment of the amino acid sequence of SEQ ED NO: 104, the fragment comprising eight contiguous amino acids of SEQ ID NO: 104; and

(d) the amino acid sequence encoded by the cDNA insert of clone CC 182_1 deposited with the ATCC under accession number 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 104 or the amino acid sequence of SEQ ID NO: 104 from amino acid 1 to amino acid 60. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ED NO: 104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 104, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 104 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO: 104. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO: 105;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 105 from nucleotide 311 to nucleotide 409; (c) a polynucleotide comprising the nucleotide sequence of SEQ ED NO: 105 from nucleotide 24 to nucleotide 414;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CG109 1 deposited with the ATCC under accession number 98264; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CG109 1 deposited with the ATCC under accession number 98264;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CG109 1 deposited with the ATCC under accession number 98264; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CG109 1 deposited with the ATCC under accession number 98264;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:106;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 106 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 106;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified in (a)-(ι); and

(m) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO: 105.

Preferably, such polynucleotide compπses the nucleotide sequence of SEQ ID NO: 105 from nucleotide 311 to nucleotide 409, the nucleotide sequence of SEQ ID NO: 105 from nucleotide 24 to nucleotide 414; the nucleotide sequence of the full-length protein coding sequence of clone CG109_1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone CG109_1 deposited with the ATCC under accession number 98264 In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CG109 1 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ED NO.106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 106, or a polynucleotide encoding a protein compnsing a fragment of the ammo acid sequence of SEQ ED NO: 106 having biological activity, the fragment compπsing the ammo acid sequence from amino acid 11 to amino acid 20 of SEQ ID NO: 106. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ D

NO: 105.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (l) preparing one or more polynucleotide probes that hybπdize in 6X

(aa) SEQ ID NO: 105, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 105; and (ab) the nucleotide sequence of the cDNA insert of clone

CG109 1 deposited with the ATCC under accession number 98264; (n) hybridizing said probe(s) to human genomic DNA m conditions at least as stringent as 4X SSC at 50 degrees C; and

(m) isolating the DNA polynucleotides detected with the probe(s); and (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ IDNO:105, butexcludingthe poly(A) tail atthe 3' end of SEQ ID NO: 105; and

(bb) the nucleotide sequence of the cDNA insert of clone CG109 1 deposited with the ATCC under accession number 98264; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ED NO: 105, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ED NO: 105 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 105 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 105. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 105 from nucleotide 311 to nucleotide 409, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ED NO: 105 fromnucleotide 311 to nucleotide

409, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 105 from nucleotide 311 to nucleotide 409. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ

ID NO: 105 from nucleotide 24 to nucleotide 414, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 105 from nucleotide 24 to nucleotide 414, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 105 from nucleotide 24 to nucleotide 414.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ED NO: 106;

(b) a fragment of the amino acid sequence of SEQ ID NO: 106, the fragment comprising eight contiguous amino acids of SEQ ID NO: 106; and

(c) the amino acid sequence encoded by the cDNA insert of clone CG109 1 deposited with the ATCC under accession number 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 106. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ED NO: 106, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 106 having biological activity, the fragment comprising the amino acid sequence from amino acid 11 to amino acid 20 of SEQ ID NO: 106.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 108;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 108 from nucleotide 471 to nucleotide 611;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CJ397_1 deposited with the ATCC under accession number 98264;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CJ397_1 deposited with the ATCC under accession number 98264;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CJ397 1 deposited with the ATCC under accession number

98264;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CJ397_1 deposited with the ATCC under accession number 98264;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:109;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 109 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 109;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO: 108.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 108 from nucleotide 471 to nucleotide 611, the nucleotide sequence of the full-length protein coding sequence of clone CJ397 1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone CJ397 1 deposited with the

ATCC under accession number 98264 In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CJ397_1 deposited with the ATCC under accession number 98264. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO.109 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ

ID NOT 09, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 109 having biological activity, the fragment compπsing the amino acid sequence from amino acid 18 to amino acid 27 of SEQ ED NO: 109.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO: 108, SEQ ID NO: 107, and SEQ ID NOT 10 .

(a) a process comprising the steps of:

(l) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 107;

(ab) SEQ ID NO: 108;

(ac) SEQ ID NO: 110, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO 110, and

(ad) the nucleotide sequence of the cDNA insert of clone CJ397 1 deposited with the ATCC under accession number 98264;

(n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and (b) a process comprising the steps of: (i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO: 107; (bb) SEQ ID NO: 108;

(be) SEQ ID NO: 110, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:110; and

(bd) the nucleotide sequence of the cDNA insert of clone CJ397 1 deposited with the ATCC under accession number 98264; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequences of SEQ ID NO:107, SEQ ID NO:108, and SEQ

ID NO: 110, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 107 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 110, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 110. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 108, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 108 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 108. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 108 from nucleotide 471 to nucleotide 611, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 108 from nucleotide 471 to nucleotide

611, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ED NO:108 from nucleotide 471 to nucleotide 611.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 109;

(b) a fragment of the amino acid sequence of SEQ ED NO : 109, the fragment comprising eight contiguous amino acids of SEQ ID NO: 109; and

(c) the amino acid sequence encoded by the cDNA insert of clone CJ397_1 deposited with the ATCC under accession number 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 109. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 109 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 109, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 109 having biological activity, the fragment comprising the amino acid sequence from amino acid 18 to amino acid 27 of SEQ ID NO: 109.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO: 111;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 111 from nucleotide 141 to nucleotide 1532;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ED NO: 111 from nucleotide 204 to nucleotide 1532;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ED NO: 111 from nucleotide 78 to nucleotide 476;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AM795 4 deposited with the ATCC under accession number 98271;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AM795 4 deposited with the ATCC under accession number 98271;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 112; (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 112 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 112;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (l) or (j) above ;

(m) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 111.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ED NO: 111 from nucleotide 141 to nucleotide 1532, the nucleotide sequence of SEQ ID NO:l l l from nucleotide 204 to nucleotide 1532; the nucleotide sequence of SEQ ED NO: 111 from nucleotide 78 to nucleotide 476; the nucleotide sequence of the full-length protein coding sequence of clone AM795 4 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone AM795_4 deposited with the ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AM795 4 deposited with the ATCC under accession number 98271. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 112 from ammo acid 1 to ammo acid 112. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO : 112 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 112, or a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NO: 112 having biological activity, the fragment comprising the amino acid sequence from amino acid 227 to ammo acid 236 of SEQ ID NO: 112. Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID

NO:l l l.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (I) preparing one or more polynucleotide probes that hybπdize in 6X

(aa) SEQ ID NO: 111 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT l l; and (ab) the nucleotide sequence of the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 111 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:l l l; and

(bb) the nucleotide sequence of the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 111, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO:l l l to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 111 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 111. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 111 from nucleotide 141 to nucleotide 1532, and extending contiguously from a nucleotide sequence coπesponding to the 5 ' end of said sequence of SEQ ID NO : 111 from nucleotide 141 to nucleotide 1532, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 111 from nucleotide 141 to nucleotide 1532. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: l l l from nucleotide 204 to nucleotide 1532, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO:l l l from nucleotide 204 to nucleotide 1532, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO:l l l from nucleotide 204 to nucleotide 1532. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 111 from nucleotide 78 to nucleotide 476, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 111 from nucleotide 78 to nucleotide 476, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ED NO: 111 from nucleotide 78 to nucleotide 476. In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 112;

(b) the amino acid sequence of SEQ ID NO: 112 from amino acid 1 to amino

(c) a fragment of the ammo acid sequence of SEQ ED NO: 112, the fragment compπsing eight contiguous ammo acids of SEQ ID NO: 112; and

(d) the amino acid sequence encoded by the cDNA insert of clone AM795 4 deposited with the ATCC under accession number 98271; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO.112 or the amino acid sequence of SEQ ID NO: 112 from amino acid 1 to amino acid 112. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 112 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ED NO: 112, or a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 112 having biological activity, the fragment comprising the amino acid sequence from ammo acid 227 to ammo acid 236 of SEQ ID NO: 112.

In one embodiment, the present invention provides a composition compπsing an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 114;

(b) a polynucleotide compπsing the nucleotide sequence of SEQ ED NO: 114 from nucleotide 19 to nucleotide 262;

(c) a polynucleotide compπsing the nucleotide sequence of SEQ ED NO: 114 from nucleotide 91 to nucleotide 262; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AT340 1 deposited with the ATCC under accession number 98271;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AT340_1 deposited with the ATCC under accession number 98271; (f) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone AT340 1 deposited with the ATCC under accession number 98271;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AT340 1 deposited with the ATCC under accession number 98271 ;

(h) a polynucleotide encoding a protein compπsing the amino acid sequence of SEQ ID NO.115;

(I) a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO.115 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 115;

(J) a polynucleotide which is an allehc vaπant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (l) above ; (1) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified in (a)-(ι); and

(m) a polynucleotide that hybπdizes under stnngent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO: 114 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 114 from nucleotide 19 to nucleotide 262, the nucleotide sequence of SEQ ID NO: 114 from nucleotide

91 to nucleotide 262; the nucleotide sequence of the full-length protein coding sequence of clone

AT340_1 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone AT340 1 deposited with the ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AT340_1 deposited with the ATCC under accession number 98271. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 115 from amino acid 1 to amino acid 66. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ

ID NO: 115 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NOT 15, or a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ED NO: 115 having biological activity, the fragment comprising the ammo acid sequence from amino acid 35 to ammo acιd 44 of SEQ ID NO:115 Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 114 and SEQ ID NO: 113.

(i) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ED NOT 13; (ab) SEQ ID NO: 114, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 114; and

(ac) the nucleotide sequence of the cDNA insert of clone AT340_1 deposited with the ATCC under accession number 98271; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NOT 13;

(bb) SEQ ID NO: 114, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 114; and (be) the nucleotide sequence of the cDNA insert of clone

AT340_1 deposited with the ATCC under accession number 98271; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequences of SEQ ID NO: 113 and SEQ ID NO: 114, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ED NO: 113 to a nucleotide sequence coπesponding to the 3' end of SEQ ED NO: 114, but excluding the poly(A) tail at the 3' end of SEQ ID NOT 14. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO 114, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO- 114 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 114, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 114. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT 14 from nucleotide 19 to nucleotide 262, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO.114 from nucleotide 19 to nucleotide 262, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 114 from nucleotide 19 to nucleotide 262. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 114 from nucleotide 91 to nucleotide 262, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NOT 14 from nucleotide 91 to nucleotide 262, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ED NOT 14 from nucleotide 91 to nucleotide 262.

In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of.

(a) the ammo acid sequence of SEQ ID NO: 115;

(b) the ammo acid sequence of SEQ ID NO: 115 from amino acid 1 to ammo acid 66;

(c) a fragment of the ammo acid sequence of SEQ ID NO : 115 , the fragment compπsing eight contiguous ammo acids of SEQ ID NO.115; and

(d) the ammo acid sequence encoded by the cDNA insert of clone AT340_1 deposited with the ATCC under accession number 98271; the protein being substantially free from other mammalian proteins. Preferably such protein compnses the amino acid sequence of SEQ ID NOT 15 or the ammo acid sequence of SEQ ID NOT 15 from amino acid 1 to amino acid 66. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 115 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NOT 15, or a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 115 having biological activity, the fragment compπsing the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NOT 15.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide compπsing the nucleotide sequence of SEQ ED NO: 116;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 116 from nucleotide 2 to nucleotide 601,

(c) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 116 from nucleotide 401 to nucleotide 601 ;

(d) a polynucleotide compπsing the nucleotide sequence of the full-length protein coding sequence of clone BG132_1 deposited with the ATCC under accession number 98271;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG 132_1 deposited with the ATCC under accession number 98271 ;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG132 1 deposited with the ATCC under accession number 98271;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271;

(h) a polynucleotide encoding a protein compπsing the ammo acid sequence of SEQ ID NO:117;

(l) a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NOT 17 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 117;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (l) above ; (1) a polynucleotide that hybridizes under stπngent conditions to any one of the polynucleotides specified in (a)-(ι); and

(m) a polynucleotide that hybridizes under stπngent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO.116 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 116 from nucleotide 2 to nucleotide 601 ; the nucleotide sequence of SEQ ID NO: 116 from nucleotide 401 to nucleotide 601 ; the nucleotide sequence of the full-length protein coding sequence of clone BG132_1 deposited with the ATCC under accession number 98271, or the nucleotide sequence of a mature protein coding sequence of clone BGl 32 1 deposited with the ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO.117 from amino acid 119 to amino acid 200. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 117 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 117, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 117 having biological activity, the fragment comprising the amino acid sequence from amino acid 95 to ammo acid 104 of SEQ ID NOT 17

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NOT 16 and SEQ ID NO 118.

(1) preparing one or more polynucleotide probes that hybridize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of.

(aa) SEQ ID NO: 116; (ab) SEQ ID NOT 18, but excluding the poly(A) tail at the 3' end of SEQ ID NO.118; and

(ac) the nucleotide sequence of the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271, (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s), and

(b) a process comprising the steps of.

(0 preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO.116;

(bb) SEQ ID NO.118, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT 18; and (bc) the nucleotide sequence of the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271, (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(ιu). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequences of SEQ ID NO: 116 and SEQ ID NOT 18, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 1 16 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO¹1 18, but excluding the poly(A) tail at the 3' end of SEQ ID NOT 18. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 116, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NOT 16 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NOT 16 Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT 16 from nucleotide 2 to nucleotide 601, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO' 116 from nucleotide 2 to nucleotide 601, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 116 from nucleotide 2 to nucleotide 601. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT 16 from nucleotide 401 to nucleotide 601, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 116 from nucleotide 401 to nucleotide 601, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 116 from nucleotide 401 to nucleotide 601.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 117;

(b) the amino acid sequence of SEQ ID NOT 17 from ammo acid 119 to

(c) a fragment of the amino acid sequence of SEQ ID NO: 117, the fragment comprising eight contiguous ammo acids of SEQ ID NOT 17; and

(d) the ammo acid sequence encoded by the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO.l 17 or the amino acid sequence of SEQ ID NO- 117 from amino acid 119 to amino acid 200. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 117 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 117, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO 117 having biological activity, the fragment comprising the amino acid sequence from amino acid 95 to ammo acid 104 of SEQ ID NOT 17. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 119;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO¹119 from nucleotide 225 to nucleotide 701 ; (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG219_2 deposited with the ATCC under accession number 98271,

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG219_2 deposited with the ATCC under accession number 98271; (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG219_2 deposited with the ATCC under accession number

98271 ;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG219_2 deposited with the ATCC under accession number 98271; (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:120;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO.120 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NOT20; (I) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(f) above;

(k) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NOT 19.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 119 from nucleotide 225 to nucleotide 701 ; the nucleotide sequence of the full-length protein coding sequence of clone BG219_2 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone BG219_2 deposited with the

ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG219_2 deposited with the ATCC under accession number 98271. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 120 from amino acid 1 to amino acid 97. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 120 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 120, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 120 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to ammo acid 83 of SEQ ID NO: 120.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NOT 19.

(1) prepanng one or more polynucleotide probes that hybπdize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO .119, but excluding the poly( A) tail at the 3 ' end of SEQ ID NOT 19; and

(ab) the nucleotide sequence of the cDNA insert of clone BG219_2 deposited with the ATCC under accession number 98271;

(π) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and (b) a process comprising the steps of: (1) prepaπng one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO: 119, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 119; and

(bb) the nucleotide sequence of the cDNA insert of clone BG219_2 deposited with the ATCC under accession number 98271; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(ιn). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 1 19, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NOT 19 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 1 19 , but excluding the poly (A) tail at the 3 ' end of SEQ ID NOT 19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 119 from nucleotide 225 to nucleotide 701, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 1 19 from nucleotide 225 to nucleotide 701, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 119 from nucleotide 225 to nucleotide 701.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the ammo acid sequence of SEQ ID NO: 120; (b) the amino acid sequence of SEQ ID NO: 120 from amino acid 1 to ammo

(c) a fragment of the ammo acid sequence of SEQ ID NO: 120, the fragment compπsing eight contiguous ammo acids of SEQ ID NO: 120; and

(d) the amino acid sequence encoded by the cDNA insert of clone BG219_2 deposited with the ATCC under accession number 98271; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 120 or the amino acid sequence of SEQ ID NO: 120 from amino acid 1 to amino acid 97. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 120 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NOT 20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NOT 20 having biological activity, the fragment compπsing the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO.120 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 121 ;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 121 from nucleotide 2115 to nucleotide 2510; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO' 121 from nucleotide 1 to nucleotide 324;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG366_2 deposited with the ATCC under accession number 98271; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271;

(f) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone BG366_2 deposited with the ATCC under accession number 98271; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 122;

(I) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NOT 22 having biological activity, the fragment compπsing eight contiguous ammo acids of SEQ ID NO: 122;

(J) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (1) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι); and

(m) a polynucleotide that hybridizes under stπngent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO: 121. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 121 from nucleotide 2115 to nucleotide 2510; the nucleotide sequence of SEQ ID NO: 121 from nucleotide 1 to nucleotide 324, the nucleotide sequence of the full-length protein coding sequence of clone BG366_2 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone BG366_2 deposited with the ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 122 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 122, or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 122 having biological activity, the fragment comprising the ammo acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO: 122. Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID

NOT21.

(a) a process comprising the steps of: (l) prepaπng one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO: 121 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT21; and (ab) the nucleotide sequence of the cDNA insert of clone

BG366_2 deposited with the ATCC under accession number 98271; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(l) preparing one or more polynucleotide primers that hybridize in

6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO .121 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT21; and

(bb) the nucleotide sequence of the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(m).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 121, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NOT21 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NOT 21 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 121. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 121 from nucleotide 2115 to nucleotide 2510, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 121 from nucleotide 2115 to nucleotide 2510, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ

ID NO: 121 from nucleotide 2115 to nucleotide 2510. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 121 from nucleotide 1 to nucleotide 324, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 121 from nucleotide 1 to nucleotide 324, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT21 from nucleotide 1 to nucleotide 324.

(a) the amino acid sequence of SEQ ID NO: 122;

(b) a fragment of the amino acid sequence of SEQ ID NO: 122, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 122; and

(c) the amino acid sequence encoded by the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 122. In further prefeπed embodiments, the present invention provides a protein compπsing a fragment of the amino acid sequence of SEQ ID NO.122 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 122, or a protein compπsing a fragment of the ammo acid sequence of SEQ ID NOT22 having biological activity, the fragment comprising the ammo acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO: 122.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 123 ;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NOT 23 from nucleotide 27 to nucleotide 215;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 123 from nucleotide 27 to nucleotide 181;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV172_2 deposited with the ATCC under accession number 98271 ;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV172_2 deposited with the ATCC under accession number 98271 ,

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV172_2 deposited with the ATCC under accession number 98271 ;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV172_2 deposited with the ATCC under accession number 98271,

(h) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 124;

(l) a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 124 having biological activity, the fragment compπsing eight contiguous ammo acids of SEQ ID NO: 124;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (l) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO 123. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 123 from nucleotide 27 to nucleotide 215; the nucleotide sequence of SEQ ID NOT23 from nucleotide 27 to nucleotide 181 ; the nucleotide sequence of the full-length protein coding sequence of clone BV172_2 deposited with the ATCC under accession number 98271 ; or the nucleotide sequence of a mature protein coding sequence of clone BVl 72_2 deposited with the ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV172_2 deposited with the ATCC under accession number 98271. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 124 from ammo acid 1 to amino acid 51. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 124, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 124 having biological activity, the fragment comprising the ammo acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO: 124.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NOT23.

(a) a process comprising the steps of:

(l) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 123 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT23; and

(ab) the nucleotide sequence of the cDNA insert of clone BV172_2 deposited with the ATCC under accession number 98271; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of: (1) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO: 123, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 123; and

(bb) the nucleotide sequence of the cDNA insert of clone BV172_2 deposited with the ATCC under accession number 98271; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(nι). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 123, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 123 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 123 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT23. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 123 from nucleotide 27 to nucleotide 215, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 123 from nucleotide 27 to nucleotide 215, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 123 from nucleotide 27 to nucleotide 215. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 123 from nucleotide 27 to nucleotide 181, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 123 from nucleotide 27 to nucleotide 181 , to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID

NO: 123 from nucleotide 27 to nucleotide 181.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 124; (b) the amino acid sequence of SEQ ID NO: 124 from ammo acid 1 to ammo

(c) a fragment of the ammo acid sequence of SEQ ID NO: 124, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 124; and

(d) the amino acid sequence encoded by the cDNA insert of clone B V 172_2 deposited with the ATCC under accession number 98271 ; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 124 or the amino acid sequence of SEQ ID NO: 124 from amino acid 1 to amino acid 51. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 124, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 124 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to ammo acid 35 of SEQ ID NO: 124. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 125 ;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 125 from nucleotide 338 to nucleotide 409; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 125 from nucleotide 362 to nucleotide 409;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 125 from nucleotide 270 to nucleotide 419;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC247_10 deposited with the ATCC under accession number 98271,

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CC247_10 deposited with the ATCC under accession number

98271;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271;

(I) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NOT26;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 126 having biological activity, the fragment compπsing eight contiguous amino acids of SEQ ID NO: 126;

(k) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(h) above, (1) a polynucleotide which encodes a species homologue of the protein of (I) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 125.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NOT 25 from nucleotide 338 to nucleotide 409; the nucleotide sequence of SEQ ID NO: 125 from nucleotide 362 to nucleotide 409; the nucleotide sequence of SEQ ID NO: 125 from nucleotide

270 to nucleotide 419; the nucleotide sequence of the full-length protein coding sequence of clone

CC247_10 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone CC247_10 deposited with the ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone CC247_10 deposited with the

ATCC under accession number 98271. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 126, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID

NO: 126 having biological activity, the fragment compπsing the amino acid sequence from ammo acid 7 to amino acid 16 of SEQ ID NO: 126.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 125. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process compπsing the steps of:

(I) prepanng one or more polynucleotide probes that hybπdize in 6X

(aa) SEQ ID NO: 125, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 125; and

(ab) the nucleotide sequence of the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and (b) a process comprising the steps of:

(I) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO: 125, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT25; and

(bb) the nucleotide sequence of the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(ιπ). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 125, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 125 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 125 , but excluding the poly(A) tail at the 3' end of SEQ ID NOT 25. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 125 from nucleotide 338 to nucleotide 409, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 125 from nucleotide 338 to nucleotide 409, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 125 from nucleotide 338 to nucleotide 409. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 125 from nucleotide 362 to nucleotide 409, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 125 from nucleotide 362 to nucleotide 409, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ

ID NO: 125 from nucleotide 362 to nucleotide 409. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT 25 from nucleotide 270 to nucleotide 419, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 125 from nucleotide 270 to nucleotide 419, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT25 from nucleotide 270 to nucleotide 419.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 126;

(b) a fragment of the amino acid sequence of SEQ ID NO: 126, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 126; and

(c) the amino acid sequence encoded by the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271 ; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the ammo acid sequence of SEQ ID NO: 126. In further prefeπed embodiments, the present invention provides a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 126, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO : 126 having biological activity, the fragment comprising the amino acid sequence from ammo acid 7 to amino acid 16 of SEQ ID NO: 126.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 127;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 127 from nucleotide 128 to nucleotide 1600;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 127 from nucleotide 281 to nucleotide 1600; (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 127 from nucleotide 62 to nucleotide 373;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CI480_9 deposited with the ATCC under accession number 98271; (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CI480_9 deposited with the ATCC under accession number 98271; (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271;

(l) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NOT28; (j) a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 128 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO.128;

(k) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (l) or (j) above ;

(n) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 127

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 127 from nucleotide 128 to nucleotide 1600; the nucleotide sequence of SEQ ID NOT27 from nucleotide 281 to nucleotide 1600; the nucleotide sequence of SEQ ID NO: 127 from nucleotide 62 to nucleotide 373; the nucleotide sequence of the full-length protein coding sequence of clone CI480_9 deposited with the ATCC under accession number 98271 ; or the nucleotide sequence of a mature protein coding sequence of clone CI480_9 deposited with the ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NOT 28 from amino acid 1 to ammo acid 82. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 128 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 128, or a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 128 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO: 128.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 127. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(1) preparing one or more polynucleotide probes that hybπdize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO: 127, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 127; and

(ab) the nucleotide sequence of the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271 ;

(I) preparing one or more polynucleotide primers that hybπdize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NOT 27, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT27; and

(bb) the nucleotide sequence of the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 127, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 127 to a nucleotide sequence coπespondmg to the 3' end of SEQ ID NO: 127 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 127. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 127 from nucleotide 128 to nucleotide 1600, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 127 from nucleotide 128 to nucleotide 1600, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 127 from nucleotide 128 to nucleotide 1600. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 127 from nucleotide 281 to nucleotide 1600, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 127 from nucleotide 281 to nucleotide 1600, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 127 from nucleotide 281 to nucleotide 1600. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 127 from nucleotide 62 to nucleotide 373, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NOT27 from nucleotide 62 to nucleotide 373, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 127 from nucleotide 62 to nucleotide 373.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 128;

(b) the amino acid sequence of SEQ ID NO: 128 from amino acid 1 to ammo acid 82;

(c) a fragment of the amino acid sequence of SEQ ID NO: 128, the fragment comprising eight contiguous amino acids of SEQ ID NO: 128; and (d) the amino acid sequence encoded by the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 128 or the amino acid sequence of SEQ ID

NO: 128 from ammo acid 1 to amino acid 82. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID

NOT28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 128, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 128 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO: 128.

(a) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 129;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 129 from nucleotide 383 to nucleotide 3958; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 129 from nucleotide 470 to nucleotide 3958;

(d) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO¹129 from nucleotide 271 to nucleotide 488, (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone C0722_l deposited with the ATCC under accession number 98271 ;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone C0722_l deposited with the ATCC under accession number 98271; (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone C0722 1 deposited with the ATCC under accession number 98271;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone C0722_l deposited with the ATCC under accession number 98271; (I) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NOT30;

(j) a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NOT30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO' 130; (k) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(h) above;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 129. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 129 from nucleotide 383 to nucleotide 3958; the nucleotide sequence of SEQ ID NO: 129 from nucleotide 470 to nucleotide 3958; the nucleotide sequence of SEQ ID NO: 129 from nucleotide 271 to nucleotide 488; the nucleotide sequence of the full-length protein coding sequence of clone C0722_l deposited with the ATCC under accession number 98271 ; or the nucleotide sequence of a mature protein coding sequence of clone C0722_l deposited with the ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone C0722_l deposited with the ATCC under accession number 98271. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 130 from amino acid 1 to ammo acid 34. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 130 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 130, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 130 having biological activity, the fragment comprising the amino acid sequence from amino acid 591 to amino acid 600 of SEQ ID NO: 130.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 129.

(aa) SEQ ID NO: 129, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT29; and

(ab) the nucleotide sequence of the cDNA insert of clone C0722_l deposited with the ATCC under accession number 98271; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(I) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO: 129, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 129; and

(bb) the nucleotide sequence of the cDNA insert of clone C0722_l deposited with the ATCC under accession number 98271; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(ιn). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 129, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 129 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 129 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 129. Also preferably the polynucleotide isolated according to the above process comprises anucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 129 from nucleotide 383 to nucleotide 3958, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 129 from nucleotide 383 to nucleotide

3958, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT29 from nucleotide 383 to nucleotide 3958. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of

SEQ ID NO: 129 from nucleotide 470 to nucleotide 3958, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 129 from nucleotide 470 to nucleotide 3958, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 129 from nucleotide 470 to nucleotide 3958. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 129 from nucleotide 271 to nucleotide 488, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 129 from nucleotide 271 to nucleotide 488, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 129 from nucleotide 271 to nucleotide 488.

In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 130;

(b) the amino acid sequence of SEQ ID NO.130 from ammo acid 1 to ammo

(c) a fragment of the ammo acid sequence of SEQ ID NO: 130, the fragment comprising eight contiguous amino acids of SEQ ID NO: 130; and

(d) the amino acid sequence encoded by the cDNA insert of clone C0722_l deposited with the ATCC under accession number 98271; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 130 or the amino acid sequence of SEQ ID NO.130 from ammo acid 1 to amino acid 34. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NOT 30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 130, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 130 having biological activity, the fragment comprising the ammo acid sequence from amino acid 591 to amino acid 600 of SEQ ID NO: 130. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 131 ;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 131 from nucleotide 914 to nucleotide 2353, (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO.131 from nucleotide 1793 to nucleotide 2353;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO- 131 from nucleotide 1037 to nucleotide 1260;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CT748_2 deposited with the ATCC under accession number 98271;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CT748_2 deposited with the ATCC under accession number

98271;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271 ;

(l) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NOT32;

(j) a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NOT 32 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 132;

(k) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (1) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and (n) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-( ) and that has a length that is at least 25% of the length of SEQ ID NO: 131.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 131 from nucleotide 914 to nucleotide 2353; the nucleotide sequence of SEQ ID NO: 131 from nucleotide 1793 to nucleotide 2353, the nucleotide sequence ofSEQ ID NO: 131 from nucleotide 1037 to nucleotide 1260; the nucleotide sequence of the full-length protein coding sequence of clone CT748_2 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone CT748_2 deposited with the ATCC under accession number 98271. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NOT32 from ammo acid 22 to ammo acid 1 16. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 132 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 132, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 132 having biological activity, the fragment comprising the amino acid sequence from amino acid 234 to amino acid 243 of SEQ ID NO: 132. Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID

NO.131

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of

(aa) SEQ ID NO: 131 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 131; and (ab) the nucleotide sequence of the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271; (n) hybridizing said probe(s) to human genomic DNA m conditions at least as stπngent as 4X SSC at 50 degrees C; and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of.

(l) preparing one or more polynucleotide primers that hybπdize m 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO: 131 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT31; and

(bb) the nucleotide sequence of the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences, and (IV) isolating the polynucleotide products of step (b)(ιπ). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 131, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 131 to a nucleotide sequence coπespondmg to the 3' end of SEQ ID NO: 131 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 131. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO' 131 from nucleotide 914 to nucleotide 2353, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 131 from nucleotide 914 to nucleotide 2353, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT31 from nucleotide 914 to nucleotide 2353. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 131 from nucleotide 1793 to nucleotide 2353, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO.131 from nucleotide 1793 to nucleotide 2353, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT31 from nucleotide 1793 to nucleotide 2353 Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 131 from nucleotide 1037 to nucleotide 1260, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NOT31 from nucleotide 1037 to nucleotide 1260, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 131 from nucleotide 1037 to nucleotide 1260. In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of.

(a) the amino acid sequence of SEQ ID NO: 132;

(b) the amino acid sequence of SEQ ID NO: 132 from ammo acid 22 to amino

(c) a fragment of the amino acid sequence of SEQ ID NOT32, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 132; and

(d) the amino acid sequence encoded by the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271; the protein being substantially free from other mammalian proteins Preferably such protein comprises the ammo acid sequence of SEQ ID NOT 32 or the amino acid sequence of SEQ ID

NO.132 from amino acid 22 to ammo acid 116. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID

NO: 132 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NOT32, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO.132 having biological activity, the fragment comprising the amino acid sequence from ammo acid 234 to ammo acid 243 of SEQ

ID NO 32

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO T 33 ,

(b) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO.133 from nucleotide 22 to nucleotide 462,

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ1_1 deposited with the ATCC under accession number 98278,

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278,

(e) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone AJ1_1 deposited with the ATCC under accession number 98278, (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278;

(g) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 134; (h) a polynucleotide encoding a protein compnsing a fragment of the amino acid sequence of SEQ ID NO: 134 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NOT 34;

(l) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; (j) ^a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(1) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO: 133.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NOT 33 from nucleotide 22 to nucleotide 462, the nucleotide sequence of the full-length protein coding sequence of clone AJ1_1 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone AJ1_1 deposited with the ATCC under accession number 98278 In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing the amino acid sequence of SEQ ID NO: 134 from amino acid 52 to ammo acid 147. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 134 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 134, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 134 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 68 to amino acid 77 of SEQ ID NO: 134.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 133 and SEQ ID NO 35.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process compπsing the steps of:

(1) prepaπng one or more polynucleotide probes that hybπdize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 133;

(ab) SEQ ID NO T 35 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT35; and

(ac) the nucleotide sequence of the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278; (π) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of: (l) prepaπng one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO: 133;

(bb) SEQ ID NO.135, but excluding the poly(A) tail at the 3 ' end of SEQ ID N0.135; and

(be) the nucleotide sequence of the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C; (m) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(ιn) Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequences of SEQ ID NO: 133 and SEQ ID NOT35, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 133 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 135, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 135. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 133, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO.133 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO.133 Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 133 from nucleotide 22 to nucleotide 462, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NOT33 from nucleotide 22 to nucleotide 462, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 133 from nucleotide 22 to nucleotide 462.

(a) the ammo acid sequence of SEQ ID NO : 134;

(b) the amino acid sequence of SEQ ID NO: 134 from amino acid 52 to amino

(c) a fragment of the amino acid sequence of SEQ ID NO : 134, the fragment compπsing eight contiguous amino acids of SEQ ID NO: 134; and

(d) the amino acid sequence encoded by the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO.134 or the ammo acid sequence of SEQ ID NO: 134 from amino acid 52 to ammo acid 147 In further prefeπed embodiments, the present invention provides a protein compπsing a fragment of the amino acid sequence of SEQ ID NO: 134 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 134, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 134 having biological activity, the fragment comprising the amino acid sequence from ammo acid 68 to ammo acid 77 of SEQ ID NO: 134.

(a) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO : 136;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO.136 from nucleotide 7 to nucleotide 1647;

(c) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 136 from nucleotide 1 to nucleotide 305,

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AQ73_3 deposited with the ATCC under accession number 98278;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278; (f) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone AQ73_3 deposited with the ATCC under accession number 98278;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278;

(h) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NOT37;

(l) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 137 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 137;

(m) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO: 136. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 136 from nucleotide 7 to nucleotide 1647; the nucleotide sequence of SEQ ID NO: 136 from nucleotide 1 to nucleotide 305; the nucleotide sequence of the full-length protein coding sequence of clone AQ73_3 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone AQ73_3 deposited with the ATCC under accession number 98278. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 137 from amino acid 1 to amino acid 68. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 137 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 137, or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 137 having biological activity, the fragment compπsing the ammo acid sequence from amino acid 268 to ammo acid 277 of SEQ ID NO: 137. Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NOT36.

(0 preparing one or more polynucleotide probes that hybπdize in 6X

(aa) SEQ ID NO.136, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO. 36; and

(ab) the nucleotide sequence of the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process compπsing the steps of:

(l) prepaπng one or more polynucleotide primers that hybridize m 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO- 136, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 136; and

(bb) the nucleotide sequence of the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278, (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 136, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NOT 36 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO.136 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 136. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 136 from nucleotide 7 to nucleotide 1647, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 136 from nucleotide 7 to nucleotide 1647, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 136 from nucleotide 7 to nucleotide 1647. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT36 from nucleotide 1 to nucleotide 305, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 136 from nucleotide 1 to nucleotide 305, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 136 from nucleotide 1 to nucleotide 305.

(a) the ammo acid sequence of SEQ ID NOT 37;

(b) the ammo acid sequence of SEQ ID NOT 37 from amino acid 1 to amino

(c) a fragment of the amino acid sequence of SEQ ID NO: 137, the fragment comprising eight contiguous amino acids of SEQ ID NO: 137; and

(d) the amino acid sequence encoded by the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the ammo acid sequence of SEQ ID NO: 137 or the amino acid sequence of SEQ ID NOT 37 from amino acid 1 to ammo acid 68. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 137 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO 37, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO- 137 having biological activity, the fragment compπsing the ammo acid sequence from amino acid 268 to amino acid 277 of SEQ

ID NO: 137

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 138; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 138 from nucleotide 62 to nucleotide 757;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 138 from nucleotide 357 to nucleotide 703; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG142_1 deposited with the ATCC under accession number 98278;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG142_1 deposited with the ATCC under accession number 98278;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278;

(h) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO 139;

(I) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO 39 having biological activity, the fragment compπsing eight contiguous amino acids of SEQ ID NO: 139;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (l) above , (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified m (a)-(ι), and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NOT38. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 138 from nucleotide 62 to nucleotide 757; the nucleotide sequence of SEQ ID NO.138 from nucleotide 357 to nucleotide 703; the nucleotide sequence of the full-length protein coding sequence of clone BG142_1 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone BG142_1 deposited with the ATCC under accession number 98278. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO.139 from amino acid 184 to ammo acid 214 In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NO: 139 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 139, or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 139 having biological activity, the fragment comprising the amino acid sequence from amino acid 1 11 to amino acid 120 of SEQ ID NO: 139.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NOT38.

(I) prepaπng one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NOT38, but excluding the ρoly(A) tail at the 3 ' end of SEQ ID NO: 138; and

(ab) the nucleotide sequence of the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278, (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (m) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of.

(I) prepaπng one or more polynucleotide primers that hybπdize m

(ba) SEQ ID NO: 138, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:138; and

(bb) the nucleotide sequence of the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278; (n) hybridizing saιdpπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C,

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT38, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NOT38 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 138 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 138. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 138 from nucleotide 62 to nucleotide 757, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 138 from nucleotide 62 to nucleotide 757, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT38 from nucleotide 62 to nucleotide 757. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 138 from nucleotide 357 to nucleotide 703, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NOT38 from nucleotide 357 to nucleotide 703, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 138 from nucleotide 357 to nucleotide 703.

(a) the ammo acid sequence of SEQ ID NOT 39;

(b) the amino acid sequence of SEQ ID NO: 139 from amino acid 184 to ammo acid 214,

(c) a fragment of the amino acid sequence of SEQ ID NO: 139, the fragment comprising eight contiguous amino acids of SEQ ID NO: 139; and

(d) the amino acid sequence encoded by the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NOT39 or the amino acid sequence of SEQ ID NO: 139 from amino acid 184 to ammo acid 214. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 139 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 139, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO T 39 having biological activity, the fragment comprising the amino acid sequence from amino acid 11 1 to ammo acid 120 of SEQ

ID NO: 139

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO- 140; (b) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 140 from nucleotide 404 to nucleotide 535;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 140 from nucleotide 1 to nucleotide 666; (d) a polynucleotide compπsing the nucleotide sequence of the full-length protein coding sequence of clone BV66_1 deposited with the ATCC under accession number 98278;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV66_1 deposited with the ATCC under accession number 98278;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278; (h) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NOT41;

(I) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 141 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 141, (]) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (l) above ;

(m) a polynucleotide that hybridizes under stπngent conditions to any one of the polynucleotides specified m (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO.140 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO.140 from nucleotide 404 to nucleotide 535; the nucleotide sequence of SEQ ID NO: 140 from nucleotide 1 to nucleotide 666; the nucleotide sequence of the full-length protein coding sequence of clone BV66_1 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone BV66_1 deposited with the ATCC under accession number 98278. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 141 from ammo acid 1 to amino acid 38. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 141 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 141 , or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 141 having biological activity, the fragment comprising the ammo acid sequence from amino acid 17 to amino acid 26 of SEQ ID NOT41. Other embodiments provide the gene coπespondmg to the cDNA sequence of SEQ ID

NO: 140.

(a) a process comprising the steps of: (I) prepaπng one or more polynucleotide probes that hybπdize m6X

(aa) SEQ ID NO : 140, but excluding the poly (A) tail at the 3 ' end of SEQ ID NO: 140; and (ab) the nucleotide sequence of the cDNA insert of clone

BV66_1 deposited with the ATCC under accession number 98278; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(I) preparing one or more polynucleotide primers that hybridize in

6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO: 140, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 140; and

(bb) the nucleotide sequence of the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C; (m) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(ιn). Preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT40, and extending contiguously from a nucleotide sequence coπespondmg to the 5' end of SEQ ID NO: 140 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 140 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 140. Also preferably the polynucleotide isolated according to the above process compπses anucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 140 from nucleotide 404 to nucleotide 535, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 140 from nucleotide 404 to nucleotide 535, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 140 from nucleotide 404 to nucleotide 535. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 140 from nucleotide 1 to nucleotide 666, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 140 from nucleotide 1 to nucleotide 666, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 140 from nucleotide 1 to nucleotide 666.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein compπses an amino acid sequence selected from the group consisting of. (a) the ammo acid sequence of SEQ ID NO : 141 ;

(b) the amino acid sequence of SEQ ID NO- 141 from amino acid 1 to amino acid 38,

(c) a fragment of the amino acid sequence of SEQ ID NO : 141 , the fragment comprising eight contiguous ammo acids of SEQ ID NO: 141; and (d) the amino acid sequence encoded by the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278; the protein being substantially free from other mammalian proteins. Preferably such protein compπses the amino acid sequence of SEQ ID NO: 141 or the ammo acid sequence of SEQ ID NO: 141 from ammo acid 1 to ammo acid 38. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID

NO: 141 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO- 141, or a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 141 having biological activity, the fragment comprising the amino acid sequence from amino acid 17 to ammo acid 26 of SEQ ID NO- 141. In one embodiment, the present invention provides a composition compπsing an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 142;

(b) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO- 142 from nucleotide 1204 to nucleotide 1389;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO- 142 from nucleotide 881 to nucleotide 1380,

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV291_3 deposited with the ATCC under accession number 98278;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV291_3 deposited with the ATCC under accession number 98278,

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV291_3 deposited with the ATCC under accession number 98278,

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV291_3 deposited with the ATCC under accession number 98278,

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 143; (l) a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 143 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 143;

(j) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(g) above, (k) a polynucleotide which encodes a species homologue of the protein of (h) or (I) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι), and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO: 142.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 142 from nucleotide 1204 to nucleotide 1389; the nucleotide sequence of SEQ ID NO- 142 from nucleotide 881 to nucleotide 1380; the nucleotide sequence of the full-length protein coding sequence of clone BV291_3 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone BV291_3 deposited with the ATCC under accession number 98278. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV291_3 deposited with the ATCC under accession number 98278. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 143 from amino acid 1 to amino acid 59. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 143 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NOT43, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 143 having biological activity, the fragment compπsing the amino acid sequence from amino acid 26 to ammo acid 35 of SEQ ID NO: 143.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 142. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of

(l) preparing one or more polynucleotide probes that hybπdize in 6X

(aa) SEQ ID NO : 142 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 142; and

(ab) the nucleotide sequence of the cDNA insert of clone BV291_3 deposited with the ATCC under accession number 98278; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(m) isolating the DNA polynucleotides detected with the probe(s), and

(b) a process comprising the steps of: (1) preparing one or more polynucleotide primers that hybπdize in

(ba) SEQ ID NO- 142, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 142; and (bb) the nucleotide sequence of the cDNA insert of clone BV291_3 deposited with the ATCC under accession number 98278; (π) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(ιn). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 142, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 142 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 142 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 142. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπespondmg to the cDNA sequence of SEQ ID NO: 142 from nucleotide 1204 to nucleotide 1389, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 142 from nucleotide 1204 to nucleotide 1389, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT42 from nucleotide 1204 to nucleotide 1389 Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 142 from nucleotide 881 to nucleotide 1380, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 142 from nucleotide 881 to nucleotide 1380, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT42 from nucleotide 881 to nucleotide 1380.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of (a) the amino acid sequence of SEQ ID NO: 143; (b) the amino acid sequence of SEQ ID NO: 143 from amino acid 1 to ammo

(c) a fragment of the ammo acid sequence of SEQ ID NO- 143, the fragment comprising eight contiguous amino acids of SEQ ID NO: 143; and

(d) the amino acid sequence encoded by the cDNA insert of clone BV291_3 deposited with the ATCC under accession number 98278, the protein being substantially free from other mammalian proteins. Preferably such protein compπses the ammo acid sequence of SEQ ID NO: 143 or the amino acid sequence of SEQ ID NO: 143 from amino acid 1 to amino acid 59. In further prefeπed embodiments, the present invention provides a protein compπsing a fragment of the amino acid sequence of SEQ ID NO: 143 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 143, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 143 having biological activity, the fragment comprising the amino acid sequence from ammo acid 26 to ammo acid 35 of SEQ ID NO: 143. In one embodiment, the present invention provides a composition compπsing an isolated polynucleotide selected from the group consisting of.

(a) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 144;

(b) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 144 from nucleotide 189 to nucleotide 1115; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO.144 from nucleotide 1 to nucleotide 451,

(d) a polynucleotide compπsing the nucleotide sequence of the full-length protein coding sequence of clone CK201_1 deposited with the ATCC under accession number 98278, (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278;

(f) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone CK201_1 deposited with the ATCC under accession number 98278; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278;

(h) a polynucleotide encoding a protein compπsing the amino acid sequence of SEQ ID NO 145,

(0 a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO.145 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 145,

(j) a polynucleotide which is an allehc vaπant of a polynucleotide of (a)-(g) above,

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (I) above ,

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO: 144 Preferably, such polynucleotide compπses the nucleotide sequence of SEQ ID NO: 144 from nucleotide 189 to nucleotide 11 15; the nucleotide sequence of SEQ ID NOT44 from nucleotide 1 to nucleotide 451 ; the nucleotide sequence of the full-length protein coding sequence of clone CK201_1 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone CK201_1 deposited with the ATCC under accession number 98278. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 145 from amino acid 1 to amino acid 88. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO- 145 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO- 145, or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO- 145 having biological activity, the fragment comprising the ammo acid sequence from amino acid 149 to ammo acid 158 of SEQ ID NO- 145

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO- 144.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of

(a) a process comprising the steps of

(I) prepaπng one or more polynucleotide probes that hybridize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of (aa) SEQ ID NO: 144, but excluding the poly(A) tail at the 3' end of SEQ ID NOT 44; and

(ab) the nucleotide sequence of the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278, (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of. (1) preparing one or more polynucleotide pπmers that hybπdize in

6X SSC at 65 degrees C to a nucleotide sequence selected 'from the group consisting of:

(ba) SEQ ID NO : 144, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 144; and

(bb) the nucleotide sequence of the cDNA insert of clone CK201_ 1 deposited with the ATCC under accession number 98278; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C; (m) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 144, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 144 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 144 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 144. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 144 from nucleotide 189 to nucleotide 1 1 15, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 144 from nucleotide 189 to nucleotide 1115, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 144 from nucleotide 189 to nucleotide 1115. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO - 144 from nucleotide 1 to nucleotide 451, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 144 from nucleotide 1 to nucleotide 451, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 144 from nucleotide 1 to nucleotide 451.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the ammo acid sequence of SEQ ID NO: 145, (b) the ammo acid sequence of SEQ ID NO: 145 from ammo acid 1 to amino

(c) a fragment of the ammo acid sequence of SEQ ID NO: 145, the fragment comprising eight contiguous amino acids of SEQ ID NO: 145; and

(d) the ammo acid sequence encoded by the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278; the protein being substantially free from other mammalian proteins. Preferably such protein compπses the ammo acid sequence of SEQ ID NO: 145 or the ammo acid sequence of SEQ ID NO: 145 from amino acid 1 to ammo acid 88. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 145 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 145, or a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 145 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 149 to ammo acid 158 of SEQ ID NO.145 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 146;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 146 from nucleotide 117 to nucleotide 923; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 146 from nucleotide 174 to nucleotide 923;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 146 from nucleotide 1 to nucleotide 316;

(e) a polynucleotide compπsing the nucleotide sequence of the full-length protein coding sequence of clone CQ331_2 deposited with the ATCC under accession number 98278;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278;

(g) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone CQ331_2 deposited with the ATCC under accession number

98278;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278;

(I) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 147;

(j) a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NO: 147 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 147,

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and (n) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 146.

Preferably, such polynucleotide compπses the nucleotide sequence of SEQ ID NO: 146 from nucleotide 117 to nucleotide 923; the nucleotide sequence of SEQ ID NO: 146 from nucleotide 174 to nucleotide 923; the nucleotide sequence of SEQ ID NOT46 from nucleotide 1 to nucleotide 316; the nucleotide sequence of the full-length protein coding sequence of clone CQ331_2 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone CQ331_2 deposited with the ATCC under accession number 98278. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 147 from ammo acid 1 to amino acid 57. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 147 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 147, or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NOT 47 having biological activity, the fragment compπsing the ammo acid sequence from ammo acid 129 to amino acid 138 of SEQ ID NO: 147. Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID

NO: 146.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process compπsing the steps of. (l) preparing one or more polynucleotide probes that hybπdize in 6X

(aa) SEQ ID NO : 146, but excluding the poly(A) tail at the 3 ' end of SEQ ID N0.146; and (ab) the nucleotide sequence of the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278, (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(l) preparing one or more polynucleotide pπmers that hybridize in

6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of

(ba) _SEQ ID NO- 146, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 146, and

(bb) the nucleotide sequence of the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C,

(in) amplifying human DNA sequences, and (IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 146, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 146 to a nucleotide sequence coπespondmg to the 3' end of SEQ ID NO: 146 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 146. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO.146 from nucleotide 117 to nucleotide 923, and extending contiguously from a nucleotide sequence coπespondmg to the 5' end of said sequence of SEQ ID NO: 146 from nucleotide 1 17 to nucleotide 923, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO 146 from nucleotide 1 17 to nucleotide 923. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO.146 from nucleotide 174 to nucleotide 923, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO 146 from nucleotide 174 to nucleotide 923, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO- 146 from nucleotide 174 to nucleotide 923. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 146 from nucleotide 1 to nucleotide 316, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 146 from nucleotide 1 to nucleotide 316, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 146 from nucleotide 1 to nucleotide 316.

(a) the ammo acid sequence of SEQ ID NO- 147;

(b) the ammo acid sequence of SEQ ID NO: 147 from ammo acid 1 to amino

(c) a fragment of the amino acid sequence of SEQ ID NO.147, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 147; and

(d) the ammo acid sequence encoded by the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 147 or the ammo acid sequence of SEQ ID NO.147 from ammo acid 1 to amino acid 57. In further prefeπed embodiments, the present invention provides a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 147 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO- 147, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 147 having biological activity, the fragment compπsing the amino acid sequence from ammo acid 129 to amino acid 138 of SEQ ID NO.147

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO.148, (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO- 148 from nucleotide 223 to nucleotide 483,

(c) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 148 from nucleotide 22 to nucleotide 397;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CT550_1 deposited with the ATCC under accession number 98278;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278, (f) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone CT550_1 deposited with the ATCC under accession number 98278,

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278,

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO- 149;

(l) a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO- 149 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO.149,

(j) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(g) above,

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (I) above , (1) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO.148. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO- 148 from nucleotide 223 to nucleotide 483; the nucleotide sequence of SEQ ID NO 148 from nucleotide 22 to nucleotide 397; the nucleotide sequence of the full-length protein coding sequence of clone CT550_1 deposited with the ATCC under accession number 98278, or the nucleotide sequence of a mature protein coding sequence of clone CT550_1 deposited with the ATCC under accession number 98278 In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278 In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing the amino acid sequence of SEQ ID NOT49 from amino acid 1 to amino acid 58. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NO- 149 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 149, or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO- 149 having biological activity, the fragment compπsing the ammo acid sequence from ammo acid 38 to ammo acid 47 of SEQ ID NO: 149 Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO- 148.

(I) preparing one or more polynucleotide probes that hybπdize in 6X

(aa) SEQ ID NO: 148, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO.148; and

(ab) the nucleotide sequence of the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278; (π) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) prepaπng one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO.148, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 148, and

(bb) the nucleotide sequence of the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278, (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 148, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO- 148 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO- 148 , but excluding the poly(A) tail at the 3' end of SEQ ID NO' 148 Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 148 from nucleotide 223 to nucleotide 483, and extending contiguously from a nucleotide sequence coπespondmg to the 5' end of said sequence of SEQ ID NO: 148 from nucleotide 223 to nucleotide 483, to a nucleotide sequence coπespondmg to the 3' end of said sequence of SEQ ID NO: 148 from nucleotide 223 to nucleotide 483. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 148 from nucleotide 22 to nucleotide 397, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 148 from nucleotide 22 to nucleotide 397, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 148 from nucleotide 22 to nucleotide 397.

(a) the amino acid sequence of SEQ ID NO: 149;

(b) the amino acid sequence of SEQ ID NO: 149 from ammo acid 1 to ammo

(c) a fragment of the ammo acid sequence of SEQ ID NO: 149, the fragment compπsing eight contiguous amino acids of SEQ ID NO: 149; and

(d) the am o acid sequence encoded by the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the ammo acid sequence of SEQ ID NO: 149 or the amino acid sequence of SEQ ID NO: 149 from amino acid 1 to ammo acid 58. In further prefeπed embodiments, the present invention provides a protein compπsing a fragment of the amino acid sequence of SEQ ID NO: 149 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 149, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO.149 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to ammo acid 47 of SEQ

ID NO: 149.

(a) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 150, (b) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 150 from nucleotide 1 12 to nucleotide 969;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO.150 from nucleotide 154 to nucleotide 969;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 150 from nucleotide 1 to nucleotide 423; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CT585_1 deposited with the ATCC under accession number 98278,

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CT585_1 deposited with the ATCC under accession number 98278;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278,

(I) a polynucleotide encoding a protein compnsing the ammo acid sequence of SEQ ID NO: 151;

(J) a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO.151 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO- 151,

(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-( ); and

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO 150 Preferably, such polynucleotide compπses the nucleotide sequence of SEQ ID NO- 150 from nucleotide 1 12 to nucleotide 969; the nucleotide sequence of SEQ ID NO- 150 from nucleotide 154 to nucleotide 969, the nucleotide sequence of SEQ ID NO- 150 from nucleotide 1 to nucleotide 423; the nucleotide sequence of the full-length protein coding sequence of clone CT585_1 deposited with the ATCC under accession number 98278, or the nucleotide sequence of a mature protein coding sequence of clone CT585_1 deposited with the ATCC under accession number 98278 In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing the ammo acid sequence of SEQ ID NO 151 from amino acid 1 to amino acid 104 In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 151 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 151 , or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 151 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 138 to amino acid 147 of SEQ ID NO 151

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO.150.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of.

(a) a process comprising the steps of:

(l) preparing one or more polynucleotide probes that hybπdize m 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO.150, but excluding the poly(A) tail at the 3' end of SEQ ID NO-150, and

(ab) the nucleotide sequence of the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278, (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C, and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(l) prepaπng one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO- 150, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT50; and

(bb) the nucleotide sequence of the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278;

(π) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C,

(in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 150, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 150 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 150 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 150. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 150 from nucleotide 112 to nucleotide 969, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 150 from nucleotide 112 to nucleotide 969, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 150 from nucleotide 112 to nucleotide 969. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 150 from nucleotide 154 to nucleotide 969, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 150 from nucleotide 154 to nucleotide 969, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO.150 from nucleotide 154 to nucleotide 969. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπespondmg to the cDNA sequence of SEQ ID NO- 150 from nucleotide 1 to nucleotide 423, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 150 from nucleotide 1 to nucleotide 423, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 150 from nucleotide 1 to nucleotide 423.

In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein compπses an amino acid sequence selected from the group consisting of:

(a) the ammo acid sequence of SEQ ID NO- 151;

(b) the amino acid sequence of SEQ ID NO- 151 from amino acid 1 to amino acid 104,

(c) a fragment of the ammo acid sequence of SEQ ID NO.151, the fragment comprising eight contiguous ammo acids of SEQ ID NO.T51; and

(d) the ammo acid sequence encoded by the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO- 151 or the amino acid sequence of SEQ ID NO: 151 from amino acid 1 to ammo acid 104. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NOT 51 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 151, or a protein compπsmg a fragment of the ammo acid sequence of SEQ ID NO: 151 having biological activity, the fragment comprising the amino acid sequence from amino acid 138 to amino acid 147 of SEQ ID NOT51.

In one embodiment, the present invention provides a composition compnsing an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide compπsing the nucleotide sequence of SEQ ED NO- 152,

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO- 152 from nucleotide 37 to nucleotide 2766;

(c) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO 152 from nucleotide 243 to nucleotide 789;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CT797_3 deposited with the ATCC under accession number 98278;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278,

(f) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone CT797_3 deposited with the ATCC under accession number 98278;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278,

(h) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NOT53;

(I) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO.153 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO.T53;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (l) above ; (1) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι); and

(m) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified m (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO- 152. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 152 from nucleotide 37 to nucleotide 2766, the nucleotide sequence of SEQ ID NO.T52 from nucleotide 243 to nucleotide 789; the nucleotide sequence of the full-length protein coding sequence of clone CT797_3 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone CT797_3 deposited with the ATCC under accession number 98278. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 153 from ammo acid 75 to ammo acid 251. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 153 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NOT 53, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 153 having biological activity, the fragment comprising the ammo acid sequence from amino acid 450 to amino acid 459 of SEQ ID NO: 153.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 152.

(a) a process compπsing the steps of:

(I) prepaπng one or more polynucleotide probes that hybridize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 152, but excluding the poly(A) tail at the 3' end of SEQ ID NOT 52; and

(ab) the nucleotide sequence of the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278; (n) hybridizing said probe(s) to human genomic DNA m conditions at least as stringent as 4X SSC at 50 degrees C; and

(m) isolating the DNA polynucleotides detected with the probe(s), and

(b) a process compπsing the steps of: (1) preparing one or more polynucleotide pπmers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO: 152, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 152; and

(bb) the nucleotide sequence of the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278; (π) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(ιn). Preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 152, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 152 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 152 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 152. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO.152 from nucleotide 37 to nucleotide 2766, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 152 from nucleotide 37 to nucleotide 2766, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 152 from nucleotide 37 to nucleotide 2766. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 152 from nucleotide 243 to nucleotide 789, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 152 from nucleotide 243 to nucleotide 789, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ

ID NO- 152 from nucleotide 243 to nucleotide 789.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein compπses an ammo acid sequence selected from the group consisting of. (a) the ammo acid sequence of SEQ ID NO : 153 ; (b) the amino acid sequence of SEQ ID NO: 153 from amino acid 75 to amino

(c) a fragment of the ammo acid sequence of SEQ ID NO: 153, the fragment compπsing eight contiguous ammo acids of SEQ ID NO: 153; and

(d) the amino acid sequence encoded by the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the ammo acid sequence of SEQ ID NOT 53 or the amino acid sequence of SEQ ID NO: 153 from ammo acid 75 to amino acid 251. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 153 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 153, or a protein compπsing a fragment of the amino acid sequence of SEQ ID NO- 153 having biological activity, the fragment comprising the ammo acid sequence from amino acid 450 to amino acid 459 of SEQ ID NO: 153. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO- 155,

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 155 from nucleotide 41 to nucleotide 760, (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CB107_ 1 deposited with the ATCC under accession number 98279;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CB107_1 deposited with the ATCC under accession number 98279; (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CB107_1 deposited with the ATCC under accession number 98279;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CB107_1 deposited with the ATCC under accession number 98279, (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NOT56;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO- 156 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO- 156; (I) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j ) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ,

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified m (a)-(h), and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO: 155.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 155 from nucleotide 41 to nucleotide 760; the nucleotide sequence of the full-length protein coding sequence of clone CB107_1 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CB107_1 deposited with the

ATCC under accession number 98279. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CB107_1 deposited with the ATCC under accession number 98279 In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 156 from amino acid 127 to amino acid 240. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO- 156 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 156, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO.156 having biological activity, the fragment comprising the amino acid sequence from ammo acid 115 to amino acid 124 of SEQ ID NO: 156.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 155, SEQ ID NO 154, and SEQ ID NO: 157 .

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of (a) a process comprising the steps of:

(l) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of

(aa) SEQ ID NO: 154,

(ab) SEQ ID NO- 155;

(ac) SEQ ID NO 157, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 157; and

(ad) the nucleotide sequence of the cDNA insert of clone CB107_1 deposited with the ATCC under accession number 98279; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C, and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process compπsing the steps of:

(1) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO: 154;

(bb) SEQ ID NO: 155;

(be) SEQ ED NOT 57, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:157; and (bd) the nucleotide sequence of the cDNA insert of clone

CB107_1 deposited with the ATCC under accession number 98279; (n) hybndizmg said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(uι).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequences of SEQ ID NO: 154, SEQ ID NO: 155, and SEQ ID NO: 157, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 154 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 157, but excluding the poly(A) tail at the 3' end of SEQ ID NOT57. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 155, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 155 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 155. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 155 from nucleotide 41 to nucleotide 760, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 155 from nucleotide 41 to nucleotide 760, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 155 from nucleotide 41 to nucleotide 760. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 156,

(b) the ammo acid sequence of SEQ ID NO: 156 from ammo acid 127 to

(c) a fragment of the ammo acid sequence of SEQ ED NO: 156, the fragment comprising eight contiguous amino acids of SEQ ID NO: 156, and

(d) the ammo acid sequence encoded by the cDNA insert of clone CB 107_ 1 deposited with the ATCC under accession number 98279; the protein being substantially free from other mammalian proteins. Preferably such protein compπses the ammo acid sequence of SEQ ID NO: 156 or the amino acid sequence of SEQ ID NO- 156 from amino acid 127 to amino acid 240 In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO- 156 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 156, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 156 having biological activity, the fragment compπsing the ammo acid sequence from ammo acid 115 to ammo acid 124 of SEQ ID NOT 56.

(a) a polynucleotide compπsing the nucleotide sequence ofSEQ ID NO 158;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO.158 from nucleotide 374 to nucleotide 1108,

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 158 from nucleotide 500 to nucleotide 1 108,

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO.158 from nucleotide 1 to nucleotide 387;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CG300_3 deposited with the ATCC under accession number 98279,

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279,

(g) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone CG300_3 deposited with the ATCC under accession number 98279;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279;

(I) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO.159, (j) a polynucleotide encoding a protein compπsmg a fragment of the amino acid sequence of SEQ ID NO: 159 having biological activity, the fragment compπsing eight contiguous ammo acids of SEQ ID NO: 159;

(k) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(h) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 158.

Preferably, such polynucleotide compπses the nucleotide sequence of SEQ ID NO- 158 from nucleotide 374 to nucleotide 1108; the nucleotide sequence of SEQ ID NO: 158 from nucleotide 500 to nucleotide 1108; the nucleotide sequence of SEQ ID NO: 158 from nucleotide 1 to nucleotide 387; the nucleotide sequence of the full-length protein coding sequence of clone CG300_3 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CG300_3 deposited with the ATCC under accession number 98279. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 159 from amino acid 23 to amino acid 57. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO 159 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO- 159, or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NOT 59 having biological activity, the fragment comprising the amino acid sequence from amino acid 1 17 to amino acid 126 of SEQ ID NO 159 Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID

NO.158

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process compπsing the steps of. (1) prepaπng one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO: 158, but excluding the ρoly(A) tail at the 3 ' end of SEQ ID NOT58, and

(ab) the nucleotide sequence of the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279, (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(1) preparing one or more polynucleotide primers that hybridize m 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO- 158, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 158; and

(bb) the nucleotide sequence of the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279, (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C,

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 158, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 158 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 158 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 158. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 158 from nucleotide 374 to nucleotide 1108, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 158 from nucleotide 374 to nucleotide 1108, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT58 from nucleotide 374 to nucleotide 1108. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 158 from nucleotide 500 to nucleotide 1108, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 158 from nucleotide 500 to nucleotide 1108, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID N0.158 from nucleotide 500 to nucleotide 1108. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence ofSEQ ID NO: 158 from nucleotide 1 to nucleotide 387, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO.158 from nucleotide 1 to nucleotide 387, to a nucleotide sequence coπespondmg to the 3' end of said sequence of SEQ ID NO: 158 from nucleotide 1 to nucleotide 387

(a) the ammo acid sequence of SEQ ID NO: 159;

(b) the ammo acid sequence of SEQ ID NO: 159 from amino acid 23 to amino

(c) a fragment of the amino acid sequence of SEQ ID NO.159, the fragment compπsing eight contiguous ammo acids of SEQ ID NO: 159; and

(d) the amino acid sequence encoded by the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO- 159 or the ammo acid sequence of SEQ ID NO: 159 from ammo acid 23 to ammo acid 57 In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO- 159 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 159, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO.159 having biological activity, the fragment comprising the amino acid sequence from ammo acid 117 to amino acid 126 of SEQ

ID NO 159.

(a) a polynucleotide compnsmg the nucleotide sequence of SEQ ID NO: 160, (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 160 from nucleotide 126 to nucleotide 3053;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO- 160 from nucleotide 180 to nucleotide 3053;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 160 from nucleotide 49 to nucleotide 382; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CJ145_1 deposited with the ATCC under accession number 98279;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CJ145_1 deposited with the ATCC under accession number 98279;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279;

(I) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 161;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 161 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO- 161,

(n) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO.160 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO.160 from nucleotide 126 to nucleotide 3053; the nucleotide sequence of SEQ ID NO- 160 from nucleotide 180 to nucleotide 3053; the nucleotide sequence of SEQ ID NO: 160 from nucleotide 49 to nucleotide 382; the nucleotide sequence of the full-length protein coding sequence of clone CJ145_1 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CJ145_1 deposited with the ATCC under accession number 98279. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO.161 from ammo acid 1 to amino acid 87 In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsmg a fragment of the amino acid sequence of SEQ ID NO: 161 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO- 161, or a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO.161 having biological activity, the fragment compπsing the ammo acid sequence from amino acid 482 to ammo acid 491 of SEQ ID NO: 161

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 160.

(a) a process compπsing the steps of:

(I) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO.160, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 160; and

(ab) the nucleotide sequence of the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279, (n) hybridizing said probe(s) to human genomic DNA m conditions at least as stringent as 4X SSC at 50 degrees C, and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 160, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO- 160; and

(bb) the nucleotide sequence of the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279;

(n) hybridizing said pπmer(s) to human genomic DNA m conditions at least as stπngent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(πι). Preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 160, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 160 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 160 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 160. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO ^• 160 from nucleotide 126 to nucleotide 3053, and extending contiguously from a nucleotide sequence coπespondmg to the 5' end of said sequence of SEQ ID NO: 160 fromnucleotide 126 to nucleotide 3053, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT60 from nucleotide 126 to nucleotide 3053. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 160 from nucleotide 180 to nucleotide 3053, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NOT60 from nucleotide 180 to nucleotide 3053, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 160 from nucleotide 180 to nucleotide 3053. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 160 from nucleotide 49 to nucleotide 382, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 160 from nucleotide 49 to nucleotide 382, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 160 from nucleotide 49 to nucleotide

382.

In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of: (a) the ammo acid sequence of SEQ ID NO: 161; (b) the amino acid sequence of SEQ ID NO: 161 from am o acid 1 to amino

(c) a fragment of the amino acid sequence of SEQ ID NO: 161, the fragment comprising eight contiguous amino acids of SEQ ID NO: 161; and

(d) the ammo acid sequence encoded by the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279; the protein being substantially free from other mammalian proteins. Preferably such protein compπses the amino acid sequence of SEQ ID NO: 161 or the ammo acid sequence of SEQ ID NO: 161 from amino acid 1 to ammo acid 87. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 161 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 161, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 161 having biological activity, the fragment comprising the amino acid sequence from ammo acid 482 to ammo acid 491 of SEQ ID NO- 161. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO.162;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 162 from nucleotide 40 to nucleotide 342; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 162 from nucleotide 127 to nucleotide 342;

(d) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO- 162 from nucleotide 11 to nucleotide 181;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CJ1 0_11 deposited with the ATCC under accession number 98279;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279;

(g) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone CJ160_1 1 deposited with the ATCC under accession number

98279;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279;

(l) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO- 163;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 163 having biological activity, the fragment compπsing eight contiguous amino acids of SEQ ID NO- 163,

(m) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(j), and (n) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified m (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 162.

Preferably, such polynucleotide compπses the nucleotide sequence of SEQ ID NO: 162 from nucleotide 40 to nucleotide 342; the nucleotide sequence of SEQ ID NO: 162 from nucleotide 127 to nucleotide 342; the nucleotide sequence of SEQ ID NOT62 from nucleotide 11 to nucleotide 181, the nucleotide sequence of the full-length protein coding sequence of clone CJ160_11 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CJ 160_1 1 deposited with the ATCC under accession number 98279. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing the ammo acid sequence of SEQ ID NO: 163 from ammo acid 7 to ammo acid 48. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 163 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 163, or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 163 having biological activity, the fragment compπsing the ammo acid sequence from ammo acid 45 to ammo acιd 54 of SEQ ID NOT63.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 162

(i) prepaπng one or more polynucleotide probes that hybπdize in 6X

(aa) SEQ ID NO: 162, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 162; and

(ab) the nucleotide sequence of the cDNA insert of clone CJ160_1 1 deposited with the ATCC under accession number 98279; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C, and (in) isolating the DNA polynucleotides detected with the probe(s), and

(b) a process comprising the steps of

(1) preparing one or more polynucleotide primers that hybπdize m

(ba) SEQ ID NO 162, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO 162, and

(bb) the nucleotide sequence of the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279, (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C,

(in) amplifying human DNA sequences, and (IV) isolating the polynucleotide products of step (b)(uι) Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO 162, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO 162 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO 162 , but excluding the poly(A) tail at the 3' end of SEQ ID NO 162 Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO 162 from nucleotide 40 to nucleotide 342, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO 162 from nucleotide 40 to nucleotide 342, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO 162 from nucleotide 40 to nucleotide 342 Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO 162 from nucleotide 127 to nucleotide 342, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO 162 from nucleotide 127 to nucleotide 342, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO 162 from nucleotide 127 to nucleotide 342 Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO 162 from nucleotide 11 to nucleotide 181, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO 162 from nucleotide 11 to nucleotide 181, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO 162 from nucleotide 11 to nucleotide 181

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein compπses an ammo acid sequence selected from the group consisting of (a) the ammo acid sequence of SEQ ID NO: 163;

(b) the amino acid sequence of SEQ ID NO: 163 from ammo acid 7 to ammo

(c) a fragment of the amino acid sequence of SEQ ID NO: 163, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 163; and

(d) the amino acid sequence encoded by the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279, the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO 163 or the amino acid sequence of SEQ ID NO.163 from amino acid 7 to ammo acid 48. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 163 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 163, or a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 163 having biological activity, the fragment comprising the amino acid sequence from ammo acid 45 to ammo acid 54 of SEQ ID NO: 163.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO- 164; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO.164 from nucleotide 180 to nucleotide 467;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 164 from nucleotide 267 to nucleotide 467,

(d) a polynucleotide compπsing the nucleotide sequence of the full-length protein coding sequence of clone CO20_1 deposited with the ATCC under accession number 98279;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CO20_1 deposited with the ATCC under accession number

98279;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO- 165; (1) a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 165 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 165,

(1) a polynucleotide that hybridizes under stπngent conditions to any one of the polynucleotides specified in (a)-(ι); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NOT 64.

Preferably, such polynucleotide compπses the nucleotide sequence of SEQ ID NO.164 from nucleotide 180 to nucleotide 467; the nucleotide sequence of SEQ ID NO: 164 from nucleotide 267 to nucleotide 467; the nucleotide sequence of the full-length protein coding sequence of clone CO20_1 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CO20_1 deposited with the ATCC under accession number 98279. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO- 165 from ammo acid 1 to amino acid 37. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO- 165 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 165, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 165 having biological activity, the fragment compπsing the amino acid sequence from ammo acid 43 to ammo acid 52 of SEQ ID NO- 165.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO 164 and SEQ ID NO: 166.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of. (a) a process comprising the steps of (1) prepaπng one or more polynucleotide probes that hybridize m 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO: 164; (ab) SEQ ID NO: 166, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 166; and

(ac) the nucleotide sequence of the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of.

(1) preparing one or more polynucleotide primers that hybπdize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO: 164;

(bb) SEQ ID NO: 166, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:166; and (be) the nucleotide sequence of the cDNA insert of clone

CO20_1 deposited with the ATCC under accession number 98279; (n) hybridizing saιdpπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(ιn).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequences of SEQ ID NO: 164 and SEQ ID NO: 166, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 164 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 166, but excluding the poly(A) tail at the 3' end of SEQ ID NO- 166. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπespondmg to the cDNA sequence of SEQ ID NO: 164, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NOT64 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 164. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 164 from nucleotide 180 to nucleotide 467, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 164 from nucleotide 180 to nucleotide 467, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 164 from nucleotide 180 to nucleotide 467. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 164 from nucleotide 267 to nucleotide 467, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 164 from nucleotide 267 to nucleotide 467, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO 164 from nucleotide 267 to nucleotide 467 In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 165,

(b) the ammo acid sequence of SEQ ID NOT65 from amino acid 1 to amino

(c) a fragment ofthe ammo acid sequence ofSEQ ID NO: 165, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 165; and

(d) the ammo acid sequence encoded by the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 165 or the amino acid sequence of SEQ ID NO- 165 from amino acid 1 to amino acid 37 In further prefeπed embodiments, the present invention provides a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO- 165 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 165, or a protein compπsing a fragment ofthe amino acid sequence of SEQ ID NO- 165 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 43 to amino acid 52 of SEQ ID NO.165.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of (a) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 167;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 167 from nucleotide 176 to nucleotide 520;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 167 from nucleotide 317 to nucleotide 520; (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 167 from nucleotide 1 18 to nucleotide 413;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone C0223_3 deposited with the ATCC under accession number 98291;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone C0223_3 deposited with the ATCC under accession number 98291;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone C0223_3 deposited with the ATCC under accession number 98291;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone C0223_3 deposited with the ATCC under accession number 98291;

(I) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 168, 0) ^a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NO- 168 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 168;

(k) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(h) above, (1) a polynucleotide which encodes a species homologue ofthe protein of (I) or (j) above ;

(n) a polynucleotide that hybridizes under stπngent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 167.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 167 from nucleotide 176 to nucleotide 520; the nucleotide sequence of SEQ ID NO: 167 from nucleotide 317 to nucleotide 520; the nucleotide sequence of SEQ ID NO- 167 from nucleotide 118 to nucleotide 413 ; the nucleotide sequence ofthe full-length protein coding sequence of clone

C0223_3 deposited with the ATCC under accession number 98291; or the nucleotide sequence of a mature protein coding sequence of clone C0223_3 deposited with the ATCC under accession number 98291 In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone C0223_3 deposited with the ATCC under accession number 98291. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing the amino acid sequence of SEQ ID NO: 168 from amino acid 1 to ammo acid 80. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 168 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 168, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 168 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 52 to ammo

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 167.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of. (a) a process comprising the steps of

(I) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of

(aa) SEQ ID NO .167, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT67; and

(ab) the nucleotide sequence of the cDNA insert of clone C0223_3 deposited with the ATCC under accession number 98291,

(in) isolating the DNA polynucleotides detected with the probe(s); and (b) a process comprising the steps of.

(I) prepaπng one or more polynucleotide primers that hybπdize in

(ba) SEQ ID NO ^• 167, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:167; and

(bb) the nucleotide sequence of the cDNA insert of clone C0223_3 deposited with the ATCC under accession number 98291, (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(ιn). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT 67, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 167 to a nucleotide sequence coπespondmg to the 3 ' end of SEQ ID NO : 167 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO 67. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO.167 from nucleotide 176 to nucleotide 520, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 167 from nucleotide 176 to nucleotide 520, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 167 from nucleotide 176 to nucleotide 520. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 167 from nucleotide 317 to nucleotide 520, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 167 from nucleotide 317 to nucleotide 520, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO.T67 from nucleotide 317 to nucleotide 520. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 167 from nucleotide 118 to nucleotide 413, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO.167 from nucleotide 118 to nucleotide 413, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 167 from nucleotide 118 to nucleotide 413

In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the ammo acid sequence of SEQ ID NO- 168, (b) the amino acid sequence of SEQ ID NO: 168 from ammo acid 1 to amino acid 80;

(c) a fragment ofthe ammo acid sequence of SEQ ID NO- 168, the fragment comprising eight contiguous amino acids of SEQ ID NO- 168; and

(d) the amino acid sequence encoded by the cDNA insert of clone C0223_3 deposited with the ATCC under accession number 98291 ; the protein being substantially free from other mammalian proteins. Preferably such protein compπses the ammo acid sequence of SEQ ID NO: 168 or the ammo acid sequence of SEQ ID NO- 168 from ammo acid 1 to amino acid 80 In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the am o acid sequence of SEQ ID NO: 168 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 168, or a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO: 168 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO. l 68. In one embodiment, the present invention provides a composition compπsing an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 169,

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 169 from nucleotide 303 to nucleotide 542; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 169 from nucleotide 1 to nucleotide 435;

(d) a polynucleotide compπsing the nucleotide sequence of the full-length protein coding sequence of clone CO310_2 deposited with the ATCC under accession number 98279; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone C0310_2 deposited with the ATCC under accession number 98279;

(f) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone CO310_2 deposited with the ATCC under accession number 98279; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CO310_2 deposited with the ATCC under accession number 98279,

(h) a polynucleotide encoding a protein compπsing the amino acid sequence of SEQ ID NO-170;

(I) a polynucleotide encoding a protein compπsing a fragment ofthe amino acid sequence of SEQ ID NO: 170 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 170;

(k) a polynucleotide which encodes a species homologue ofthe protein of (h) or (I) above ,

(1) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified in (a)-(ι), and

(m) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified m (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO: 169. Preferably, such polynucleotide compπses the nucleotide sequence of SEQ ID NO: 169 from nucleotide 303 to nucleotide 542; the nucleotide sequence of SEQ ID NO: 169 from nucleotide 1 to nucleotide 435 ; the nucleotide sequence ofthe full-length protein coding sequence of clone CO310_2 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone C0310_2 deposited with the ATCC under accession number 98279. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone CO310_2 deposited with the ATCC under accession number 98279. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 170 from amino acid 1 to ammo acid 44. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 170 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 170, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 170 having biological activity, the fragment comprising the ammo acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO: 170

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO.169.

(a) a process compπsing the steps of.

(l) prepaπng one or more polynucleotide probes that hybridize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 169, but excluding the poly(A) tail at the 3' end of SEQ ID NOT 69; and

(ab) the nucleotide sequence of the cDNA insert of clone C0310_2 deposited with the ATCC under accession number 98279; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(m) isolating the DNA polynucleotides detected with the probe(s), and

(b) a process comprising the steps of (ι) prepaπng one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO: 169, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT 69; and

(bb) the nucleotide sequence of the cDNA insert of clone C0310_2 deposited with the ATCC under accession number 98279; (π) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(ιn). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 169, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 169 to a nucleotide sequence coπesponding to the 3 ' end of SEQ ID NO - 169 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 169. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 169 from nucleotide 303 to nucleotide 542, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 169 from nucleotide 303 to nucleotide 542, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 169 from nucleotide 303 to nucleotide 542. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 169 from nucleotide 1 to nucleotide 435, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NOT69 from nucleotide 1 to nucleotide 435, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID

NO 169 from nucleotide 1 to nucleotide 435

In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of (a) the ammo acid sequence of SEQ ID NO.170, (b) the ammo acid sequence of SEQ ID NO : 170 from ammo acid 1 to ammo

(c) a fragment ofthe amino acid sequence of SEQ ID NO- 170, the fragment comprising eight contiguous amino acids of SEQ ID NO- 170, and

(d) the ammo acid sequence encoded by the cDNA insert of clone C0310_2 deposited with the ATCC under accession number 98279; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the ammo acid sequence of SEQ ID NO: 170 or the ammo acid sequence of SEQ ID NO: 170 from amino acid 1 to ammo acid 44. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO- 170 having biological activity, the fragment preferably compπsing eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 170, or a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO: 170 having biological activity, the fragment compπsing the ammo acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO. l 70. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO¹171,

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 171 from nucleotide 40 to nucleotide 455; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 171 from nucleotide 85 to nucleotide 455;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO 171 from nucleotide 265 to nucleotide 515;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CP258_3 deposited with the ATCC under accession number 98279;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279,

(g) a polynucleotide compπsing the nucleotide sequence of a mature protein coding sequence of clone CP258_3 deposited with the ATCC under accession number

98279;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279,

(I) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 172;

(j) a polynucleotide encoding a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO: 172 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO.172;

(k) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue ofthe protein of (I) or (j) above ;

(m) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified in (a)-(j); and (n) a polynucleotide that hybridizes under stπngent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 171.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 171 from nucleotide 40 to nucleotide 455 , the nucleotide sequence of SEQ ID NO: 171 from nucleotide 85 to nucleotide 455, the nucleotide sequence of SEQ ID NO: 171 from nucleotide 265 to nucleotide 515, the nucleotide sequence of the full-length protein coding sequence of clone CP258_3 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CP258_3 deposited with the ATCC under accession number 98279 In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO- 172 from ammo acid 64 to ammo acid 138. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment ofthe amino acid sequence of SEQ ID NO: 172 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 172, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO.172 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 64 to ammo acid 73 of SEQ ID NO: 172. Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID

NOT71.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of. (a) a process comprising the steps of: (I) prepaπng one or more polynucleotide probes that hybπdize m6X

(aa) SEQ ID NO- 171 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO 71, and (ab) the nucleotide sequence of the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279; (n) hybπdizing said probe(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C; and (m) isolating the DNA polynucleotides detected with the probe(s), and

(b) a process comprising the steps of.

(I) preparing one or more polynucleotide primers that hybridize m

(ba) SEQ ID NO: 171 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:171, and

(bb) the nucleotide sequence of the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C,

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπespondmg to the cDNA sequence of SEQ ID NO- 171, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 171 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NOT 71 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 171. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 171 from nucleotide 40 to nucleotide 455, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 171 from nucleotide 40 to nucleotide 455, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT71 from nucleotide 40 to nucleotide 455. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 171 from nucleotide 85 to nucleotide 455, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 171 from nucleotide 85 to nucleotide 455, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 171 from nucleotide 85 to nucleotide 455. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 171 from nucleotide 265 to nucleotide 515, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 171 from nucleotide 265 to nucleotide 515, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 171 from nucleotide 265 to nucleotide 515.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein compπses an ammo acid sequence selected from the group consisting of.

(a) the ammo acid sequence of SEQ ID NO: 172;

(b) the amino acid sequence of SEQ ID NO: 172 from ammo acid 64 to ammo acid 138;

(c) a fragment ofthe amino acid sequence of SEQ ID NO.172, the fragment compπsing eight contiguous amino acids of SEQ ID NO: 172, and

(d) the ammo acid sequence encoded by the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO- 172 or the amino acid sequence of SEQ ID NOT 72 from amino acid 64 to ammo acid 138. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 172 having biological activity, the fragment preferably compnsmg eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 172, or a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO: 172 having biological activity, the fragment comprising the amino acid sequence from ammo acid 64 to amino acid 73 of SEQ ID NO- 172.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of.

(a) a polynucleotide compπsing the nucleotide sequence of SEQ ED NO: 173, (b) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 173 from nucleotide 105 to nucleotide 1007;

(c) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO- 173 from nucleotide 801 to nucleotide 1007;

(d) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO ^• 173 from nucleotide 1 to nucleotide 352;

(e) a polynucleotide compnsmg the nucleotide sequence of the full-length protein coding sequence of clone CW1155_3 deposited with the ATCC under accession number 98279;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279; (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CW1155_3 deposited with the ATCC under accession number 98279;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279;

(I) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NOT74;

(j) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 174 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 174;

(1) a polynucleotide which encodes a species homologue ofthe protein of (I) or (j) above ; (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified m (a)-( ) and that has a length that is at least 25% of the length of SEQ ID NO: 173. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO.173 from nucleotide 105 to nucleotide 1007; the nucleotide sequence of SEQ ID NO. l 73 from nucleotide 801 to nucleotide 1007; the nucleotide sequence of SEQ ID NO: 173 from nucleotide

1 to nucleotide 352; the nucleotide sequence ofthe full-length protein coding sequence of clone

CW1155_3 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CW1 155_3 deposited with the ATCC under accession number 98279. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 174 from ammo acid 1 to ammo acid 83 In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compnsmg a fragment ofthe ammo acid sequence of SEQ ID NO- 174 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO- 174, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 174 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 145 to amino acid 154 of SEQ ID NO: 174.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO-173. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(l) prepaπng one or more polynucleotide probes that hybπdize m 6X

(aa) SEQ ID NO: 173, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:173; and

(ab) the nucleotide sequence of the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C, and

(in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of: (I) preparing one or more polynucleotide primers that hybπdize in

(ba) SEQ ID NO ^■ 173 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO-173; and (bb) the nucleotide sequence of the cDNA insert of clone

CW1155_3 deposited with the ATCC under accession number 98279; (u) hybπdizmg said pπmer(s) to human genomic DNA in conditions at least as stπngent as 4X SSC at 50 degrees C;

Preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 173, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NOT 73 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO' 173 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 173. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 173 from nucleotide 105 to nucleotide 1007, and extending contiguously from a nucleotide sequence coπespondmg to the 5' end ofsaid sequence ofSEQ ID NO: 173 fromnucleotide 105 to nucleotide 1007, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 173 from nucleotide 105 to nucleotide 1007 Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 173 from nucleotide 801 to nucleotide 1007, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 173 from nucleotide 801 to nucleotide 1007, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT73 from nucleotide 801 to nucleotide 1007. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 173 from nucleotide 1 to nucleotide 352, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 173 from nucleotide 1 to nucleotide 352, to a nucleotide sequence coπesponding to the 3' end ofsaid sequence of SEQ ID NO: 173 from nucleotide 1 to nucleotide 352.

In other embodiments, the present invention provides a composition compπsing a protein, wherein said protein compπses an ammo acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 174;

(b) the amino acid sequence of SEQ ID NO : 174 from ammo acid 1 to amino acid 83,

(c) a fragment ofthe ammo acid sequence of SEQ ID NO: 174, the fragment compnsmg eight contiguous ammo acids of SEQ ID NOT 74; and

(d) the ammo acid sequence encoded by the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279; the protein being substantially free from other mammalian proteins Preferably such protein compπses the ammo acid sequence of SEQ ID NO: 174 or the ammo acid sequence of SEQ ID NO- 174 from amino acid 1 to ammo acid 83. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO- 174 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 174, or a protein compnsmg a fragment ofthe amino acid sequence of SEQ ID NO- 174 having biological activity, the fragment compπsing the ammo acid sequence from am o acid 145 to ammo acid 154 of SEQ ID NO: 174.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 175;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 175 from nucleotide 11 to nucleotide 1699;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 175 from nucleotide 1682 to nucleotide 1699;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO- 175 from nucleotide 737 to nucleotide 1134;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CZ247_2 deposited with the ATCC under accession number 98279;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CZ247_2 deposited with the ATCC under accession number 98279,

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279;

(l) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO.176; (j) a polynucleotide encoding a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO.176 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 176;

(k) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue ofthe protein of (i) or (j) above ,

(m) a polynucleotide that hybridizes under stπngent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified m (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO- 175.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 175 from nucleotide 1 1 to nucleotide 1699; the nucleotide sequence of SEQ ID NO: 175 from nucleotide 1682 to nucleotide 1699; the nucleotide sequence of SEQ ID NOT 75 from nucleotide 737 to nucleotide 1134; the nucleotide sequence of the full-length protein coding sequence of clone CZ247_2 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CZ247_2 deposited with the ATCC under accession number 98279. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO- 176 from amino acid 298 to amino acid 374. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO.176 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 176, or a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 176 having biological activity, the fragment comprising the ammo acid sequence from amino acid 276 to ammo acid 285 of SEQ ID NO: 176

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO-175.

(I) prepaπng one or more polynucleotide probes that hybπdize m 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of

(aa) SEQ ID NO.175, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO- 175; and

(ab) the nucleotide sequence of the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279;

(n) hybridizing said probe(s) to human genomic DNA m conditions at least as stringent as 4X SSC at 50 degrees C; and

(I) prepaπng one or more polynucleotide pnmers that hybndize in

(ba) SEQ ID NO: 175 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO- 175, and (bb) the nucleotide sequence of the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279; (n) hybπdizmg said pπmer(s) to human genomic DNA m conditions at least as stringent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(ιn). Preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO.T75, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO- 175 to a nucleotide sequence coπesponding to the 3 ' end of SEQ ID NO : 175 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 175. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 175 from nucleotide 11 to nucleotide 1699, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 175 from nucleotide 11 to nucleotide 1699, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO- 175 from nucleotide 11 to nucleotide 1699 Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 175 from nucleotide 1682 to nucleotide 1699, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 175 from nucleotide 1682 to nucleotide 1699, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 175 from nucleotide 1682 to nucleotide 1699. Also preferably the polynucleotide isolated according to the above process composes a nucleotide sequence coπespondmg to the cDNA sequence of SEQ ID NO.175 from nucleotide 737 to nucleotide 1134, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 175 from nucleotide 737 to nucleotide 1134, to a nucleotide sequence coπesponding to the 3' end ofsaid sequence of SEQ ID NO: 175 from nucleotide 737 to nucleotide 1134

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein compπses an amino acid sequence selected from the group consisting of. (a) the ammo acid sequence of SEQ ID NO- 176;

(b) the ammo acid sequence of SEQ ID NO: 176 from ammo acid 298 to

(c) a fragment of the ammo acid sequence of SEQ ID NO .176, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 176, and (d) the amino acid sequence encoded by the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279, the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO - 176 or the ammo acid sequence of SEQ ID NO: 176 from ammo acid 298 to amino acid 374. In further prefeπed embodiments, the present invention provides a protein compnsmg a fragment of the ammo acid sequence of SEQ ID

NO: 176 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO- 176, or a protein compnsmg a fragment ofthe amino acid sequence of SEQ ID NO: 176 having biological activity, the fragment compπsing the amino acid sequence from ammo acid 276 to ammo acid 285 of SEQ

ID NO: 176.

In one embodiment, the present invention provides a composition compπsing an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 177; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 177 from nucleotide 918 to nucleotide 1262;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 177 from nucleotide 999 to nucleotide 1262;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 177 from nucleotide 928 to nucleotide 1 134;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AM666_1 deposited with the ATCC under accession number 98292;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AM666_1 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292;

(l) a polynucleotide encoding a protein compnsmg the ammo acid sequence of SEQ ID NO: 178;

(]) a polynucleotide encoding a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO- 178 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 178; (k) a polynucleotide which is an allelic vaπant of a polynucleotide of (a)-(h) above;

(1) a polynucleotide which encodes a species homologue ofthe protein of (I) or (j) above ; (m) a polynucleotide that hybπdizes under stπngent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 177. Preferably, such polynucleotide compπses the nucleotide sequence of SEQ ID NO: 177 from nucleotide 918 to nucleotide 1262, the nucleotide sequence of SEQ ID NO: 177 from nucleotide 999 to nucleotide 1262; the nucleotide sequence of SEQ ID NO: 177 from nucleotide 928 to nucleotide 1134, the nucleotide sequence of the full-length protein coding sequence of clone AM666_1 deposited with the ATCC under accession number 98292, or the nucleotide sequence of a mature protein coding sequence of clone AM666_1 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compnsmg the ammo acid sequence of SEQ ID NO.178 from ammo acid 5 to amino acid 72. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 178 having biological activity, the fragment preferably compnsmg eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NOT 78, or a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 178 having biological activity, the fragment compnsmg the ammo acid sequence from ammo acid 52 to ammo acid 61 of SEQ ID NO: 178

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO.177.

(a) a process comprising the steps of:

(l) prepaπng one or more polynucleotide probes that hybπdize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO : 177, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT 77; and

(ab) the nucleotide sequence of the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292; (n) hybπdizmg said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(m) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of. (i) preparing one or more polynucleotide primers that hybridize m

(ba) SEQ ID NO: 177, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 177; and (bb) the nucleotide sequence of the cDNA insert of clone

AM666_1 deposited with the ATCC under accession number 98292; (π) hybridizing said pnmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(m).

Preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 177, and extending contiguously from a nucleotide sequence coπespondmg to the 5' end of SEQ ID NO: 177 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 177 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 177. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 177 from nucleotide 918 to nucleotide 1262, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO- 177 from nucleotide 918 to nucleotide 1262, to a nucleotide sequence coπespondmg to the 3' end of said sequence of SEQ ID NOT 77 from nucleotide 918 to nucleotide 1262. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 177 from nucleotide 999 to nucleotide 1262, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 177 from nucleotide 999 to nucleotide 1262, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 177 from nucleotide 999 to nucleotide 1262. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 177 from nucleotide 928 to nucleotide 1134, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 177 from nucleotide 928 to nucleotide 1134, to a nucleotide sequence coπesponding to the 3' end ofsaid sequence of SEQ ID NO: 177 from nucleotide 928 to nucleotide 1134.

In other embodiments, the present invention provides a composition compnsmg a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of. (a) the amino acid sequence of SEQ ID NO: 178; (b) the ammo acιd sequence ofSEQ IDNOT78 from amιno acιd 5 to ammo

(c) a fragment ofthe amino acid sequence of SEQ ID NO: 178, the fragment comprising eight contiguous amino acids of SEQ ID NOT 78; and

(d) the ammo acid sequence encoded by the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the ammo acid sequence of SEQ ID NO: 178 or the amino acid sequence of SEQ ID NO: 178 from amino acid 5 to ammo acid 72. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 178 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 178, or a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO: 178 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to ammo acid 61 of SEQ ID NO: 178. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 179,

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 179 from nucleotide 751 to nucleotide 906; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO 79 from nucleotide 829 to nucleotide 906;

(d) a polynucleotide compπsing the nucleotide sequence of SEQ ID NO: 179 from nucleotide 556 to nucleotide 831; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BN387_3 deposited with the ATCC under accession number 98292;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292;

(g) a polynucleotide compnsmg the nucleotide sequence of a mature protein coding sequence of clone BN387_3 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292;

(l) a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 180;

(j) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO.180 having biological activity, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 180;

(n) a polynucleotide that hybπdizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 179 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 179 from nucleotide 751 to nucleotide 906; the nucleotide sequence of SEQ ID NO- 179 from nucleotide 829 to nucleotide 906; the nucleotide sequence of SEQ ID NO: 179 from nucleotide 556 to nucleotide 831 , the nucleotide sequence ofthe full-length protein coding sequence of clone BN387_3 deposited with the ATCC under accession number 98292, or the nucleotide sequence of a mature protein coding sequence of clone BN387_3 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO- 180 from ammo acid 1 to ammo acid 27. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 180 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NOT 80, or a polynucleotide encoding a protein compnsmg a fragment ofthe amino acid sequence of SEQ ID NO: 180 having biological activity, the fragment compnsmg the amino acid sequence from amino acid 21 to amino acιd 30 of SEQ ID NOT80.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO 179.

(a) a process comprising the steps of:

(I) prepaπng one or more polynucleotide probes that hybπdize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of (aa) SEQ ID NO.179, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 179; and

(ab) the nucleotide sequence of the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292; (n) hybπdizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(m) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process compπsing the steps of:

(I) prepaπng one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NOT 79, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO- 179; and

(bb) the nucleotide sequence of the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292;

(n) hybridizing said pnmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C,

(in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(πι). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 179, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 179 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO 79 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 179. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 179 from nucleotide 751 to nucleotide 906, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO.179 from nucleotide 751 to nucleotide 906, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 179 from nucleotide 751 to nucleotide 906. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO- 179 from nucleotide 829 to nucleotide 906, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 179 from nucleotide 829 to nucleotide 906, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 179 from nucleotide 829 to nucleotide 906. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO 179 from nucleotide 556 to nucleotide 831, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO- 179 from nucleotide 556 to nucleotide 831, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO.179 from nucleotide 556 to nucleotide 831.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein compπses an amino acid sequence selected from the group consisting of:

(a) the ammo acid sequence of SEQ ID NO: 180;

(b) the ammo acid sequence of SEQ ID NO- 180 from amino acid 1 to amino

(c) a fragment ofthe ammo acid sequence of SEQ ID NO- 180, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 180; and

(d) the ammo acid sequence encoded by the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins Preferably such protein comprises the ammo acid sequence of SEQ ID NO: 180 or the ammo acid sequence of SEQ ID NO- 180 from ammo acid 1 to amino acid 27 In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO.180 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO- 180, or a protein compπsmg a fragment ofthe amino acid sequence of SEQ ID NO: 180 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 21 to amino acid 30 of SEQ ID NO: 180.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ED NO: 181;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 181 from nucleotide 139 to nucleotide 765;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 181 from nucleotide 1 to nucleotide 416;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BQ135_2 deposited with the ATCC under accession number 98292,

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BQ 135_2 deposited with the ATCC under accession number 98292;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BQ135_2 deposited with the ATCC under accession number 98292;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BQ135_2 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a protein compnsmg the amino acid sequence of SEQ ID NOT82;

(I) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 182 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 182;

(k) a polynucleotide which encodes a species homologue ofthe protein of (h) or (l) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO: 181. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 181 from nucleotide 139 to nucleotide 765; the nucleotide sequence of SEQ ID NO: 181 from nucleotide 1 to nucleotide 416; the nucleotide sequence ofthe full-length protein coding sequence of clone BQ135_2 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone BQ135_2 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone BQ135_2 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO.182 from ammo acid 1 to amino acid 93. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 182 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 182, or a polynucleotide encoding a protein compπsing a fragment of the amino acid sequence of SEQ ID NO: 182 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO: 182.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NOT81.

(a) a process comprising the steps of:

(l) prepanng one or more polynucleotide probes that hybridize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 181, but excluding the poly( A) tail at the 3' end of SEQ ID NOT81; and

(ab) the nucleotide sequence of the cDNA insert of clone BQ135_2 deposited with the ATCC under accession number 98292; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(in) isolating the DNA polynucleotides detected with the probe(s), and

(b) a process comprising the steps of: (ι) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO : 181 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 181 ; and

(bb) the nucleotide sequence of the cDNA insert of clone BQ135_2 deposited with the ATCC under accession number 98292; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (in) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(uι). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 181, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 181 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 181 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 181. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO.181 from nucleotide 139 to nucleotide 765, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 181 from nucleotide 139 to nucleotide 765, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 181 from nucleotide 139 to nucleotide 765. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 181 from nucleotide 1 to nucleotide 416, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 181 from nucleotide 1 to nucleotide 416, to a nucleotide sequence coπesponding to the 3 ' end of said sequence of SEQ ID

NOT81 from nucleotide 1 to nucleotide 416.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 182; (b) the amino acid sequence of SEQ ID NO: 182 from amino acid 1 to amino

(c) a fragment ofthe amino acid sequence of SEQ ID NO: 182, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 182; and

(d) the ammo acid sequence encoded by the cDNA insert of clone BQ135 2 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 182 or the amino acid sequence of SEQ ID NO: 182 from amino acid 1 to amino acid 93. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NOT 82 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 182, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 182 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO: 182. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 183 ;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 183 from nucleotide 214 to nucleotide 714; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 183 from nucleotide 151 to nucleotide 531;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CR678_1 deposited with the ATCC under accession number 98292; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CR678_ 1 deposited with the ATCC under accession number 98292;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CR678_1 deposited with the ATCC under accession number

98292; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NOT84;

(i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 184 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 184;

(k) a polynucleotide which encodes a species homologue ofthe protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 183.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 183 from nucleotide 214 to nucleotide 714; the nucleotide sequence of SEQ ID NOT83 from nucleotide 151 to nucleotide 531; the nucleotide sequence of the full-length protein coding sequence of clone CR678_1 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone CR678_1 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 184 from amino acid 1 to amino acid 106. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 184 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 184, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO 84 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO: 184.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NOT83.

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X

SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ ID NO: 183, but excluding the poly(A) tail at the 3' end of SEQ ID NO:183; and

(ab) the nucleotide sequence of the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO: 183, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 183; and

(bb) the nucleotide sequence of the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 183, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 183 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO 83 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 183. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 183 from nucleotide 214 to nucleotide 714, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 183 from nucleotide 214 to nucleotide

714, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 183 from nucleotide 214 to nucleotide 714. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ

ID NO: 183 from nucleotide 151 to nucleotide 531, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 183 from nucleotide 151 to nucleotide 531, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 183 from nucleotide 151 to nucleotide 531. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NOT 84;

(b) the amino acid sequence of SEQ ID NO: 184 from amino acid 1 to amino acid 106; (c) a fragment ofthe amino acid sequence of SEQ ID NO: 184, the fragment comprising eight contiguous amino acids of SEQ ID NO: 184; and

(d) the amino acid sequence encoded by the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 184 or the ammo acid sequence of SEQ ID NO: 184 from amino acid 1 to amino acid 106. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 184 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 184, or a protein compπsing a fragment ofthe amino acid sequence of SEQ ID NO: 184 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 78 to ammo acid 87 of SEQ ID NO: 184.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 185 ;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NOT 85 from nucleotide 116 to nucleotide 4498;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 185 from nucleotide 1221 to nucleotide 1711;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CW420_2 deposited with the ATCC under accession number 98292;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CW420_2 deposited with the ATCC under accession number 98292;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 186;

(l) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 186 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 186; (j) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue ofthe protein of (h) or (1) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified m (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO: 185. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 185 from nucleotide 116 to nucleotide 4498; the nucleotide sequence of SEQ ID NO: 185 from nucleotide 1221 to nucleotide 1711; the nucleotide sequence of the full-length protein coding sequence of clone CW420_2 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone CW420_2 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 186 from ammo acid 370 to amino acid 532. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compnsmg a fragment ofthe ammo acid sequence of SEQ ID NO: 186 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 186, or a polynucleotide encoding a protein compnsmg a fragment of the ammo acid sequence of SEQ ID NO: 186 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 725 to amino acid 734 of SEQ ID NO: 186.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 185.

(l) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO: 185, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT85; and (ab) the nucleotide sequence of the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NO: 185, but excluding the ρoly(A) tail at the 3 ' end of SEQ ID NO: 185; and

(bb) the nucleotide sequence of the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT85, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 185 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 185 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 185. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 185 from nucleotide 116 to nucleotide 4498, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 185 from nucleotide 116 to nucleotide 4498, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT 85 from nucleotide 116 to nucleotide 4498. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 185 from nucleotide 1221 to nucleotide 1711, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 185 from nucleotide 1221 to nucleotide 1711, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 185 from nucleotide 1221 to nucleotide 1711.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 186;

(b) the amino acid sequence of SEQ ID NO: 186 from amino acid 370 to amino acid 532;

(c) a fragment ofthe amino acid sequence of SEQ ID NO: 186, the fragment comprising eight contiguous amino acids of SEQ ID NO: 186; and

(d) the amino acid sequence encoded by the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 186 or the amino acid sequence of SEQ ID NO: 186 from amino acid 370 to amino acid 532. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 186 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 186, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 186 having biological activity, the fragment comprising the amino acid sequence from amino acid 725 to amino acid 734 of SEQ ID NO: 186.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 187; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 187 from nucleotide 119 to nucleotide 2176;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 187 from nucleotide 1 to nucleotide 529;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CW795_2 deposited with the ATCC under accession number 98292;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CW795_2 deposited with the ATCC under accession number

98292;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NOT88; (1) a polynucleotide encoding a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO: 188 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 188;

(j) a polynucleotide which is an allelic vanant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue ofthe protein of (h) or (l) above ;

(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(ι) and that has a length that is at least 25% of the length of SEQ ID NO- 187.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 187 from nucleotide 119 to nucleotide 2176; the nucleotide sequence of SEQ ID NOT87 from nucleotide 1 to nucleotide 529; the nucleotide sequence ofthe full-length protein coding sequence of clone CW795_2 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone CW795_2 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 188 from ammo acid 1 to ammo acid 137. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO: 188 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 188, or a polynucleotide encoding a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 188 having biological activity, the fragment compπsing the amino acid sequence from amino acid 338 to amino acid 347 of SEQ ID NO: 188.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 187.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (1) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO: 187, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 187; and

(ab) the nucleotide sequence of the cDNA insert of clone C W795_2 deposited with the ATCC under accession number 98292; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(l) preparing one or more polynucleotide primers that hybπdize in

(ba) SEQ ID NO: 187, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO.187; and

(bb) the nucleotide sequence of the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(πι). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT 87, and extending contiguously from a nucleotide sequence coπespondmg to the 5' end of SEQ ID NO: 187 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 187 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 187. Also preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 187 from nucleotide 119 to nucleotide 2176, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 187 from nucleotide 119 to nucleotide 2176, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 187 from nucleotide 119 to nucleotide 2176. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 187 from nucleotide 1 to nucleotide 529, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 187 from nucleotide 1 to nucleotide 529, to a nucleotide sequence coπespondmg to the 3' end of said sequence of SEQ ID NO: 187 from nucleotide 1 to nucleotide 529.

(a) the ammo acid sequence of SEQ ID NO: 188;

(b) the amino acid sequence of SEQ ID NO: 188 from amino acid 1 to ammo

(c) a fragment ofthe ammo acid sequence of SEQ ID NO: 188, the fragment comprising eight contiguous amino acids of SEQ ID NO: 188; and

(d) the amino acid sequence encoded by the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the ammo acid sequence of SEQ ID NO- 188 or the amino acid sequence of SEQ ID NO: 188 from ammo acid 1 to amino acid 137. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 188 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 188, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 188 having biological activity, the fragment comprising the amino acid sequence from amino acid 338 to amino acid 347 of SEQ ID NO: 188.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 189; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 189 from nucleotide 401 to nucleotide 589;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 189 from nucleotide 258 to nucleotide 627;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CW823_3 deposited with the ATCC under accession number 98292;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CW823_3 deposited with the ATCC under accession number 98292;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 190;

(i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 190 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 190;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 189. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 189 from nucleotide 401 to nucleotide 589; the nucleotide sequence of SEQ ID NOT89 from nucleotide 258 to nucleotide 627; the nucleotide sequence of the full-length protein coding sequence of clone CW823_3 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone CW823_3 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 190 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ

ID NO: 190, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 190 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO: 190.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 189. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:

(aa) SEQ ID NO: 189, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 189; and

(ab) the nucleotide sequence of the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292;

(l) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO: 189, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 189; and

(bb) the nucleotide sequence of the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292; (π) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (m) amplifying human DNA sequences; and

(IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 189, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 189 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 189 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 189. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 189 from nucleotide 401 to nucleotide 589, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 189 from nucleotide 401 to nucleotide 589, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 189 from nucleotide 401 to nucleotide 589. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 189 from nucleotide 258 to nucleotide 627, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 189 from nucleotide 258 to nucleotide 627, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 189 from nucleotide 258 to nucleotide 627.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 190; (b) a fragment ofthe amino acid sequence of SEQ ID NO: 190, the fragment comprising eight contiguous amino acids of SEQ ID NO: 190; and

(c) the amino acid sequence encoded by the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 190. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ

ID NO: 190 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 190, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO : 190 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ

ID NO: 190.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 191; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 191 from nucleotide 548 to nucleotide 868;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 191 from nucleotide 590 to nucleotide 868;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone DF989_3 deposited with the ATCC under accession number 98292;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone DF989_3 deposited with the ATCC under accession number 98292;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO.T92;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 192 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 192;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 191. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 191 from nucleotide 548 to nucleotide 868; the nucleotide sequence of SEQ ID NO: 191 from nucleotide 590 to nucleotide 868; the nucleotide sequence of the full-length protein coding sequence of clone DF989_3 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone DF989_3 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 192 from amino acid 75 to amino acid 107. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 192 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 192, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 192 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO: 192. Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NOT91 and SEQ ID NO: 193.

(i) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO: 191; (ab) SEQ IDNOT93, but excluding thepoly(A) tail atthe 3' end of SEQ ID NO: 193; and

(ac) the nucleotide sequence of the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NOT91;

(bb) SEQ ID NO : 193 , but excluding the poly( A) tail at the 3 ' end of SEQ ID NO: 193; and (be) the nucleotide sequence of the cDNA insert of clone

DF989_3 deposited with the ATCC under accession number 98292; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequences of SEQ ID NOT91 and SEQ ID NOT93, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 191 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 193, but excluding the poly(A) tail at the 3' end of SEQ ID NO: 193. Also preferably the polynucleotide isolated accordmg to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 191, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 191 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 191. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO -191 from nucleotide 548 to nucleotide 868, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 191 from nucleotide 548 to nucleotide 868, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 191 from nucleotide 548 to nucleotide 868. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 191 from nucleotide 590 to nucleotide 868, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 191 from nucleotide 590 to nucleotide 868, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 191 from nucleotide 590 to nucleotide 868. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NOT 92;

(b) the amino acid sequence of SEQ ID NO: 192 from amino acid 75 to amino acid 107; (c) a fragment ofthe ammo acid sequence ofSEQ ID NO- 192, the fragment comprising eight contiguous amino acids of SEQ ID NO: 192; and

(d) the ammo acid sequence encoded by the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the ammo acid sequence of SEQ ID NO: 192 or the amino acid sequence of SEQ ID

NO: 192 from amino acid 75 to amino acid 107. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the ammo acid sequence of SEQ ID NO: 192 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous ammo acids of SEQ ID NO: 192, or a protein comprising a fragment ofthe ammo acid sequence of SEQ ID NO: 192 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 48 to ammo acid 57 of SEQ ID NO: 192.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequenceof SEQIDNOT94; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 194 from nucleotide 251 to nucleotide 787;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 194 from nucleotide 371 to nucleotide 787; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone DL162_1 deposited with the ATCC under accession number 98292;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone DL162_1 deposited with the ATCC under accession number 98292; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone DL162_1 deposited with the ATCC under accession number 98292;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone DL162_1 deposited with the ATCC under accession number 98292; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NOT95;

(i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 195 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 195; (j) ^a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue ofthe protein of (h) or (i) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 194. Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 194 from nucleotide 251 to nucleotide 787; the nucleotide sequence of SEQ ID NO: 194 from nucleotide 371 to nucleotide 787; the nucleotide sequence of the full-length protein coding sequence of clone DL162_1 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone DL162_1 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone DL162_1 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 195 from amino acid 38 to amino acid 170. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 195 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 195, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 195 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ ID NO: 195. Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID

NO: 194.

(aa) SEQ ID NOT 94, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 194; and (ab) the nucleotide sequence of the cDNA insert of clone

DL162_1 deposited with the ATCC under accession number 98292; (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO: 194, but excluding the poly(A) tail at the 3' end of SEQ ID NOT94; and

(bb) the nucleotide sequence of the cDNA insert of clone DL162_1 deposited with the ATCC under accession number 98292; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 194, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 194 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 194 , but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 194. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 194 from nucleotide 251 to nucleotide 787, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NOT 94 from nucleotide 251 to nucleotide 787, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 194 from nucleotide 251 to nucleotide 787. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 194 from nucleotide 371 to nucleotide 787, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NOT94 from nucleotide 371 to nucleotide 787, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT 94 from nucleotide 371 to nucleotide 787.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NOT 95;

(b) the amino acid sequence ofSEQ ID NO: 195 from amino acid 38 to amino acid 170;

(c) a fragment ofthe amino acid sequence of SEQ ID NO: 195, the fragment comprising eight contiguous amino acids of SEQ ID NO: 195; and (d) the amino acid sequence encoded by the cDNA insert of clone DL162 1 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 195 or the amino acid sequence of SEQ ID NO: 195 from amino acid 38 to amino acid 170. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID

NOT 95 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 195, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NOT 95 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ ID NO: 195. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 196;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 196 from nucleotide 121 to nucleotide 3345;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 196 from nucleotide 160 to nucleotide 3345;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 196 from nucleotide 2592 to nucleotide 3318; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone DL162_2 deposited with the ATCC under accession number 98292;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone DL162_2 deposited with the ATCC under accession number 98292; (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone DL162_2 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone DL162_2 deposited with the ATCC under accession number 98292; (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 197;

(j) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 197 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 197; (k) a polynucleotide which is an allehc variant of a polynucleotide of (a)-(h) above;

(1) a polynucleotide which encodes a species homologue ofthe protein of (i) or (j) above ;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NOT 96.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 196 from nucleotide 121 to nucleotide 3345; the nucleotide sequence of SEQ ID NO: 196 from nucleotide 160 to nucleotide 3345; the nucleotide sequence of SEQ ID NO: 196 from nucleotide 2592 to nucleotide 3318; the nucleotide sequence of the full-length protein coding sequence of clone DL162_2 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone DL162_2 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full- length or a mature protein encoded by the cDNA insert of clone DL162_2 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the ammo acid sequence of SEQ ID NO: 197 from ammo acid 860 to amino acid 1066. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO : 197 having biological activity, the fragment preferably compnsmg eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 197, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 197 having biological activity, the fragment comprising the ammo acid sequence from ammo acid 532 to ammo acid 541 of SEQ ID NO: 197.

Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID NO: 196.

(I) preparing one or more polynucleotide probes that hybπdize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO- 196, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO:196; and

(ab) the nucleotide sequence of the cDNA insert of clone DL162_2 deposited with the ATCC under accession number 98292; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(I) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (ba) SEQ ID NO: 196, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 196; and

(bb) the nucleotide sequence of the cDNA insert of clone DL162_2 deposited with the ATCC under accession number 98292; (n) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(nι). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT 96, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 196 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 196 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 196. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 196 from nucleotide 121 to nucleotide 3345, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 196 from nucleotide 121 to nucleotide 3345, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 196 from nucleotide 121 to nucleotide 3345. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 196 from nucleotide 160 to nucleotide 3345, and extending contiguously from a nucleotide sequence coπespondmg to the 5' end of said sequence of SEQ ID NO: 196 from nucleotide 160 to nucleotide 3345, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT96 from nucleotide 160 to nucleotide 3345. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 196 from nucleotide 2592 to nucleotide

3318, and extending contiguously from a nucleotide sequence coπesponding to the 5' end ofsaid sequence of SEQ ID NO: 196 from nucleotide 2592 to nucleotide 3318, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 196 from nucleotide 2592 to nucleotide 3318. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 197;

(b) the ammo acid sequence of SEQ ID NOT97 from amino acid 860 to

(c) a fragment ofthe amino acid sequence of SEQ ID NO: 197, the fragment comprising eight contiguous amino acids of SEQ ID NO: 197; and

(d) the amino acid sequence encoded by the cDNA insert of clone DL 162_2 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NOT 97 or the amino acid sequence of SEQ ID NO: 197 from amino acid 860 to amino acid 1066. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 197 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 197, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 197 having biological activity, the fragment comprising the amino acid sequence from amino acid 532 to amino acid 541 of SEQ ID NO: 197.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 198;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 198 from nucleotide 117 to nucleotide 2600;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 198 from nucleotide 2130 to nucleotide 2600;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO : 198 from nucleotide 1 to nucleotide 506;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone EC 172_1 deposited with the ATCC under accession number 98292;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone EC172_1 deposited with the ATCC under accession number 98292;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 199; ( ) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 199 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 199;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO: 198.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 198 from nucleotide 117 to nucleotide 2600; the nucleotide sequence of SEQ ID NO: 198 from nucleotide 2130 to nucleotide 2600; the nucleotide sequence of SEQ ID NO: 198 from nucleotide 1 to nucleotide 506; the nucleotide sequence ofthe full-length protein coding sequence of clone EC172_1 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone EC 172_1 deposited with the ATCC under accession number 98292. In other prefeπed embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292. In yet other prefeπed embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 199 from ammo acid 1 to ammo acid 130. In further prefeπed embodiments, the present invention provides a polynucleotide encoding a protein compπsing a fragment of the ammo acid sequence of SEQ ID NO: 199 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 199, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO : 199 having biological activity, the fragment comprising the amino acid sequence from ammo acid 409 to ammo acid 418 of SEQ ID NOT99. Other embodiments provide the gene coπesponding to the cDNA sequence of SEQ ID

NO: 198.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of. (a) a process comprising the steps of: (1) preparing one or more polynucleotide probes that hybridize in 6X

(aa) SEQ ID NO: 198, but excluding the poly(A) tail at the 3 ' end of SEQ ID NO: 198; and

(ab) the nucleotide sequence of the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292; (n) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C, and (in) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(l) preparing one or more polynucleotide primers that hybridize in

(ba) SEQ ID NOT 98, but excluding the poly(A) tail at the 3 ' end of SEQ ID NOT98; and

(bb) the nucleotide sequence of the cDNA insert of clone EC172_ 1 deposited with the ATCC under accession number 98292; (π) hybridizing said pπmer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(in) amplifying human DNA sequences; and (IV) isolating the polynucleotide products of step (b)(m). Preferably the polynucleotide isolated according to the above process compπses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 198, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of SEQ ID NO: 198 to a nucleotide sequence coπesponding to the 3' end of SEQ ID NO: 198 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 198. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 198 from nucleotide 117 to nucleotide 2600, and extending contiguously from a nucleotide sequence coπespondmg to the 5' end ofsaid sequence of SEQ ID NO: 198 from nucleotide 117 to nucleotide 2600, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 198 from nucleotide 117 to nucleotide 2600. Also preferably the polynucleotide isolated according to the above process compnses a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NOT98 from nucleotide 2130 to nucleotide 2600, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 198 from nucleotide 2130 to nucleotide 2600, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NO: 198 from nucleotide 2130 to nucleotide 2600. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence coπesponding to the cDNA sequence of SEQ ID NO: 198 from nucleotide 1 to nucleotide 506, and extending contiguously from a nucleotide sequence coπesponding to the 5' end of said sequence of SEQ ID NO: 198 from nucleotide 1 to nucleotide 506, to a nucleotide sequence coπesponding to the 3' end of said sequence of SEQ ID NOT98 from nucleotide 1 to nucleotide 506.

(a) the ammo acid sequence of SEQ ID NO: 199;

(b) the ammo acid sequence of SEQ ID NO: 199 from ammo acid 1 to ammo

(c) a fragment ofthe amino acid sequence of SEQ ID NO: 199, the fragment comprising eight contiguous ammo acids of SEQ ID NO: 199; and

(d) the amino acid sequence encoded by the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292; the protein being substantially free from other mammalian proteins. Preferably such protein compπses the amino acid sequence of SEQ ID NO: 199 or the ammo acid sequence of SEQ ID NO: 199 from amino acid 1 to amino acid 130. In further prefeπed embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 199 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 199, or a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 199 having biological activity, the fragment comprising the ammo acid sequence from amino acid 409 to ammo acid 418 of SEQ

ID NO: 199.

In certain prefeπed embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) coπesponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

(a) growing a culture ofthe host cell transformed with such polynucleotide compositions in a suitable culture medium; and (b) purifying the protein from the culture. The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable caπier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention. Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable caπier.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and IB are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

DETAILED DESCRIPTION ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence ofthe protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing. As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane ofthe endoplasmic reticulum.

Clone "AX65 22"

A polynucleotide of the present invention has been identified as clone "AX65_22".

AX65_22 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. AX65_22 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AX65_22 protein").

The nucleotide sequence ofthe 5' portion of AX65_22 as presently determined is reported in SEQ ID NO . What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:2. The predicted amino acid sequence ofthe AX65_22 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 8 to 20 of SEQ ID NO:2 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe AX65_22 protein. Additional nucleotide sequence from the 3' portion of AX65_22, including a poly(A) tail, is reported in SEQ ID NO:3.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AX65_22 should be approximately 3500 bp.

The nucleotide sequence disclosed herein for AX65_22 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AX65_22 demonstrated at least some similarity with sequences identified as T08476 (Eukaryotic expression vector p APEX-3p) and U46493 (Cloning vector pFlp recombinase gene, complete cds) . The predicted AX65_22 protein demonstrated at least some homology with sequences identified as JO 1969 (DNA polymerase [Human adeno virus type 5]), R07640 (Deduced protein sequence of pi 70-2 comprising T4), and X57205 (fibroblast growth factor receptor [Homo sapiens]). Based upon sequence similarity, AX65_22 proteins and each similar protein or peptide may share at least some activity.

Clone "BD335 14"

A polynucleotide of the present invention has been identified as clone "BD335_14". BD335_14 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. BD335_14 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BD335_14 protein").

The nucleotide sequence of BD335 14 as presently determined is reported in SEQ ID NO:4, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BD335_14 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:5.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BD335_14 should be approximately 3000 bp. The nucleotide sequence disclosed herein for BD335_14 was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. The predicted BD335_14 protein demonstrated at least some similarity with sequences identified as U83511 (APXL [Homo sapiens]). Based upon sequence similarity, BD335_ 14 proteins and each homologous protein or peptide may share at least some activity. The TopPredll computer program predicts three potential transmembrane domains within the BD335_14 protein sequence, one centered around amino acid 80, another around amino acid 320, and a third around ammo acid 700 of SEQ ID NO: 5.

Clone "BG241 1" A polynucleotide of the present invention has been identified as clone "BG241_1 ".

BG241_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe ammo acid sequence of the encoded protein. BG241_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BG241_1 protein").

The nucleotide sequence ofthe 5' portion of BG241_1 as presently determined is reported in SEQ ID NO:6. An additional internal nucleotide sequence from BG241_1 as presently determined is reported in SEQ ID NO:7. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO: 8. Additional nucleotide sequence from the 3' portion of BG241 1, including a poly(A) tail, is reported in SEQ ID NO:9.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BG241_1 should be approximately 800 bp.

The nucleotide sequence disclosed herein for BG241_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG241_1 demonstrated at least some similarity with sequences identified as AI082187 (ox75f01.xl Soares_NhHMPu_Sl Homo sapiens cDNA clone IMAGE 1662169 3' similar to contains element MSR1 repetitive element; mRNA sequence), W38781 (zb27g08.rl Soares parathyroid tumor NbHPA Homo sapiens), and Y12781 (Homo sapiens mRNA for transducin (beta) like 1 protein). The predicted BG241_1 protein demonstrated at least some similarity to sequences identified as Y12781 (transducin (beta) like 1 protein [Homo sapiens]) and other beta-transducin-like proteins (see GenBank accession numbers L28125 and T86738). Based upon sequence similarity, BG241_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BLl 87 4"

A polynucleotide of the present invention has been identified as clone "BL187_4". BLl 87 4 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. BL187_4 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BL187_4 protein").

The nucleotide sequence of BL187_4 as presently determined is reported in SEQ ID NO: 10, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BL187_4 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NOT 1. Amino acids 17 to 29 of SEQ ID NO: 11 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BLl 87_4 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BL187_4 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for BL 187_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BL187_4 demonstrated at least some similarity with sequences identified as

AA476210 (zw35g01.si Soares ovary tumor NbHOT Homo sapiens cDNA clone 771312 3', mRNA sequence), AA868505 (ak43b04.sl Soares testis NHT Homo sapiens cDNA clone IMAGE 1408687 3' similar to SW PLZF HUMAN Q05516 ZINC FINGER PROTEIN PLZF; mRNA sequence), AA927876 (oml8b09.sl Soares NFL T GBC SI Homo sapiens cDNA clone IMAGE: 1541369 3', mRNA sequence), AD000671 (Homo sapiens DNA from chromosome 19-cosmid £24109 containing HRX2, genomic sequence), H48938 (EST0010 Homo sapiens cDNA clone HTN-6-15), and Z63958 (H.sapiens CpG DNA, clone 93dl0, forward read cpg93dl0.ftla). The predicted amino acid sequence disclosed herein for BL187_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BL187_4 protein demonstrated at least some similarity to sequences identified as R95242 (HIC-1 polypeptide), Z 19002 (kruppel-like zinc finger protein [Homo sapiens]), and a number of other zinc- finger proteins. Based upon sequence similarity, BL 187_4 proteins and each similar protein or peptide may share at least some activity. Motifs analysis indicates the presence of two zinc-finger (C2H2 type) domains centered around amino acids 375 and 430 of SEQ ID NO: 11 , respectively. The TopPredll computer program predicts two potential transmembrane domains within the BL187_4 protein sequence, one centered around ammo acid 30 and another around ammo acid 260 of SEQ ID NO: 11. BL 187_4 protein appears to be a novel secreted or membrane-associated zmc-finger protein.

Clone "BL249 18"

A polynucleotide of the present invention has been identified as clone "BL249_18". BL249_18 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BL249_18 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BL249_18 protein").

The nucleotide sequence of BL249_18 as presently determined is reported in SEQ ID NO: 12, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BL249_18 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 13. Ammo acids 32 to 44 of SEQ ID NO: 13 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 45. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BL249_18 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BL249_18 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for BL249_18 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BL249_18 demonstrated at least some similarity with sequences identified as AA034864 (mi53f01.rl Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 467257 5'), AA115100 (zl02hl2.sl Soares pregnant uterus NbHPU Homo sapiens cDNA clone 491207 3'), AA219365 (zr04c06.rl Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone 650506 5'), AA399095 (zt59b06.rl Soares testis NHT Homo sapiens cDNA clone 72661 1 5'), R82633 (yj20a05.sl Homo sapiens cDNA clone 149264 3'), and T22047 (Human gene signature HUMGS03590). The predicted amino acid sequence disclosed herein for BL249_18 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BL249_18 protein demonstrated at least some similarity to sequences identified as AC003673 (unknown protein (AAC09020.1) [Arabidopsis thaliana]) and Z98598 (hypothetical protein [Schizosaccharomyces pombe]). Based upon sequence similarity, BL249_18 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains within the BL249_ 18 protein sequence, one centered around amino acid 45 and another around amino acid 680 of SEQ ID NO: 13.

Clone "BQ71 1"

A polynucleotide of the present invention has been identified as clone "B071_l". B071_1 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. B071_l is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "B071_l protein").

The nucleotide sequence ofthe 5' portion of B071 1 as presently determined is reported in SEQ ID NO: 14. An additional internal nucleotide sequence from B071_l as presently determined is reported in SEQ ID NO: 15. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO: 16. Additional nucleotide sequence from the 3' portion of B071 1, including a poly(A) tail, is reported in SEQ ID NO: 17. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone

B071_l should be approximately 2000 bp.

The nucleotide sequence disclosed herein for B071 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. B071_l demonstrated at least some similarity with sequences identified as X86809 (H.sapiens mRNA for major astrocytic phosphoprotein PEA-15). The predicted amino acid sequence disclosed herein for B071_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted B071_l protein demonstrated at least some similarity to sequences identified as U06144 (cellular disintegrin-related protein [Mus musculus]). Based upon sequence similarity, B071_l proteins and each similar protein or peptide may share at least some activity. Clone "BQ365 2"

A polynucleotide of the present invention has been identified as clone "B0365_2". B0365_2 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5 ,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. B0365_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "B0365_2 protein").

The nucleotide sequence of B0365_2 as presently determined is reported in SEQ ID NO: 18, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the B0365_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 19.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone B0365_2 should be approximately 2800 bp.

The nucleotide sequence disclosed herein for B0365_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. B0365_2 demonstrated at least some similarity with sequences identified as D63876 (Human mRNA for KIAAO 154 gene, partial cds) and Z83844 (Human DNA sequence * * * SEQUENCING IN PROGRESS *** from clone 37E16; HTGS phase 1). The predicted amino acid sequence disclosed herein for B0365_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted B0365_2 protein demonstrated at least some similarity to sequences identified as D 10250 (alpha-fetoprotein enhancer binding protein [Homo sapiens]), D63876 (KIAA0154 gene product is related to mouse gamma adaptin [Homo sapiens]), and R23962 (AFP-1). Based upon sequence similarity, B0365_2 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts three potential transmembrane domains within the B0365_2 protein sequence, centered around amino acids 70, 140, and 180 of SEQ ID NO: 19, respectively.

Clone "BV51 1" A polynucleotide of the present invention has been identified as clone "BV51_1".

BV51_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BV51_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BV51_1 protein"). The nucleotide sequence ofthe 5' portion of BV51_1 as presently determined is reported in SEQ ID NO:20. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:21. The predicted amino acid sequence ofthe BV51_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:21. Additional nucleotide sequence from the 3' portion of BV51_1 , including a poly(A) tail, is reported in SEQ ID NO:22.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BV51_1 should be approximately 970 bp.

The nucleotide sequence disclosed herein for BV51_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV51_1 demonstrated at least some similarity with sequences identified as ABOl 2130 (Homo sapiens SBC2 mRNA for sodium bicarbonate cotransporter2, complete cds) and U46493 (Cloning vector pFlp recombinase gene, complete cds). The predicted amino acid sequence disclosed herein for BV51_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BV51_1 protein demonstrated at least some similarity to sequences identified as ABOl 213 (sodium bicarbonate cotransporter2 [Homo sapiens]). Based upon sequence similarity, BV51_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BV140 3"

A polynucleotide of the present invention has been identified as clone "BV140_3". BV140_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5 ,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BV140_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BV140_3 protein").

The nucleotide sequence ofthe 5' portion of BV 140_3 as presently determined is reported in SEQ ID NO:23. An additional internal nucleotide sequence from BV140_3 as presently determined is reported in SEQ ID NO:24. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID

NO:25. Additional nucleotide sequence from the 3' portion of BV140_3, including a poly(A) tail, is reported in SEQ ID NO:26.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BV140_3 should be approximately 3500 bp. The nucleotide sequence disclosed herein for BV140_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV140_3 demonstrated at least some similarity with sequences identified as H72799 (yu07dl0.rl Homo sapiens cDNA clone 233107 5') and T94057 (ye33g08.rl Homo sapiens cDNA clone 119582 5'). Based upon sequence similarity, BV140_3 proteins and each similar protein or peptide may share at least some activity.

Clone "BV141 2"

A polynucleotide of the present invention has been identified as clone "BV141_2". BV141_2 was isolated from a human adult bram cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BV141_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BV141_2 protein"). The nucleotide sequence of BV141_2 as presently determined is reported in SEQ ID

NO:27, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BV141_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO.28.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BV141_2 should be approximately 1100 bp.

The nucleotide sequence disclosed herein for BV 141_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV141_2 demonstrated at least some similarity with sequences identified as L26860 (Mus musculus (C6e) heavy chain immunoglobulin variable region gene). Based upon sequence similarity, B V 141_2 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains withm the B V 141_2 protein sequence, one centered around ammo acid 34 and another around amino acid 65 of SEQ ID NO:28. The nucleotide sequence of BV141_2 indicates that it may contain one or more ofthe following repetitive element(s): LI repeat.

Clone "CC 194 4"

A polynucleotide of the present invention has been identified as clone "CC194_4". CC194_4 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CC194_4 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CC194_4 protein").

The nucleotide sequence ofthe 5' portion of CC 194_4 as presently determined is reported in SEQ ID NO:29. What applicants presently believe is the proper reading frame for the coding region is indicated m SEQ ID NO:30. The predicted amino acid sequence ofthe CC194 4 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Amino acids 88 to 100 of SEQ ID NO:30 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 101. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe CC194_4 protein. Additional nucleotide sequence from the 3' portion of CC194_4, including a poly(A) tail, is reported in SEQ ID NO:31.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone CC194_4 should be approximately 3300 bp. The nucleotide sequence disclosed herein for CC 194_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC194_4 demonstrated at least some similarity with sequences identified as AA722214 (zh20fl0.sl Soares pineal gland N3HPG Homo sapiens cDNA clone 412651 3', mRNA sequence), HI 1476 (ymlOhOδ.sl Homo sapiens cDNA clone 47781 3'), HI 1581 (ymlOhOδ.rl Soares infant brain INIB Homo sapiens cDNA clone IMAGE:47781 5' similar to SP:C36E8.3 CE00911 ; mRNA sequence), H23044 (ym51d07.rl Homo sapiens cDNA clone 52058 5' similar to SP:C36E8.3 CE00911), N93789 (zb64g05.sl Soares fetal lung NbHL19W Homo sapiens cDNA clone 308408 3'), and W54544 (mc99a01.rl Soares mouse embryo NbME 13.5 14.5 Musmusculus). The predicted amino acid sequence disclosed herein for CC194_4 was searched against the GenPept and GeneSeq ammo acid sequence databases using the BLASTX search protocol. The predicted CC194_4 protein demonstrated at least some similarity to sequences identified as M38561 (CAD [Homo sapiens]). Based upon sequence similarity, CC 194_4 proteins and each similar protein or peptide may share at least some activity.

Clone "DAI 36 11"

A polynucleotide of the present invention has been identified as clone "DA136_11". DA136_11 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. DA136_1 1 includes at least a portion of the coding sequence of a secreted protein (also refeπed to herein as "DA136_11 protein"). The nucleotide sequence of DA 136 11 as presently determined is reported in SEQ ID

NO:32, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the DA136_11 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:33.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone DA136_11 should be approximately 3800 bp.

The nucleotide sequence disclosed herein for DA136_11 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. DA136_11 demonstrated at least some similarity with sequences identified as AA523414 (ng30a07.sl NCI_CGAP_Co3 Homo sapiens cDNA clone 936276), H89334 (yw25h09.rl Homo sapiens cDNA clone 253313 5'), R59925 (yhl lbl2.sl Homo sapiens cDNA clone 42891 3), T66165 (Human interleukin-12 receptor alpha chain NR4 DNA), Y09328 (H.sapiens mRNA for IL13 receptor alpha-1 chain), and Y10659 (H.sapiens IL-13Ra mRNA). The predicted amino acid sequence disclosed herein for DA136_11 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted DA136_11 protein demonstrated at least some similarity to sequences identified as L08960 (cell adhesion molecule [Gallus gallus]), M34083 (lactogen receptor precursor [Rattus norvegicus]), M59941 (GM-CSF receptor beta chain [Homo sapiens]), W09822 (Human interleukin-12 receptor alpha chain NR4), X61178 (interleukin-5 receptor type 3 [Homo sapiens]), and Y10659 (IL-13Ra [Homo sapiens]). Based upon sequence similarity, DA136_11 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the DA136_11 protein sequence, centered around amino acid 215 of SEQ ID NO:33.

Clone "AR415 4"

A polynucleotide of the present invention has been identified as clone "AR415_4". AR415_4 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. AR415_4 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AR415_4 protein").

The nucleotide sequence of AR415_4 as presently determined is reported in SEQ ID NO:34, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AR415_4 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:35. Amino acids 14 to 26 of SEQ ID NO:35 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the AR415_4 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AR415_4 should be approximately 1500 bp.

The nucleotide sequence disclosed herein for AR415_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AR415_4 demonstrated at least some similarity with sequences identified as AA100799 (zm26d01.sl Stratagene pancreas (#937208) Homo sapiens cDNA clone 526753 3'), AA100852 (zm26d01.rl Stratagene pancreas (#937208) Homo sapiens cDNA clone 526753 5' similar to SW CO02_HUMAN PI 9075 TUMOR-ASSOCIATED ANTIGEN CO-029), AA146605 (zo35c09.rl Stratagene colon (#937204) Homo sapiens cDNA clone 588880 5' similar to SW:CO02_HUMAN P19075 TUMOR- ASSOCIATED ANTIGEN CO-029), AA224847 (nc33cl2.sl NCI CGAP Pr2 Homo sapiens cDNA clone 4079 similar to SW:CO02_HUMAN P19075 TUMOR-ASSOCIATED ANTIGEN CO-029), AA225191 (nc21h08.sl NCI CGAP Prl Homo sapiens cDNA clone 2968), AA593864 (nnl9f08.sl NCI_CGAP_Col2 Homo sapiens cDNA clone IMAGE: 1084359), D26483 (Mouse mRNA for PE31/TALLA), M33680 (Human 26-kDa cell surface protein TAPA-1 mRNA, complete cds), T14726 (Human CD53 antigen cDNA), and T23814 (Human gene signature HUMGS05723). The predicted amino acid sequence disclosed herein for AR415_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AR415_4 protein demonstrated at least some sequence similarity with sequences identified as D29808 (TALLA-1 [Homo sapiens]), M35252 (tumor-associated antigen [Homo sapiens]), and R22360 (CO-029 tumour associated antigen protein). Based upon sequence similarity, AR415_4 proteins and each homologous protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the AR415_4 protein sequence centered around amino acid 100 of SEQ ID NO:35. Clone "AS63 29"

A polynucleotide of the present invention has been identified as clone "AS63_29". AS63_29 was isolated from a human fetal bram cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. AS63_29 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AS63_29 protein").

The nucleotide sequence ofthe 5' portion of AS63 29 as presently determined is reported in SEQ ID NO:36. What applicants presently believe is the proper reading frame for the coding region is indicated m SEQ ID NO:37. The predicted ammo acid sequence ofthe AS63_29 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:37. Amino acids 28 to 40 of SEQ ID NO:37 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at ammo acid 41. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe AS63_29 protein. Additional nucleotide sequence from the 3' portion of AS63 29, including a poly(A) tail, is reported in SEQ ID NO:38.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AS63_29 should be approximately 1700 bp. The nucleotide sequence disclosed herein for AS63_29 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AS63_29 demonstrated at least some similarity with sequences identified as L26877 (Mus musculus (B20c) heavy chain immunoglobulin variable region gene), T09146 (EST07039 Homo sapiens cDNA clone HIBBP68 5' end), T23466 (seq3050 Homo sapiens cDNA clone Hyl8-Chl3-Charon40-cDNA-100 3'), and W55739 (ma35f05.rl Life Tech mouse brain Mus musculus cDNA clone 312705 5'). The predicted amino acid sequence disclosed herein for AS63_29 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AS63_29 protein demonstrated at least some sequence similarity with sequences identified as R04032 (Full length T4 encoded by plasmid pBG381). Based upon sequence similarity, AS63_29 proteins and each homologous protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the AS63_29 protein sequence, near the ammo terminus.

Clone "AY304 14" A polynucleotide of the present invention has been identified as clone "AY304_14". AY304_14 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. AY304_14 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AY304_14 protein").

The nucleotide sequence of AY304_14 as presently determined is reported in SEQ ID NO:39, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AY304_14 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:40.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AY304_14 should be approximately 2200 bp.

The nucleotide sequence disclosed herein for AY304_14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AY304_14 demonstrated at least some similarity with sequences identified as AA127688 (zk92fD5.sl Soares pregnant uterus NbHPU Homo sapiens cDNA clone 490305 3'), AA179609 (zp49gl l.rl Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 612836 5'), AA276253 (vc40f05.rl Barstead MPLRB1 Mus musculus cDNA clone 777057 5'), H15545 (ym27d04.sl Homo sapiens cDNA clone 49495 3' similar to contains PTR5 repetitive element), L08441 (Human autonomously replicating sequence (ARS) mRNA), N34949 (yy49h09.s 1 Homo sapiens cDNA clone 276929 3'), R48594 (yj65d07.sl Homo sapiens cDNA clone 153613 3'), T21160 (Human gene signature HUMGS02466), U43284 (Cloning vector phGFP-S65T, complete sequence, green fluorescent protein (gfp) gene, complete cds), and Z45151 (H. sapiens partial cDNA sequence; clone c-2hh04). The predicted amino acid sequence disclosed herein for AY304_14 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AY304_14 protein demonstrated at least some sequence similarity with sequences identified as D86984 (similar to yeast adenylate cyclase (S56776) [Homo sapiens]), J01415 (cytochrome oxidase subunit 3 [Homo sapiens]), V00662 (cytochrome oxidase III [Homo sapiens]), and X68948 (envelope glycoprotein [Spleen focus-forming virus]). Based upon sequence similarity, AY304_14 proteins and each homologous protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains within the AY304_14 protein sequence, one centered around amino acid 81 and another around amino acid 120 of SEQ ID NO:40.

Clone "BGl 60 1" A polynucleotide of the present invention has been identified as clone "BG160_1". BG 160_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. BG160_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BG160_1 protein").

The nucleotide sequence of BG160 1 as presently determined is reported in SEQ ID NO:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG160_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 588 to 600 of SEQ ID NO:42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 601. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BG160_1 protein. The EcoRI Notl restriction fragment obtainable from the deposit containing clone

BG160_1 should be approximately 2300 bp.

The nucleotide sequence disclosed herein forBG160_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG160_1 demonstrated at least some similarity with sequences identified as A60021 (tropomyosin-related protein, neuronal - rat jcontains element MER27 repetitive element),

AA081525 (zn20e02.rl Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone 547994 5'), AA092565 (115773. seq.F Fetal heart, Lambda ZAP Express Homo sapiens cDNA 5'), D56138 (Human fetal brain cDNA 5'-end GEN-416H11), D61090 (Human fetal brain cDNA 5'-end GEN-155A07), D61184 (Human fetal brain cDNA 5'-end GEN-165A01), L10335 (Homo sapiens neuro-endocrine-specific protein C (NSP) mRNA, complete cds), N21304 (yx53f07.sl Homo sapiens cDNA clone 265477 3' similar to SP:A60021 A60021 TROPOMYOSIN-RELATED PROTEIN, NEURONAL), and W95814 (ze07fl l.rl Soares fetal heart NbHH19W Homo sapiens cDNA clone 358317 5' similar to PIR:A60021). The predicted amino acid sequence disclosed herein for BG160_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted

BG160_1 protein demonstrated at least some sequence similarity with sequences identified as L10334 (neuroendocrine-specific protein B [Homo sapiens]), L10335 (neuroendocrine-specific protein C [Homo sapiens]). Based upon sequence similarity, BG160_1 proteins and each homologous protein or peptide may share at least some activity. The TopPredll computer program predicts three potential transmembrane domains within the BG160_1 protein sequence, centered around amino acids 84, 484, and 595 of SEQ ID NO:42, respectively.

BG160_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 110 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "BO432 4"

A polynucleotide of the present invention has been identified as clone "BO432 4". BO432_4 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BO432_4 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BO432_4 protein").

The nucleotide sequence ofthe 5' portion of BO432 4 as presently determined is reported in SEQ ID NO:43. An additional internal nucleotide sequence from BO432_4 as presently determined is reported in SEQ ID NO:44. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:45. Additional nucleotide sequence from the 3' portion of BO432_4, including a poly(A) tail, is reported in SEQ ID NO:46. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone

BO432_4 should be approximately 1700 bp.

The nucleotide sequence disclosed herein for BO432_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BO432_4 demonstrated at least some similarity with sequences identified as AA283626 (ztl5e09.sl Soares NbHTGBC Homo sapiens cDNA clone 713224 3'), AA406486 (zvl2g02.rl Soares NhHMPu SI Homo sapiens cDNA clone 753458 5' similar to WP F35G2.2 CE05809 E.COLI YCAC LEKE), AA570446 (nk62c 12.s 1 NCI_CGAP_Sch 1 Homo sapiens cDNA clone IMAGE: 1018102), N55855 (J3389F Homo sapiens cDNA clone J3389 5'), Q10613 (Rianodin receptor gene), T62691 (yc70d 10.r 1 Homo sapiens cDNA clone 860355 '), and W90766 (zh79h04.sl Soares fetal liver spleen 1NFLS SI Homo sapiens cDNA clone 418327 3'). The predicted amino acid sequence disclosed herein for BO432_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BO432_4 protein demonstrated at least some sequence similarity with sequences identified as Z69637 (F35G2.2 [Caenorhabditiselegans]). Based upon sequence similarity, BO432_4 proteins and each homologous protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain at the amino terminus of the BO432_4 protein sequence. The BO432_4 protein may also contain the bacterial lysR family signature, a motif found in bacterial transcriptional regulators and which is possibly indicative of a helix-turn-helix structure.

Clone "BO538 2"

A polynucleotide of the present invention has been identified as clone "BO538_2". BO538_2 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BO538_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BO538_2 protein").

The nucleotide sequence ofthe 5' portion of BO538 2 as presently determined is reported in SEQ ID NO:47. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:48. The predicted amino acid sequence ofthe BO538_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:48. Additional nucleotide sequence from the 3' portion of BO538_2, including a poly(A) tail, is reported in SEQ ID NO:49.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BO538_2 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for BO538_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BO538_2 demonstrated at least some similarity with sequences identified as AA503100 (ne44h01.sl NCI_CGAP_Co3 Homo sapiens cDNA clone 900241), R44035 (yg21g09.sl Homo sapiens cDNA clone 33167 3'), T21630 (Human gene signature

HUMGS03066), and W64854 (me06dl2.rl Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 386711 5' similar to PIR S40989 S40989 hypothetical protein F55H2.6 - Caenorhabditis elegans). The predicted amino acid sequence disclosed herein for BO538_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BO538_2 protein demonstrated at least some sequence similarity with sequences identified as M60525 (nerve growth factor inducible protein [Rattus norvegicus]), R28916 (Type III procollagen), and Z27080 (F55H2.6 [Caenorhabditis elegans]). Based upon sequence similarity, BO538_2 proteins and each homologous protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains within the BO538_2 protein sequence. Clone "BR595 4"

A polynucleotide of the present invention has been identified as clone "BR595_4". BR595_4 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BR595_4 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BR595_4 protein").

The nucleotide sequence ofthe 5' portion of BR595 4 as presently determined is reported in SEQ ID NO:50. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:51. The predicted amino acid sequence ofthe BR595_4 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:51. Additional nucleotide sequence from the 3' portion of BR595 4, including a poly(A) tail, is reported in SEQ ID NO:52.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BR595_4 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for BR595 4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BR595_4 demonstrated at least some similarity with sequences identified as AA443742 (zw95b02.sl Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 784683 3'), AA600820 (np45b08.sl NCI_CGAP_Brl .l Homo sapiens cDNA clone IMAGE: 1129239), T19410 (Human gene signature HUMGS00435), W87465 (zh67c04.sl Soares fetal liver spleen 1NFLS SI Homo sapiens cDNA clone 417126 3'), and Z33587 (H. sapiens partial cDNA sequence; clone HEA89P; single read). Based upon sequence similarity, BR595_4 proteins and each homologous protein or peptide may share at least some activity.

Clone "CI490 2"

A polynucleotide of the present invention has been identified as clone "CI490_2". CI490_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CI490 2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CI490_2 protein").

The nucleotide sequence of CI490_2 as presently determined is reported in SEQ ID

NO:53, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CI490_2 protein coπesponding to the foregomg nucleotide sequence is reported in SEQ ID NO:54. Ammo acids 64 to 76 of SEQ ID NO: 54 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 77. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CI490_2 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CI490_2 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for CI490_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CI490_2 demonstrated at least some similarity with sequences identified as H30751 (yo79a04.rl Homo sapiens cDNA clone 184110 5'), H49766 (yo24f01.rl Homo sapiens cDNA clone 178873 5' similar to SP:S19586 N-METHYL-D-ASPARTATE RECEPTOR GLUTAMATE-BINDING CHAIN), H51158 (yo32d04.rl Homo sapiens cDNA clone 1796235'), R85211 (yo41dl l.sl Homo sapiens cDNA clone 180501 3' similar to SP S19586 N-METHYL-D-ASPARTATE RECEPTOR GLUTAMATE-BINDING CHAIN), SI 9586 (N-METHYL-D-ASPARTATE RECEPTOR GLUTAMATE-BINDING CHAIN), S61973 (NMDA receptor glutamate-binding subumt [rat, mRNA]), TO 1031 (Human leucine zipper protem-kinase cDNA sequence), and W56893 (zc01g05.rl Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 321080 5' similar to PER S19586 S19586 N-methyl-D-aspartate receptor glutamate -binding chain - rat). The predicted ammo acid sequence disclosed herein for CI490_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CI490_2 protein demonstrated at least some sequence similarity with sequences identified as S61973 (NMDA receptor glutamate-binding subumt [Rattus sp.]) and U08020 (collagen pro-alpha- 1 type I chain [Mus musculus]). Based upon sequence similarity, CI490_2 proteins and each homologous protein or peptide may share at least some activity. The TopPredll computer program predicts six potential transmembrane domains withm the CI490_2 protein sequence, with the most amino-termmal transmembrane domain centered around ammo acid 77 of SEQ ID NO:54.

Clone "CI522 1"

A polynucleotide of the present invention has been identified as clone "CI522_1". CI522_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CI522_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CI522_1 protein").

The nucleotide sequence ofthe 5' portion of CI522_1 as presently determined is reported in SEQ ID NO:55. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:56. The predicted amino acid sequence ofthe CI522_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:56. Amino acids 7 to 19 of SEQ ID NO:56 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe CI522_1 protein. Additional nucleotide sequence from the 3' portion of CI522_1, including a poly(A) tail, is reported in SEQ ID NO:57.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CI522_1 should be approximately 1400 bp. The nucleotide sequence disclosed herein for CI522_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CI522_1 demonstrated at least some similarity with sequences identified as AA028557 (mιl8g05.rl Soares mouse p3NMF19.5 Mus musculus cDNA clone 463928 5'), H32238 (EST107136 Rattus sp. cDNA 5' end), T33525 (EST58140 Homo sapiens cDNA 5' end similar to None), U66468 (Human cell growth regulator CGR11 mRNA, complete cds), and X00525 (Mouse 28S nbosomal RNA). The predicted amino acid sequence disclosed herein for CI522_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CI522_1 protein demonstrated at least some sequence similarity with sequences identified as U66468 (cell growth regulator CGR11 [Homo sapiens]). Based upon sequence similarity, CI522_1 proteins and each homologous protein or peptide may share at least some activity.

Clone "CN238 1"

A polynucleotide of the present invention has been identified as clone "CN238_1". CN238_1 was isolated from a human fetal bram cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5 ,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CN238_1 includes at least a portion ofthe coding sequence of a secreted protein (also refeπed to herein as "CN238_1 protein"). The nucleotide sequence of CN238_1 as presently determined is reported in SEQ ID NO:58, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CN238_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:59. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone

CN238_1 should be approximately 2190 bp.

The nucleotide sequence disclosed herein for CN238_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CN238_1 demonstrated at least some similarity with sequences identified as AA044097 (zk5 lb02.r 1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 486315 5'), AA044287 (zk51b02.sl Soares pregnant uterus NbHPU Homo sapiens cDNA clone 486315 3'), AA045440 (zk67c03.sl Soares pregnant uterus NbHPU Homo sapiens cDNA clone 487876 3'), AA143007 (zl48f01.rl Soares pregnant uterus NbHPU Homo sapiens cDNA clone 505177 5'), D51196 (Human fetal brain cDNA 3'-end GEN-016G05), D60310 (Human fetal brain cDNA 3'-end GEN-098A09), N69344 (yz43e04.sl Homo sapiens cDNA clone 285822 3' similar to gb:K00558 TUBULIN ALPHA-1 CHAIN (HUMAN)), W22250 (64B8 Human retina cDNA Tsp509I-cleaved sublibrary Homo), and X01703 (Human gene for alpha-tubulin (b alpha 1)). The predicted amino acid sequence disclosed herein for CN238_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CN238_1 protein demonstrated at least some sequence similarity with sequences identified as

K00557 (alpha-tubulin [Homo sapiens]) and U51583 (zinc finger homeodomain enhancer-binding protein-1 [Rattus norvegicus]). Based upon sequence similarity, CN238_1 proteins and each homologous protein or peptide may share at least some activity.

Clone "CO390 1"

A polynucleotide of the present invention has been identified as clone "CO390_1". CO390_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CO390_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CO390_1 protein").

The nucleotide sequence of CO390_1 as presently determined is reported in SEQ ID NO:60, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CO390 1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:61. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CO390_1 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for CO390_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CO390_1 demonstrated at least some similarity with sequences identified as H84353 (yv85al 1.rl Homo sapiens cDNA clone 2495005'), L35532 (Pan troglodytes Alu repeat region), N80616 (Genomic clone encoding SAP(Phe)), R53922 (yi03hl0.sl Homo sapiens cDNA clone 138211 3' similar to contains Alu repetitive element;contains TAR1 repetitive element), X75335 (H.sapiens Alu insertion in COL3A1 gene), X95882 (R.norvegicus mRNA for ATP ligand gated ion channel), and Y09561 (H.sapiens mRNA for P2X7 receptor). The predicted amino acid sequence disclosed herein for CO390_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CO390_1 protein demonstrated at least some sequence similarity with sequences identified as U45448 (P2xl receptor [Homo sapiens]), W04216 (Rat superior cervical ganglion p2x receptor), X83688 (ATP receptor [Homo sapiens]), X95882 (P2X7 gene product [Rattus norvegicus]), and Y09561 (ATP receptor [Homo sapiens]). Based upon sequence similarity, CO390_1 proteins and each homologous protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the CO390_1 protein sequence, centered around amino acid 249 of SEQ ID NO:61. The nucleotide sequence of CO390 1 may contain an Alu repetitive element.

CO390_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 75 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "AJ20 2"

A polynucleotide ofthe present invention has been identified as clone "AJ20_2". AJ20_2 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. AJ20_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AJ20_2 protein").

The nucleotide sequence ofthe 5' portion of AJ20_2 as presently determined is reported in SEQ ID NO:62. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO.63. The predicted ammo acid sequence ofthe AJ20_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:63. Amino acids 8 to 20 of SEQ ID NO:63 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the AJ20_2 protein. Additional nucleotide sequence from the 3' portion of AJ20_2, including a poly(A) tail, is reported in SEQ ID NO:64.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AJ20_2 should be approximately 850 bp.

The nucleotide sequence disclosed herein for AJ20_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "AR440 1 "

A polynucleotide of the present invention has been identified as clone "AR440_1". AR440_1 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5 ,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. AR440_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AR440_1 protein").

The partial nucleotide sequence of AR440_1, including its 3' end and a poly(A) tail, as presently determined is reported in SEQ ID NO:66. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:67. The predicted amino acid sequence of the AR440_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:67. Additional nucleotide sequence from the 5' portion of AR440_1 is reported in SEQ ID NO:65.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AR440_1 should be approximately 1400 bp. The nucleotide sequence disclosed herein for AR440_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The nucleotide sequence of AR440_1 indicates that it may contain an Alu repetitive element.

Clone "AS164 1" A polynucleotide of the present invention has been identified as clone "AS164_1". AS164_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. AS164_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AS164_1 protein").

The nucleotide sequence of AS164_1 as presently determined is reported in SEQ ID NO:68, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AS164_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:69.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AS164_1 should be approximately 1600 bp.

The nucleotide sequence disclosed herein for AS 164_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AS164_1 demonstrated at least some similarity with sequences identified as H24668 (yl40hl0.rl Homo sapiens cDNA clone 160771 5'), N29757 (yw90hl0.sl Homo sapiens cDNA clone 259555 3'), T62184 (yb96d08.rl Homo sapiens cDNA clone 79023 5'), Z69706 (Human DNA sequence from cosmid COS 12 from a contig from the tip ofthe short arm of chromosome 16, spanning 2Mb of 16pl3.3. Contains ESTs, Flanking sequences of 3' alpha globin H), and Z69890 (Human DNA sequence from cosmid RJ14 from a contig from the tip ofthe short arm of chromosome 16, spanning 2Mb of 16p 13.3. Contains ESTs and CpG island). The predicted amino acid sequence disclosed herein for AS164_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AS164_1 protein demonstrated at least some similarity to sequences identified as A20359_l (ryanodine receptor gene product [Homo sapiens]) and U78866 (putative arginine-aspartate-rich RNA binding protein [Arabidopsis thaliana]). Based upon sequence similarity, AS164_1 proteins and each similar protein or peptide may share at least some activity. The predicted AS164_1 protein sequence also contains repeated Asp-Arg RNA-binding motifs.

Clone "AX8 1"

A polynucleotide ofthe present invention has been identified as clone "AX8_1 ". AX8_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. AX8_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AX8_1 protein").

The nucleotide sequence of AX8_1 as presently determined is reported in SEQ ID NO:70, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted ammo acid sequence of the AX8_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:71. Amino acids 106 to 118 ofSEQ ID NO:71 are a predicted leader/signal sequence, with the predicted mature ammo acid sequence beginning at amino acid 119. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the AX8_1 protein.

The EcoRI/Notl restnction fragment obtainable from the deposit containing clone AX8_1 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for AX8_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The TopPredll computer program predicts three potential transmembrane domains within the AX8_ 1 protein sequence, centered around amino acids 111, 144, and 182 of SEQ ID NO:71, respectively.

AX8_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 35 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "BD176 3"

A polynucleotide of the present invention has been identified as clone "BD176_3". BD176_3 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BD176_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BD176_3 protein").

The nucleotide sequence ofthe 5' portion of BD 176_3 as presently determined is reported in SEQ ID NO:72. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 73. The predicted ammo acid sequence ofthe BD 176_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO : 73. Ammo acids 2 to 14 of SEQ ID NO:73 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at ammo acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe BD176_3 protein. Additional nucleotide sequence from the 3' portion of BD176 3, including a poly(A) tail, is reported in SEQ ID NO:74.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BD176_3 should be approximately 1300 bp.

The nucleotide sequence disclosed herein for BD 176_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols BD176_3 demonstrated at least some similarity with sequences identified as AA029679 (ze94gl0.rl Soares fetal heart NbHH19W Homo sapiens cDNA clone 366690 5'), D45913 (Mouse NLRR-1 mRNA for leucme-πch-repeat protein, complete cds), R55610 (yg88h08.rl Homo sapiens cDNA clone 406065'), and T07640 (EST05530 Homo sapiens cDNA clone HFBEM16). The predicted amino acid sequence disclosed herein for BD176_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol The predicted BD176_3 protein demonstrated at least some similarity to sequences identified as D45913 (leucine-πch-repeat protein [Mus musculus]) and M59472 (asparagine-πch antigen Pfa55-6 [Plasmodium falcrparum]). Based upon sequence similarity, BD176_3 proteins and each similar protein or peptide may share at least some activity.

Clone "BD339 1" A polynucleotide of the present invention has been identified as clone "BD339_1".

BD339_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe ammo acid sequence ofthe encoded protein. BD339_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BD339 1 protein").

The nucleotide sequence of BD339 1 as presently determined is reported in SEQ ID NO:75, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BD339_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:76. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone

BD339_1 should be approximately 650 bp.

The nucleotide sequence disclosed herein for BD339 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BD339_1 demonstrated at least some similarity with sequences identified as H82422 (yu80d08.sl Homo sapiens cDNA clone 240111 3), N62058 (EST53c05 Homo sapiens cDNA clone), U21730 Human 5'-nucleotidase (CD73)), W01979 (za30h09.rl Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 294113 5'), and W02015 (za32bl 1.rl Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 294237 5'). Based upon sequence similarity, BD339_1 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts three potential transmembrane domains within the BD339_1 protein sequence, centered around amino acids 14, 46, and 76 of SEQ ID NO:76, respectively.

Clone "BD427 1"

A polynucleotide of the present invention has been identified as clone "BD427_1". BD427_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BD427_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BD427_1 protein"). The nucleotide sequence of BD427_1 as presently determined is reported in SEQ ID

NO:77, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BD427_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:78.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BD427_1 should be approximately 1810 bp.

The nucleotide sequence disclosed herein for BD427_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BD427_1 demonstrated at least some similarity with sequences identified as BD427_1 demonstrated at least some similarity with sequences identified as AA027122 (zk04a03.r 1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 469516 5'), N24735 (yx56b02.sl Homo sapiens cDNA clone 265707 3'), and W84644 (zd91a06.rl Soares fetal heart NbHH19W Homo sapiens cDNA clone 356818 5'). Based upon sequence similarity, BD427_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BL229 22"

A polynucleotide of the present invention has been identified as clone "BL229_22". BL229_22 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BL229_22 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BL229_22 protein").

The nucleotide sequence of the 5' portion of BL229_22 as presently determined is reported in SEQ ID NO:79. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 80. The predicted amino acid sequence of the BL229_22 protein coπesponding to the foregoing nucleotide sequence is reported m SEQ ID NO.80. Additional nucleotide sequence from the 3' portion of BL229 22, including a poly(A) tail, is reported in SEQ ID NO:81.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone BL229_22 should be approximately 870 bp

The nucleotide sequence disclosed herein for BL229_22 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "BV123 16"

A polynucleotide of the present invention has been identified as clone "BV123_16". BV123_16 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. BV123_16 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BVl 23_16 protein").

The nucleotide sequence of BV123_16 as presently determined is reported in SEQ ID NO: 82, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BV123_16 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 83.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BV123_16 should be approximately 1080 bp.

The nucleotide sequence disclosed herein for BV123_16 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV123_16 demonstrated at least some similarity with sequences identified as

H29610 (ym61e03.sl Homo sapiens cDNA clone 52653 3'), H52374 (yq81bl2.rl Homo sapiens cDNA clone 202175 5'), H66213 (yulόhlO si Homo sapiens cDNA), L08092 (Homo sapiens dystrophm (DMD) gene, mtron 7, transposon-hke sequence), L35670 (Homo sapiens (subclone H8 10_g5 from PI 35 H5 C8) DNA sequence), M62716 (Human CSP-B gene flanking sequence), N46985 (yy83a05.sl Homo sapiens cDNA clone 280112 3'), R94603 (yq38a04.sl Homo sapiens cDNA clone 198030 3'), U91321 (Human chromosome 16pl3 BAC clone CIT987SK-363E6, complete sequence), and Z82200 (Human DNA sequence from clone J333E231). Based upon sequence similarity, BV123_16 proteins and each similar protein or peptide may share at least some activity.

Clone "CH377 1"

A polynucleotide of the present invention has been identified as clone "CH377_1". CH377_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CH377_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CH377_1 protein").

The nucleotide sequence of CH377_1 as presently determined is reported in SEQ ID NO:84, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CH377_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 85. Amino acids 5 to 17 of SEQ ID NO: 85 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CH377_1 protein.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone CH377_1 should be approximately 570 bp.

The nucleotide sequence disclosed herein for CH377_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CH377_1 demonstrated at least some similarity with sequences identified as AA507382 (nh73b01.sl NCI_CGAP_Brl.l Homo sapiens cDNA clone IMAGE 964105) and N70479 (za74fl2.sl Homo sapiens cDNA clone 298319 3'). Based upon sequence similarity, CH377_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BD441 1"

A polynucleotide of the present invention has been identified as clone "BD441_1". BD441_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. BD441_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BD441_1 protein").

The nucleotide sequence ofthe 5' portion of BD441 1 as presently determined is reported in SEQ ID NO:86. An additional internal nucleotide sequence from BD441_1 as presently determined is reported in SEQ ID NO: 87. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:88. Additional nucleotide sequence from the 3' portion of BD441_1 , including a poly(A) tail, is reported in SEQ ID NO: 89.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BD441_1 should be approximately 2400 bp.

The predicted amino acid sequence disclosed herein for BD441_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.

The predicted BD441_1 protein demonstrated at least some similarity to sequences identified as

X61615 (leukemia inhibitory factor receptor [Homo sapiens]). Based upon sequence similarity, BD441_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BD441 2"

A polynucleotide of the present invention has been identified as clone "BD441_2". BD441_2 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BD441_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BD441_2 protein").

The nucleotide sequence ofthe 5' portion of BD441_2 as presently determined is reported in SEQ ID NO:90. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 91. The predicted amino acid sequence ofthe BD441_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:91. Additional nucleotide sequence from the 3' portion of BD441_2, including a poly(A) tail, is reported in SEQ ID NO:92. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone

BD441_2 should be approximately 1200 bp.

The predicted amino acid sequence disclosed herein for BD441_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BD441_2 protein demonstrated at least some similarity to sequences identified as X61615 (leukemia inhibitory factor receptor [Homo sapiens]). Based upon sequence similarity, BD441_2 proteins and each similar protein or peptide may share at least some activity.

Clone "BG102 3" A polynucleotide of the present invention has been identified as clone "BG102_3".

BG 102_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5 ,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. BG102_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BG102_3 protein").

The nucleotide sequence of BG102 3 as presently determined is reported in SEQ ID NO:93, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG102_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:94. Amino acids 11 to 23 of SEQ ID NO:94 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BG102_3 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BG102_3 should be approximately 1100 bp.

The nucleotide sequence disclosed herein for BG 102_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG102_3 demonstrated at least some similarity with sequences identified as AC002078 (Human BAC clone RG111H14 from 7q22, complete sequence), LI 1910 (Human retinoblastoma susceptibility gene exons 1-27, complete cds), U62317 (Chromosome 22q 13 BAC

Clone CIT987SK-384D8 complete sequence), Z54147 (Human DNA sequence from cosmid L129H7, Huntington's Disease Region, chromosome 4pl6.3 contains CpG island), Z75747 (Human DNA sequence from cosmid U96H1, between markers DXS366 and DXS87 on chromosome X *), and Z80899 (Human DNA sequence from cosmid FI 121 on chromosome 6). The predicted amino acid sequence disclosed herein for BG102_3 was searched against the

GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BG102_3 protein demonstrated at least some similarity to sequences identified as M13100 (unknown protein [Rattus norvegicus]) and U15647 (reverse transcriptase [Mus musculus]). Based upon sequence similarity, BG102_3 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of BG102 3 indicates that it may contain an LI repetitive element.

BG102_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 55 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "BK158 1"

A polynucleotide of the present invention has been identified as clone "BK158_1". BK 158_1 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5 ,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BK158_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BK158_1 protein").

The nucleotide sequence of BK158_1 as presently determined is reported in SEQ ID NO:95, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BK158_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:96.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BK158_1 should be approximately 1150 bp. The nucleotide sequence disclosed herein for BK 158 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BK158_1 demonstrated at least some similarity with sequences identified as N39195 (yv26e08.sl Homo sapiens cDNA clone 243878 3') and N45263 (yv26e08.rl Homo sapiens cDNA clone 243878 5'). Based upon sequence similarity, BK158_1 proteins and each similar protein or peptide may share at least some activity.

BK158_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 28 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "BP 163 1"

A polynucleotide of the present invention has been identified as clone "BP163 1". BP 163_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. BP163_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BP163_1 protein").

The nucleotide sequence ofthe 5' portion of BP163_1 as presently determined is reported in SEQ ID NO:97. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:98. The predicted amino acid sequence ofthe BP163_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:98. Additional nucleotide sequence from the 3' portion of BP163_1, including a poly(A) tail, is reported in SEQ ID NO:99.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BP163_1 should be approximately 1240 bp.

The nucleotide sequence disclosed herein for BP 163_ 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BP 163_1 demonstrated at least some similarity with sequences identified as AA187086 (zp58h06.rl Stratagene endothelial cell 937223 Homo sapiens cDNA clone 624443 5' similar to TR G285943 G285943 ORF, COMPLETE CDS), AA301506 (EST14475 Testis tumor Homo sapiens cDNA 5' end similar to hypothetical protein (GB D14659)), D14659 (Human mRNA for KIAA0103 gene, complete cds), and W57328 (ma26dl0.rl Life Tech mouse brain Mus musculus cDNA clone). The predicted amino acid sequence disclosed herein for BP163_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BP163_1 protein demonstrated at least some similarity to sequences identified as D14659 (KIAA0103 [Homo sapiens]). Based upon sequence similarity, BP163_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BZ16 3" A polynucleotide ofthe present invention has been identified as clone "BZ 16_3 " . BZ 16_3 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BZ16 3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BZ16_3 protein").

The partial nucleotide sequence of BZ16 3, including its 3' end and a poly(A) tail, as presently determined is reported in SEQ ID NO: 101. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 102. The predicted amino acid sequence of the BZ16_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 102. Additional nucleotide sequence from the 5' portion of BZ16 3 is reported in SEQ ID NO: 100.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BZ16_3 should be approximately 2120 bp. The nucleotide sequence disclosed herein for BZ 16_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BZ16 3 demonstrated at least some similarity with sequences identified as F06886 (H. sapiens partial cDNA sequence; clone c-lnf02), F06870 (H. sapiens partial cDNA sequence; clone c-lncl l), N53511 (yz26b08.sl Homo sapiens cDNA clone 284151 3'), T65313 (yc79gl2.sl Homo sapiens cDNA clone 22132 3'), U00084 (Haemophilus influenzae), W44815 (zc21d01.sl Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 322945 3'), and Z49128 (Caenorhabditis elegans cosmid M03C11). The predicted amino acid sequence disclosed herein for BZ 16_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BZ16_3 protein demonstrated at least some similarity to sequences identified as D26185 (cell division protein [Bacillus subtilis]), L46096 (HEAHI1465_1 cell division protein [Haemophilus influenzae]), and Z49128 (CEM03C11_5 M03C11.5 [Caenorhabditis elegans]). The BZ16_3 protein demonstrated at least some similarity to ATP-dependent proteases such as ftsH. Based upon sequence similarity, BZ16 3 proteins and each similar protein or peptide may share at least some activity.

Clone "CC 182 1"

A polynucleotide of the present invention has been identified as clone "CC182_1". CC182_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CC182_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CC182_1 protein").

The nucleotide sequence of CC182_1 as presently determined is reported in SEQ ID NO: 103, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CC182_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 104. Amino acids 26 to 38 of SEQ ID NO: 104 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 39. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe CC182_1 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CC182_1 should be approximately 1600 bp. The nucleotide sequence disclosed herein for CC 182_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC182_1 demonstrated at least some similarity with sequences identified as H61159 (yu37f08.sl Homo sapiens cDNA clone 236007 3' similar to contains LI repetitive element), L09709 (Human lysosomal-associated membrane glycoproteιn-2 (LAMP2) gene, 5' end of CDS and flanking region), W44797 (zb98el0.sl Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 3208743' similar to contains Alu repetitive element), and X62167 (H.sapiens mRNA for P2 protein of peripheral myelin). Based upon sequence similarity, CC 182_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CC182_1 indicates that it may contain an LI repetitive element and/or a MER42C repetitive element.

Clone "CG109 1"

A polynucleotide of the present invention has been identified as clone "CG109_1". CG 109_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CG109_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CG109_1 protein").

The nucleotide sequence of CG109 1 as presently determined is reported in SEQ ID NO: 105, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CG109_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 106.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CG109_1 should be approximately 600 bp.

The nucleotide sequence disclosed herein for CG109_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "CJ397 1"

A polynucleotide of the present invention has been identified as clone "CJ397_1". CJ397_1 was isolated from a human fetal bram cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CJ397_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CJ397_1 protein"). The nucleotide sequence ofthe 5' portion of CJ397_1 as presently determined is reported in SEQ ID NO: 107. An additional internal nucleotide sequence from CJ397_1 as presently determined is reported in SEQ ID NO: 108. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO: 109. Additional nucleotide sequence from the 3' portion of CJ397_1 , including a poly(A) tail, is reported in SEQ ID NOT 10.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CJ397_1 should be approximately 1900 bp.

The nucleotide sequence disclosed herein for CJ397_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CJ397_1 demonstrated at least some similarity with sequences identified as H18685 (yn52b08.sl Homo sapiens cDNA clone 172023 3'), H46001 (yol3f06.sl Homo sapiens cDNA clone 177827 3'), and T77612 (yc91f06.rl Homo sapiens cDNA clone 23298 5'). Based upon sequence similarity, CJ397_1 proteins and each similar protein or peptide may share at least some activity.

Clone "AM795 4"

A polynucleotide of the present invention has been identified as clone "AM795_4". AM795_4 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. AM795_4 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AM795_4 protein").

The nucleotide sequence of AM795_4 as presently determined is reported in SEQ ID NO: 111, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AM795_4 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NOT 12. Amino acids 9 to 21 of SEQ ID NOT 12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Amino acids 138 to 150 of SEQ ID NO: 112 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 151. Due to the hydrophobic nature of the predicted and the possible leader/signal sequences, each of such sequences may act as a transmembrane domain should that leader/signal sequence not be separated from the remainder of the AM795_4 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AM795_4 should be approximately 1900 bp. The nucleotide sequence disclosed herein for AM795_4 was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AM795_4 demonstrated at least some similarity with sequences identified as AF002700 (Homo sapiens GDNF family receptor alpha 2 (GFRalpha2) mRNA, complete cds), H05619 (yl70al0.sl Homo sapiens cDNA clone 43207 3'), U46493 (Cloning vector pFlp recombinase gene, complete cds), U59486 (Rattus norvegicus GDNF receptor alpha mRNA, complete cds), V00248 (Human Ret ligand retL2 cDNA), W73633 (zd55h01.si Soares fetal heart NbHH19W Homo sapiens cDNA clone 344593 3', mRNA sequence), and W73681 (zd55h01.rl Soares fetal heart NbHH19W Homo sapiens cDNA clone 344593 5', mRNA sequence). The predicted amino acid sequence disclosed herein for AM795_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AM795_4 protein demonstrated at least some similarity to sequences identified as AF002700 (GDNF family receptor alpha 2 (GFRalpha2) [Homo sapiens]), U59486 (GDNF receptor alpha [Rattus norvegicus]), and W37460 (Human Ret ligand retL2 cDNA). A receptor complex comprised of TmRl (GDNFR alpha) and Ret was found to be capable of mediating both GDNF and NTN signaling. The receptor called TrnR2, identified based on homology to TπiRl , is 48% identical to TmRl and is encoded by a gene located on the short arm of chromosome 8. TrnR2 is attached to the cell surface via a GPI-linkage, and can mediate both NTN and GDNF signaling through Ret in vitro (Baloh et al., 1997, Neuron 18(5): 793-802, which is incorporated by reference herein). Based upon sequence similarity, AM795_4 proteins and each similar protein or peptide may share at least some activity.

AM795_4 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 76 kDa was detected in conditioned media fractions using SDS polyacrylamide gel electrophoresis.

Clone "AT340 1"

A polynucleotide of the present invention has been identified as clone "AT340_1". AT340_1 was isolated from a human adult blood (lymphocytes and dendritic cells treated with mixed lymphocyte reaction) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AT340_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AT340_1 protein").

The partial nucleotide sequence of AT340_1, including its 3' end and a poly(A) tail, as presently determined is reported in SEQ ID NOT 14. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 115. The predicted amino acid sequence of the AT340_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NOT 15. Amino acids 12 to 24 of SEQ ID NO: 115 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 25. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the AT340_1 protein. Additional nucleotide sequence from the 5' portion of AT340_1 is reported in SEQ ID NO: 113.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone AT340_1 should be approximately 1100 bp. The nucleotide sequence disclosed herein for AT340_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AT340_1 demonstrated at least some similarity with sequences identified as AA039343 (zk39g04.sl Soares pregnant uterus NbHPU Homo sapiens cDNA clone 485238 3'), R68951 (yi43g06.rl Homo sapiens cDNA clone 142042 5' similar to SP:C35D10.1 CEO 1190), R77532 (yi76c01.rl Homo sapiens cDNA), R92619 (yq04a04.rl Homo sapiens cDNA clone 195918 5' similar to SP:C35D10.1 CE01190), and W60997 (zc99f09.sl Pancreatic Islet Homo sapiens cDNA clone 339305 3'). The predicted amino acid sequence disclosed herein for AT340_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AT340_1 protein demonstrated at least some similarity to sequences identified as U21324 (similar to S. cerevisiae hypothetical protein YKL166 [Caenorhabditis elegans]). Based upon sequence similarity, AT340_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BG132 1" A polynucleotide of the present invention has been identified as clone "BG132_1 ".

BGl 32 1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BG132_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BG132_1 protein"). The nucleotide sequence ofthe 5' portion of BGl 32_1 as presently determined is reported in SEQ ID NO: 116. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NOT 17. The predicted amino acid sequence of the BG132_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 117. Amino acids 121 to 133 of SEQ ID NO: 117 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 134. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe BG132_1 protein. Additional nucleotide sequence from the 3' portion of BG 132_1 , including a poly(A) tail, is reported in SEQ ID NO: 118.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BG132_1 should be approximately 2000 bp.

The nucleotide sequence disclosed herein for BG 132_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG132_1 demonstrated at least some similarity with sequences identified as AA078587 (7P05H12 Chromosome 7 Placental cDNA Library Homo sapiens cDNA clone 7P05H12), H14301 (ym63c04.rl Homo sapiens cDNA clone 163590 5' similar to gb:U03642_cdsl PROBABLE G PROTEIN-COUPLED RECEPTOR APJ (HUMAN)), L09249 (putative G-protein coupled receptor, rhodopsin family), S79811 (adrenomedullin receptor [rats, lung, mRNA]), T36034 (rchd523 gene differentially expressed in cardiovascular disease), U58828 (Human IL8-related receptor (DRY12) mRNA, complete cds), and Y08162 (H.sapiens mRNA for heptahelix receptor). The predicted amino acid sequence disclosed herein for BG132_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BG132_1 protein demonstrated at least some similarity to sequences identified as L06109 (G protein-coupled receptor [Gallus gallus]), L34339 (galanin receptor [Homo sapiens]), U30290 (galanin receptor GALR1 [Rattus norvegicus]), U58828 (IL8-related receptor [Homo sapiens]), W03739 (rchd523 gene product (G protein-coupled receptor)), X98510 (G protein-coupled receptor [Homo sapiens]), and Y08162 (heptahelix receptor [Homo sapiens]). Based upon sequence similarity, BG132_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BG219 2"

A polynucleotide of the present invention has been identified as clone "BG219_2".

BG219_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BG219_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BG219_2 protein").

The nucleotide sequence of BG219 2 as presently determined is reported in SEQ ID NO: 119, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG219_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 120.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BG219_2 should be approximately 700 bp. The nucleotide sequence disclosed herein for BG219_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG219_2 demonstrated at least some similarity with sequences identified as AA210695 (zr88b05.sl Soares NbHTGBC Homo sapiens cDNA clone 682737 3'), C01459 (HUMGS0008450, Human Gene Signature, 3'-dιrected cDNA sequence), N22628 (EST49pl 15 Homo sapιens cDNAclone49pl l5), andT26211 (Human gene signature HUMGS08450). Based upon sequence similarity, BG219_2 proteins and each similar protein or peptide may share at least some activity.

Clone "BG366 2" A polynucleotide of the present invention has been identified as clone "BG366_2".

BG366_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BG366_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BG366_2 protein").

The nucleotide sequence of BG366_2 as presently determined is reported in SEQ ID NOT21, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG366_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 122. The amino acid sequence of another protein that could be encoded by BG366_2 is reported in SEQ ID NO:283.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BG366_2 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for BG366_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG366_2 demonstrated at least some similarity with sequences identified as N39453 (yy49h03.sl Homo sapiens cDNA clone 276917 3'). Based upon sequence similarity, BG366_2 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the BG366_2 protein sequence centered around ammo acid 92 of SEQ ID NO: 122.

Clone "BVl 72 2"

A polynucleotide of the present invention has been identified as clone "BV172_2". BV172_2 was isolated from a human adult bram cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BV172_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BV172_2 protein").

The nucleotide sequence of BV172_2 as presently determined is reported in SEQ ID NO: 123, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BV172_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 124.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BV172_2 should be approximately 1650 bp.

The nucleotide sequence disclosed herein for B V 172_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV172_2 demonstrated at least some similarity with sequences identified as No significant hits were found in the database. The TopPredll computer program predicts a potential transmembrane domain within the BV172_2 protein sequence centered around ammo acid 19 of SEQ ID NO: 124. The nucleotide sequence of BVl 72_2 indicates that it may contain one or more of the following types of repetitive elements: an element similar to chicken CR1, human LI, Mer33.

Clone "CC247 10"

A polynucleotide of the present invention has been identified as clone "CC247_10". CC247_10 was isolated from a human adult bram cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe ammo acid sequence of the encoded protein. CC247_10 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CC247_10 protein").

The nucleotide sequence of CC247_10 as presently determined is reported in SEQ ID NO: 125, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CC247_10 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 126. Amino acids 1 to 8 of SEQ ID NO: 126 are a predicted leader/signal sequence, with the predicted mature ammo acid sequence beginning at ammo acid 9. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe CC247_10 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CC247_10 should be approximately 550 bp.

The nucleotide sequence disclosed herein for CC247_10 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC247_10 demonstrated at least some similarity with sequences identified as AA291226 (zs47d03.rl NCI_CGAP_GCB 1 Homo sapiens cDNA clone 700613 5'), T05738 (EST03627 Homo sapiens cDNA clone HFBDF64), W51195 (ma 14b04.r 1 Life Tech mouse brain Mus musculus cDNA clone 304495 5'), and W93640 (zd95d09.sl Soares fetal heart NbHH19W Homo sapiens cDNA clone 357233 3'). The predicted amino acid sequence disclosed herein for CC247_10 was searched against the GenPept and GeneSeq ammo acid sequence databases using the BLASTX search protocol. The predicted CC247_10 protein demonstrated at least some similarity to sequences identified as M62424 (thrombin receptor [Homo sapiens]). The predicted CC247_10 protein is highly hydrophobic. Based upon sequence similarity, CC247_10 proteins and each similar protein or peptide may share at least some activity.

Clone "CI480 9"

A polynucleotide of the present invention has been identified as clone "CI480_9". CI480_9 was isolated from a human adult bram cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CI480_9 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CI480_9 protein").

The nucleotide sequence of CI480_9 as presently determined is reported in SEQ ID NO: 127, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CI480_9 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 128. Amino acids 39 to 51 of SEQ ID NO: 128 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 52. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CI480_9 protein.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone CI480_9 should be approximately 1940 bp.

The nucleotide sequence disclosed herein for CI480_9 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CI480_9 demonstrated at least some similarity with sequences identified as N99342 (IMAGE:20093 Homo sapiens cDNA clone 20093), R89725 (ym99d09.rl Homo sapiens cDNA clone 1670575'), and U60644 (Human HU-K4 mRNA, complete cds). The predicted amino acid sequence disclosed herein for CI480_9 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CI480_9 protein demonstrated at least some similarity to sequences identified as U60644 (HU-K4 [Homo sapiens]). Based upon sequence similarity, CI480_9 proteins and each similar protein or peptide may share at least some activity.

CI480_9 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 63 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "CO722 1"

A polynucleotide of the present invention has been identified as clone "CO722_l". CO722_l was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CO722_l is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CO722_l protein"). The nucleotide sequence of CO722_l as presently determined is reported in SEQ ID

NO: 129, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CO722_l protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 130. Amino acids 17 to 29 of SEQ ID NO: 130 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CO722_l protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CO722_l should be approximately 6800 bp. The nucleotide sequence disclosed herein for CO722_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CO722_l demonstrated at least some similarity with sequences identified as AA186616 (zp71a08.sl Stratagene endothelial cell 937223 Homo sapiens cDNA clone 625622 3' similar to contains Alu repetitive element), H10376 (ym08a03.sl Homo sapiens cDNA clone 47067 3'), N86013 (J5997F Fetal heart, Lambda ZAP Express Homo sapiens cDNA), U55258 (Human hBRAVO Nr-CAM precursor (hBRAVO/ Nr-CAM) gene, complete cds), W 19770 (zb39d01.rl Soares parathyroid tumor NbHPA Homo sapiens), W31608 (zb91d09.rl Soares parathyroid tumor NbHPA Homo sapiens cDNA clone), and X58482 (Chicken mRNA for neuronal transmembrane protein Nr-CAM, ng-CAM related). The predicted amino acid sequence disclosed herein for CO722_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CO722_l protein demonstrated at least some similarity to sequences identified as AB002341 (KIAA0343 [Homo sapiens]) and X58482 (Nr-CAM protein [Gallus gallus]). Based upon sequence similarity, CO722_l proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains within the CO722_ 1 protein sequence, centered around amino acids 610 and 1070 of SEQ ID NO: 130, respectively.

CO722_l protein was expressed in a COS cell expression system, and an expressed protein band of approximately 160 kDa was detected in conditioned media fractions using SDS polyacrylamide gel electrophoresis.

Clone "CT748 2"

A polynucleotide of the present invention has been identified as clone "CT748_2". CT748_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CT748_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CT748_2 protein").

The nucleotide sequence of CT748_2 as presently determined is reported in SEQ ID

NO: 131, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CT748_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 132. Amino acids 281 to 293 of SEQ ID NO: 132 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 294. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CT748_2 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CT748_2 should be approximately 5500 bp.

The nucleotide sequence disclosed herein for CT748_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CT748_2 demonstrated at least some similarity with sequences identified as T48063 (yb24f03.sl Homo sapiens cDNA clone 72125 3') andX54175 (Human specific Alu element (HS C4N2) DNA). The predicted amino acid sequence disclosed herein for CT748_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CT748_2 protein demonstrated at least some similarity to sequences identified as Z36714 (cyclin F [Homo sapiens]). Based upon sequence similarity, CT748_2 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CT748_2 indicates that it may contain an Alu repetitive element.

Clone "AJl 1" A polynucleotide ofthe present invention has been identified as clone "AJ1_1". AJ1_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. AJ1_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AJ1_1 protein").

The nucleotide sequence of the 5' portion of AJ1_1 as presently determined is reported in SEQ ID NO: 133. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 134. The predicted amino acid sequence ofthe AJ1_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 134. Additional nucleotide sequence from the 3' portion of AJ1_1 , including a poly(A) tail, is reported in SEQ ID

NOT35.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone AJ1_1 should be approximately 925 bp.

The predicted amino acid sequence disclosed herein for AJ1_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AJ1_1 protein demonstrated at least some similarity to sequences identified as U39060 (GRIPl [Mus musculus]). Based upon sequence similarity, AJ1_1 proteins and each similar protein or peptide may share at least some activity.

Clone "AO73 3"

A polynucleotide of the present invention has been identified as clone "AQ73_3". AQ73_3 was isolated from a human adult ovary (PA-1 teratocarcinoma, untreated tissue pooled with retinoic-acid-treated and activin-treated tissue) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. AQ73_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AQ73_3 protein").

The nucleotide sequence of AQ73_3 as presently determined is reported in SEQ ID NO: 136, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AQ73_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 137.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AQ73_3 should be approximately 2800 bp.

The nucleotide sequence disclosed herein for AQ73_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AQ73_3 demonstrated at least some similarity with sequences identified as AA514474 (nf57g01.sl NCI_CGAP_Co3 Homo sapiens cDNA clone 924048), T47520 (Human hepatoma-derived growth factor (HDGF-2) cDNA), W24708 (zb62e08.rl Soares fetal lung NbHL19W Homo sapiens cDNA clone 308198 5'), and W45513 (zc27g08.sl Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 323582 3'). The predicted amino acid sequence disclosed herein for AQ73_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AQ73_3 protein demonstrated at least some similarity to sequences identified as D 16431 (hepatoma-derived GF [Homo sapiens]), D63707 (mouse hepatoma derived growth factor (HDGF) [Mus musculus]), R66727 (Human hepatoma derived growth factor), U 18997 (ORF_f299 [Escherichia coli]), U97193 (similar to S. cerevisiae SIR2 (SP P06700) and mouse hepatoma derived growth factor HDGF (NED g945418) [Caenorhabditis elegans]), and W09404 (Human hepatoma-derived growth factor (HDGF-2)). Based upon sequence similarity, AQ73_3 proteins and each similar protein or peptide may share at least some activity. AQ73_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 67 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "BG142 1"

A polynucleotide of the present invention has been identified as clone "BG142_1". BGl 42_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BG142_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BG142_1 protein").

The nucleotide sequence of BG142_1 as presently determined is reported in SEQ ID NO: 138, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG142_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 139.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BG142_1 should be approximately 1100 bp.

The nucleotide sequence disclosed herein for BG 142_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG142_1 demonstrated at least some similarity with sequences identified as AA170261 (ms87hl l.rl Soares mouse 3NbMS Mus musculus cDNA clone 618597 5' similar to TR E245601 E245601 G-RICH BOX-BINDING PROTEIN), L04282 (Human CACCC box-binding protein mRNA, complete cds), N27696 (yx51hl2.rl Homo sapiens cDNA clone 265319 5'), W96110 (ze09al l.rl Soares fetal heart NbHH19W Homo sapiens cDNA clone 358460 5'), and W96111 (ze09al 1.si Soares fetal heart NbHH19W Homo sapiens cDNA clone

358460 3')- The predicted amino acid sequence disclosed herein for BG142_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BG142_1 protein demonstrated at least some similarity to sequences identified as U80078 (transcription factor BFCOL1 [Mus musculus]) and X98096 (G-rich box-binding protein [Mus musculus]). Based upon sequence similarity, BG142_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BV66 1"

A polynucleotide of the present invention has been identified as clone "BV66_1". BV66_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or fransmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BV66_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BV66_1 protein"). The nucleotide sequence of BV66_1 as presently determined is reported in SEQ ID

NO: 140, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BV66_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 141.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BV66_1 should be approximately 870 bp.

The nucleotide sequence disclosed herein for B V66_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The nucleotide sequence of BV66_1 indicates that it may contain a TAAAl simple repeat element.

Clone "BV291 3"

A polynucleotide of the present invention has been identified as clone "BV291_3". BV291_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. BV291_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BV291_3 protein").

The nucleotide sequence of BV291_3 as presently determined is reported in SEQ ID NO: 142, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BV291_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 143.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BV291_3 should be approximately 2000 bp.

The nucleotide sequence disclosed herein for B V291_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV291_3 demonstrated at least some similarity with sequences identified as H10954 (ym06e09.rl Homo sapiens cDNA clone 47034 5'), H10955 (ym06e09.sl Homo sapiens cDNA clone 47034 3'), N25300 (yw52cl0.sl Homo sapiens cDNA clone 255858 3'), T25940 (Human gene signature HUMGS08173), T68890 (yc30gl l.sl Homo sapiens cDNA clone 82244 3'), T78286 (yc99a08.rl Homo sapiens cDNA clone 24033 5'), Z39987 (H. sapiens partial cDNA sequence; clone c-loh05), and Z47073 (Caenorhabditis elegans cosmid ZC506). The predicted amino acid sequence disclosed herein for BV291_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BV291_3 protein demonstrated at least some similarity to sequences identified as X02155 (BTTGR_1 thyroglobulin [Bos taurus]). Based upon sequence similarity, BV291 3 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts a potential transmembrane domain within the B V291_3 protein sequence centered around ammo acid 48 of SEQ ID NO: 143.

BV291_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 30 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "CK201 1"

A polynucleotide of the present invention has been identified as clone "CK201_1". CK201_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or fransmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CK201_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CK201_1 protein"). The nucleotide sequence of CK201_1 as presently determined is reported in SEQ ID

NO: 144, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CK201_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 145.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CK201_1 should be approximately 1080 bp.

The nucleotide sequence disclosed herein for CK201 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CK201_1 demonstrated at least some similarity with sequences identified as AA129133 (zo09hl2.sl Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone 567239 3' similar to contains Alu repetitive element), D81444 (Human fetal brain cDNA

5'-end GEN-164G10), R36326 (yg69h09.rl Homo sapiens cDNA clone 38821 5'), T08553 (Oncogene R-ras mutant cDNA (exons 2-6)), T31595 (Probe (BLUR 13) for Alu repeat sequence), X03273 (Human Alu-family cluster 5' of alpha(l)-acid glycoprotein gene), and X69907 (H.sapiens gene for mitochondrial ATP synthase c subunit). The predicted amino acid sequence disclosed herein for CK201_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CK201_1 protein demonstrated at least some similarity to sequences identified as D21827 (major surface glycoprotein [Pneumocystis carinii]). Based upon sequence similarity, CK201_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CK201_1 indicates that it may contain an Alu repetitive element.

CK201_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 40 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "CO331 2"

A polynucleotide of the present invention has been identified as clone "CQ331_2". CQ331 2 was isolated from a human adult heart cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CQ331_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CQ331_2 protein").

The nucleotide sequence of CQ331_2 as presently determined is reported in SEQ ID NO: 146, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CQ331_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 147. Amino acids 7 to 19 of SEQ ID NO: 147 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CQ331_2 protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone

CQ331_2 should be approximately 1600 bp.

The nucleotide sequence disclosed herein for CQ331_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CQ331_2 demonstrated at least some similarity with sequences identified as J03766 (Canine cardiac calsequesfrin mRNA, complete cds), L29766 (Homo sapiens epoxide hydrolase

(EPHX) gene, complete cds), N83601 (KK1173F Homo sapiens cDNA clone KK1173 5' similar to CALSEQUESTRIN (CARDIAC)), T99646 (ye73fl2.sl Homo sapiens cDNA clone 123407 3' similar to contains Alu repetitive element; contains PTR5 repetitive element), and W76326 (zd60d04.rl Soares fetal heart NbHH19W Homo sapiens cDNA clone 345031 5' similar to contains Alu repetitive element). The predicted amino acid sequence disclosed herein for CQ331_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CQ331_2 protein demonstrated at least some similarity to sequences identified as J03766 (DOGCAL_l Canine cardiac calsequesfrin mRNA, complete cds [Canis canis]) and X55040 (calsequesfrin [Oryctolagus cuniculus]). Based upon sequence similarity, CQ331 _2 proteins and each similar protein or peptide may share at least some activity.

Clone "CT550 1"

A polynucleotide of the present invention has been identified as clone "CT550_1". CT550_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CT550_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CT550_1 protein"). The nucleotide sequence of CT550_1 as presently determined is reported in SEQ ID

NO: 148, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CT550_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 149.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CT550_1 should be approximately 1070 bp.

The nucleotide sequence disclosed herein for CT550_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The TopPredll computer program predicts a potential transmembrane domain within the CT550_1 protein sequence centered around amino acid 25 of SEQ ID NO: 149.

CT550_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 7 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "CT585 1"

A polynucleotide of the present invention has been identified as clone "CT585 _ 1". CT585_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CT585_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CT585_1 protein").

The nucleotide sequence of CT585_1 as presently determined is reported in SEQ ID NO: 150, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CT585_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 151. Amino acids 2 to 14 of SEQ ID NO: 151 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CT585_1 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CT585_1 should be approximately 2710 bp.

The nucleotide sequence disclosed herein for CT585_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CT585_1 demonstrated at least some similarity with sequences identified as AA069442 (zf74b02.sl Soares pineal gland N3HPG Homo sapiens cDNA clone 382635 3'), L38961 (Homo sapiens putative fransmembrane protein (B5) mRNA, complete cds), N34932 (yy49bl0.sl Homo sapiens cDNA clone 276859 3'), N60101 (TgESTzyl lflO.rl Toxoplasma gondii cDNA clone tgzyl lflO.rl 5'), and Ul 3019 (Caenorhabditis elegans cosmid T12A2). The predicted amino acid sequence disclosed herein for CT585_1 was searched against the GenPept, GeneSeq, and

SwissProt amino acid sequence databases using the BLASTX search protocol. The predicted CT585_1 protein demonstrated at least some similarity to sequences identified as L34260 (transmembrane protein [Mus musculus]), L38961 (transmembrane protein [Homo sapiens]), P46975 (Caenorhabditis elegans oligosaccharyl transferase stt3 [Caenorhabditis elegans]), and U13019 (Caenorhabditis eleganscosmidT12A2 [Caenorhabditis elegans]). Based upon sequence similarity, CT585_1 proteins and each similar protein or peptide may share at least some activity.

Clone "CT797 3"

A polynucleotide of the present invention has been identified as clone "CT797_3". CT797_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CT797_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CT797_3 protein"). The nucleotide sequence of CT797_3 as presently determined is reported in SEQ ID NO: 152, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CT797_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 153. The EcoRI Notl restriction fragment obtainable from the deposit containing clone

CT797_3 should be approximately 3300 bp.

The nucleotide sequence disclosed herein for CT797_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CT797_3 demonstrated at least some similarity with sequences identified as AA573847 (nk08d06.sl NCI_CGAP_Co2 Homo sapiens cDNA clone IMAGE: 1012907). The predicted amino acid sequence disclosed herein for CT797_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CT797_3 protein demonstrated at least some similarity to sequences identified as U18309 (chromokinesin [Gallus gallus]) and Z82271 (T01G1.1 [Caenorhabditis elegans]). Based upon sequence similarity, CT797_3 proteins and each similar protein or peptide may share at least some activity.

CT797_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 80 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "CB 107 1"

A polynucleotide of the present invention has been identified as clone "CB107_1". CB 107_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CB107_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CB107_1 protein").

The nucleotide sequence ofthe 5' portion of CB 107 1 as presently determined is reported in SEQ ID NO: 154. An additional internal nucleotide sequence from CB107_1 as presently determined is reported in SEQ ID NO: 155. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO: 156. Additional nucleotide sequence from the 3' portion of CB 107_1 , including a poly(A) tail, is reported in SEQ ID NO: 157.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CB 107_1 should be approximately 3300 bp. The nucleotide sequence disclosed herein for CB 107_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CB 107_ 1 demonstrated at least some similarity with sequences identified as AA121485 (zn80a02.sl Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 564458 3'), AA428192 (zw5 lb08.sl Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773559 3'), D83018 (Human mRNA for nel-related protein 2, complete cds), F10919 (H. sapiens partial cDNA sequence; clone c-31g01), H15375 (ym28d09.rl Homo sapiens cDNA clone 49527 5' similar to SP A54105 A54105 FIBRILLIN-2 PRECURSOR), U48245 (Rattus norvegicus protein kinase C-binding protein Nel mRNA, complete cds), U59230 (Mus musculus mel (MEL91) mRNA, complete cds), and W28387 (46c5 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA). The predicted amino acid sequence disclosed herein for CB107_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CB107_1 protein demonstrated at least some similarity to sequences identified as D83018 (nel-related protein 2 [Homo sapiens]), R05222 (Antigen GX5401FL encoded by Eimeria tenella genomic DNA), R79964 (Connective tissue growth factor), U48245 (RNU48245_1 protein kinase C-binding protein Nel [Rattus norvegicus]), and U59230 (mel [Mus musculus]). Based upon sequence similarity, CB107_1 proteins and each similar protein or peptide may share at least some activity.

Clone "CG300 3"

A polynucleotide of the present invention has been identified as clone "CG300_3". CG300_3 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or fransmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CG300_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CG300_3 protein").

The nucleotide sequence of CG300_3 as presently determined is reported in SEQ ID NO: 158, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CG300_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 159. Amino acids 30 to 42 of SEQ ID NO: 159 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 43. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CG300_3 protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CG300_3 should be approximately 1800 bp.

The nucleotide sequence disclosed herein for CG300 3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CG300_3 demonstrated at least some similarity with sequences identified as N40185

(yy44d08.sl Homo sapiens cDNA clone 276399 3') and W01791 (za72d06.rl Soares fetal lung

NbHL19W Homo sapiens cDNA clone 298091 5'). Based upon sequence similarity, CG300_3 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts four potential transmembrane domains within the CG300_3 protein sequence, centered around amino acids 34, 98, 151, and 179 of SEQ ID NOT59, respectively.

CG300_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 29 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "CJ145 1"

A polynucleotide of the present invention has been identified as clone "CJ145_1". CJ145_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CJ145_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CJ145_1 protein").

The nucleotide sequence of CJ145_1 as presently determined is reported in SEQ ID NO: 160, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CJ145_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 161. Amino acids 6 to 18 of SEQ ID NO: 161 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CJ145_1 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CJ145_1 should be approximately 3600 bp.

The nucleotide sequence disclosed herein for CJ145_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CJ145_1 demonstrated at least some similarity with sequences identified as R43655 (yc86b04.sl Homo sapiens cDNA clone 22829 3'), R50995 (yg63f06.sl Homo sapiens cDNA clone 37377 3' similar to contains MER22 repetitive element), and W92748 (zd92h03.sl Soares fetal heart NbHH19W Homo sapiens cDNA clone 356981 3')- Based upon sequence similarity, CJ145_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CJ145_1 indicates that it may contain a CA simple repeat element.

Clone "CJl 60 11"

A polynucleotide of the present invention has been identified as clone "CJ160_11". CJl 60 11 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CJ160_1 1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CJ160_11 protein"). The nucleotide sequence of CJ160 11 as presently determined is reported in SEQ ID

NO: 162, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CJ160_11 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 163. Amino acids 17 to 29 of SEQ ID NO: 163 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CJ160_11 protein.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone CJ160_11 should be approximately 1700 bp. The nucleotide sequence disclosed herein for CJ160_11 was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CJ160_11 demonstrated at least some similarity with sequences identified as AA024511 (ze76e04.sl Soares fetal heart NbHH19W Homo sapiens cDNA clone 3649263') and AC000074 (00884; HTGS phase 3, complete sequence). Based upon sequence similarity, CJ160_11 proteins and each similar protein or peptide may share at least some activity.

CJ160_11 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 96 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "CO20 1" A polynucleotide of the present invention has been identified as clone "CO20_1". CO20_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CO20_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CO20_1 protein").

The nucleotide sequence ofthe 5' portion of CO20 1 as presently determined is reported in SEQ ID NO: 164. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 165. The predicted ammo acid sequence ofthe CO20_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 165. Ammo acids 17 to 29 of SEQ ID NO: 165 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CO20_1 protein. Additional nucleotide sequence from the 3' portion of CO20 1, including a poly(A) tail, is reported in SEQ ID NO: 166.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CO20_1 should be approximately 2400 bp.

The nucleotide sequence disclosed herein for CO20_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CO20_1 demonstrated at least some similarity with sequences identified as AA045770 (zl68bl0.sl Stratagene colon (#937204) Homo sapiens cDNA clone 509755 3' similar to SW:R13A_HUMAN P40429 60S RIBOSOMAL PROTEIN L13A), AA070899 (zm66c01.sl Stratagene neuroepithehum (#937231) Homo sapiens cDNA clone 530592 3' similar to contains Alu repetitive element), AA325205 (EST28155 Cerebellum II Homo sapiens cDNA 5' end),

N22253 (yw36a08.sl Homo sapiens cDNA clone 2542943' similar to SP S29539 S29539 BASIC PROTEIN, 23K), R01933 (ye85g07.sl Homo sapiens cDNA clone 124572 3' similar to SP:S29539 S29539 BASIC PROTEIN, 23K), R12008 (yf51f04.rl Homo sapiens cDNA clone 25456 5'), R39848 (yf51f04 sl Homo sapiens cDNA clone 25456 3' similar to contains Alu repetitive element;contains PTR5 repetitive element), R56565 (yg91cl2.rl Homo sapiens cDNA clone 40891 5'), T19487 (Human gene signature HUMGS00543), T30988 (EST25695 Homo sapiens cDNA 5' end similar to None), U37026 (Rattus norvegicus bram sodium channel beta 2 subumt (SCNB2) mRNA, complete cds), and X56932 (H.sapiens mRNA for 23 kD highly basic protein). The predicted amino acid sequence disclosed herein for CO20_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CO20_l protein demonstrated at least some similarity to sequences identified as U37026 (sodium channel beta 2 subunit [Rattus norvegicus]), U58658 (unknown [Homo sapiens]), and X56932 (23 kD highly basic protein [Homo sapiens]). The sodium channel beta 2 subunit is a glycoprotein with an extracellular domain containing an immunoglobulin-like fold with similarity to the neural cell adhesion molecule contactin. Based upon sequence similarity, CO20_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CO20 1 indicates that it may contain an Alu repetitive element.

Clone "CQ223 3" A polynucleotide of the present invention has been identified as clone "C0223_3".

C0223_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. C0223_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "C0223_3 protein").

The nucleotide sequence of C0223_3 as presently determined is reported in SEQ ID NO: 167, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the C0223_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 168. Amino acids 35 to 47 of SEQ ID NO: 168 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 48. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the C0223_3 protein.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone C0223_3 should be approximately 700 bp.

The nucleotide sequence disclosed herein for C0223_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. C0223_3 demonstrated at least some similarity with sequences identified as AA004498 (zh87b06.rl Soares fetal liver spleen 1NFLS SI Homo sapiens cDNA clone 428243 5' similar to gb M62505 C5A ANAPHYLATOXIN CHEMOTACTIC RECEPTOR

(HUMAN);contains Ll.tl LI repetitive element) and U47924 (Human chromosome 12pl3 gene cluster, surface antigen CD4 (CD4), A, B, G-protein beta-3 subunit (GNB3), isopeptidase T (ISOT) and friosephosphate isomerase (TPI) genes, complete cds). Based upon sequence similarity, C0223_3 proteins and each similar protein or peptide may share at least some activity. The 3 ' end of the C0223_3 polynucleotide sequence contains a 54-bp sequence that is repeated three times in the clone; these repeats begin at positions 314, 368, and 422 of SEQ ID NO: 167 and encode amino acids 47 to 64, 65 to 82, and 83 to 99 of SEQ ID NO: 168, respectively.

Clone "CQ310 2"

A polynucleotide of the present invention has been identified as clone "CO310_2". C0310_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or fransmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. C0310 2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "C0310_2 protein").

The nucleotide sequence of CO310 2 as presently determined is reported in SEQ ID NO: 169, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the C0310_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 170.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CO310_2 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for C0310_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The nucleotide sequence of C0310_2 indicates that it may contain an LI repetitive element.

Clone "CP258 3"

A polynucleotide of the present invention has been identified as clone "CP258_3". CP258_3 was isolated from a human adult salivary gland cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CP258_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CP258_3 protein"). The nucleotide sequence of CP258_3 as presently determined is reported in SEQ ID

NO: 171, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CP258_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 172. Amino acids 3 to 15 of SEQ ID NO: 172 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder ofthe CP258_3 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CP258_3 should be approximately 560 bp. The nucleotide sequence disclosed herein for CP258_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

CP258_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 26 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "CW1155 3"

A polynucleotide of the present invention has been identified as clone "CW1155_3". CW1155_3 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or fransmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. CW1155_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CW1155_3 protein").

The nucleotide sequence of CW1155_3 as presently determined is reported in SEQ ID NO: 173, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CW1155_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 174. Amino acids 220 to 232 of SEQ ID NO: 174 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 233. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CW1155_3 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CW1155_3 should be approximately 1170 bp.

The nucleotide sequence disclosed herein for CW1155_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CW1155_3 demonstrated at least some similarity with sequences identified as AA169043 (ms36h08.rl Stratagene mouse heart (#937316) Mus musculus cDNA clone 613695 5'), D86145 (Rat mRNA), and H29261 (ym32b03.sl Homo sapiens cDNA clone 49733 3'). Based upon sequence similarity, CW1155_3 proteins and each similar protein or peptide may share at least some activity. Clone "CZ247 2"

A polynucleotide of the present invention has been identified as clone "CZ247_2". CZ247_2 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or fransmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CZ247_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CZ247_2 protein").

The nucleotide sequence of CZ247_2 as presently determined is reported in SEQ ID NO: 175, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CZ247_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 176. Amino acids 545 to 557 of SEQ ID NO: 176 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 558. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a fransmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CZ247_2 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CZ247_2 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for CZ241 2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CZ247_2 demonstrated at least some similarity with sequences identified as T09256 (Human ara Kb beta-galactosidase fusion protein coding sequence), W27222 (26h9 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA), and W72736 (zd71e02.sl Soares fetal heart NbHH19W Homo sapiens cDNA clone 346106 3'). The predicted amino acid sequence disclosed herein for CZ247_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CZ247_2 protein demonstrated at least some similarity to sequences identified as R88069 (Human ara Kb beta-galactosidase fusion protein). Based upon sequence similarity, CZ247_2 proteins and each similar protein or peptide may share at least some activity.

Clone "AM666 1"

A polynucleotide of the present invention has been identified as clone "AM666_1". AM666_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. AM666_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "AM666_1 protein").

The nucleotide sequence of AM666_1 as presently determined is reported in SEQ ID NO: 177, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AM666_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 178. Amino acids 15 to 27 of SEQ ID NO: 178 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at ammo acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the AM666_1 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone AM666_1 should be approximately 1300 bp.

The nucleotide sequence disclosed herein for AM666_1 was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AM666_1 demonstrated at least some similarity with sequences identified as

AA493985 (nh07g08.sl NCI_CGAP_Thyl Homo sapiens cDNA clone). Based upon sequence similarity, AM666_1 proteins and each similar protein or peptide may share at least some activity.

AM666_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 17 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "BN387 3"

A polynucleotide of the present invention has been identified as clone "BN387_3". BN387_3 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe ammo acid sequence ofthe encoded protein. BN387_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BN387_3 protein").

The nucleotide sequence of BN387_3 as presently determined is reported in SEQ ID NO: 179, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted ammo acid sequence of the BN387_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 180. Ammo acids 14 to 26 of SEQ ID NO: 180 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at ammo acid 27. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BN387_3 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BN387_3 should be approximately 2000 bp. The nucleotide sequence disclosed herein for BN387_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BN387_3 demonstrated at least some similarity with sequences identified as H16912 (ym39d01.rl Homo sapiens cDNA clone 50771 5'). Based upon sequence similarity, BN387_3 proteins and each similar protein or peptide may share at least some activity. BN387_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 30 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "BO 135 2" A polynucleotide of the present invention has been identified as clone "BQ135_2".

BQ135_2 was isolated from a human adult colon (adenocarcinoma Caco2) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BQ135_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "BQ135_2 protein").

The nucleotide sequence of BQ135 2 as presently determined is reported in SEQ ID NO: 181, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BQ135_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 182.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BQ135_2 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for BQ 135 2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BQ135_2 demonstrated at least some similarity with sequences identified as

AA023751 (mh81f01.rl Soares mouse placenta 4NbMP13.5 14.5 Mus musculus cDNA clone 457369 5'), AA105433 (ml83g01.rl Stratagene mouse kidney (#937315) Mus musculus cDNA clone 5186405'), D64061 (Rat brain mRNA for annexin V-binding protein (ABP-7), partial cds), and N67257 (yz49b08.sl Homo sapiens cDNA clone 286359 3'). The predicted amino acid sequence disclosed herein for BQ135_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BQ135_2 protein demonstrated at least some similarity to sequences identified as D64061 (annexm V-binding protein (ABP-7) [Rattus norvegicus]). Annexins associate with membranes and act as ion channels, they can also act as an autocnne factor that enhances osteoclast formation and bone resorption. Annexins have been localized in nucleoh and mitochondria but also in the cytoplasm, plasma (i.e. blood) and in association with vesicles. They are probably involved in fusing vesicles to each other and to plasma membranes causing secretion of vesicular contents. Specifically they have a calcium-dependent ability to bind phospholipids. Thus they are membrane associated. It is possible that annexin-binding proteins are also membrane associated even though they are highly hydrophilic through the same mechanism (electrostatic interaction with phospholipids of membranes). Based upon sequence similarity, BQ135_2 proteins and each similar protein or peptide may share at least some activity.

Clone "CR678 1" A polynucleotide of the present invention has been identified as clone "CR678 1".

CR678_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CR678_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CR678_1 protein").

The nucleotide sequence of CR678_1 as presently determined is reported in SEQ ID NO: 183, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CR678_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 184. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone

CR678_1 should be approximately 870 bp.

The nucleotide sequence disclosed herein for CR678_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CR678_1 demonstrated at least some similarity with sequences identified as X85232 (H.sapiens chromosome 3 sequences). Based upon sequence similarity, CR678_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CR678_1 indicates that it may contain an Alu repetitive element.

Clone "CW420 2" A polynucleotide of the present invention has been identified as clone "CW420_2". CW420_2 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or fransmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CW420_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CW420_2 protein").

The nucleotide sequence of CW420_2 as presently determined is reported in SEQ ID NO: 185, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CW420_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 186.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CW420_2 should be approximately 5100 bp.

The nucleotide sequence disclosed herein for CW420_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CW420_2 demonstrated at least some similarity with sequences identified as T55440 (yb38e09.sl Homo sapiens cDNA clone 73480 3')- Based upon sequence similarity, CW420_2 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains within the CW420_2 protein sequence centered around amino acids 500 and 1270 of SEQ ID NO: 186, respetively.

Clone "CW795 2"

A polynucleotide of the present invention has been identified as clone "CW795_2". CW795_2 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5 ,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CW795_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CW795_2 protein").

The nucleotide sequence of CW795_2 as presently determined is reported in SEQ ID NO: 187, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CW795_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 188.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone CW795_2 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for CW795_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CW795_2 demonstrated at least some similarity with sequences identified as AA115676 (zl86a09.sl Stratagene colon (#937204) Homo sapiens cDNA clone 511480 3'), N22955 (yw44h07.sl Homo sapiens cDNA clone 255133 3'), and W56804 (zdl6g06.sl Soares fetal heart NbHH19W Homo sapiens cDNA clone 3408583'). The predicted amino acid sequence disclosed herein for CW795_2 was searched against the GenPept, GeneSeq, and SwissProt amino acid sequence databases using the BLASTX search protocol. The predicted CW795_2 protein demonstrated at least some similarity to sequences identified as X81068 (probable mitochondrial protein) and the yeast proteins real and afg3 (tat-binding homologues). Based upon sequence similarity, CW795_2 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts two potential transmembrane domains within the CW795_2 protein sequence centered around amino acids 60 and 170 of SEQ ID NO: 188, respectively.

CW795_2 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 10 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "CW823 3"

A polynucleotide of the present invention has been identified as clone "CW823_3". CW823_3 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. CW823_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "CW823_3 protein").

The nucleotide sequence of CW823_3 as presently determined is reported in SEQ ID NO: 189, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CW823_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 190.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone CW823_3 should be approximately 600 bp. The nucleotide sequence disclosed herein for CW823_3 was searched against the

GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. Clone "DF989 3"

A polynucleotide of the present invention has been identified as clone "DF989_3". DF989_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. DF989_3 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "DF989_3 protein").

The nucleotide sequence ofthe 5' portion of DF989 3 as presently determined is reported in SEQ ID NO: 191. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 192. The predicted amino acid sequence of the DF989_3 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 192. Amino acids 2 to 14 of SEQ ID NO : 192 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the DF989_3 protein. Additional nucleotide sequence from the 3' portion of DF989 3, including a poly(A) tail, is reported in SEQ ID NO: 193.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone DF989_3 should be approximately 1800 bp. The nucleotide sequence disclosed herein for DF989_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. DF989_3 demonstrated at least some similarity with sequences identified as R24724 (yg43c05.rl Homo sapiens cDNA clone 35337 5') and T33717 (EST58870 Homo sapiens cDNA 5' end similar to None). Based upon sequence similarity, DF989_3 proteins and each similar protein or peptide may share at least some activity.

Clone "PL 162 1"

A polynucleotide of the present invention has been identified as clone "DL162_1". DL 162_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. DL162_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "DL162_1 protein").

The nucleotide sequence of DL162 1 as presently determined is reported in SEQ ID NO: 194, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the DL162_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 195. Amino acids 28 to 40 of SEQ ID NO: 195 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 41. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the DL162_1 protein.

The EcoRI/Notl restriction fragment obtainable from the deposit containing clone DL162_1 should be approximately 875 bp.

The nucleotide sequence disclosed herein for DL 162_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "DL162 2"

A polynucleotide of the present invention has been identified as clone "DL162_2". DL 162_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), orwas identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence ofthe encoded protein. DL162_2 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "DL162_2 protein"). The nucleotide sequence of DL162_2 as presently determined is reported in SEQ ID

NO: 196, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the DL162_2 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NOT97. Amino acids 1 to 13 of SEQ ID NO: 197 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 14. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the DL162_2 protein.

The EcoRI Notl restriction fragment obtainable from the deposit containing clone DL162_2 should be approximately 4000 bp. The predicted amino acid sequence disclosed herein for DL162_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted DL162_2 protein demonstrated at least some similarity to sequences identified as AB002309 (KIAA0311 protein [Homo sapiens]). The TopPredll computer program predicts a potential transmembrane domains within the DL162_2 protein sequence near the carboxyl terminus of SEQ ID NO: 197. DL162_2 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 160 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "EC 172 1"

A polynucleotide of the present invention has been identified as clone "EC172_1". EC 172_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. EC172_1 is a full-length clone, including the entire coding sequence of a secreted protein (also refeπed to herein as "EC172_1 protein").

The nucleotide sequence of EC172_1 as presently determined is reported in SEQ ID NO: 198, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the EC172_1 protein coπesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 199. Amino acids 659 to 671 of SEQ ID NO: 199 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 672. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the EC172_1 protein. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone

EC172_1 should be approximately 4000 bp.

The nucleotide sequence disclosed herein for EC 172_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. EC172_1 demonstrated at least some similarity with sequences identified as H31192 (EST104991 Rattus sp. cDNA 3' end similar to C.elegans hypothetical protein ZK1098.10) and

U29585 (Streptococcus pyogenes emm 18.1). The predicted amino acid sequence disclosed herein for EC 172_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted EC172_1 protein demonstrated at least some similarity to sequences identified as Z22176 (ZK 1098.10 [Caenorhabditis elegans]). Based upon sequence similarity, EC 172_ 1 proteins and each similar protein or peptide may share at least some activity.

Deposit of Clones

Clones AX65_22, BD335 4, BG241_1, BL187_4, BL249_18, B071_l, B0365_2, BV51_l,BV140_3, BV141_2, CC194_4, andDA136_l l were deposited on October 3, 1996with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98196, from which each clone comprising a particular polynucleotide is obtainable. Clones AR415_4, AS63_29, BG160_1, B0432_4, B0538_2, BR595_4, CI490_2,

CI522_1, CN238_1, CO390_l, and AY304_1 (an additional isolate of clone AY304_14) were deposited on October 25, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98232, from which each clone comprising a particular polynucleotide is obtainable. Clone AY304_14 wasdeposited on October 23, 1997 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number 98561.

Clones AJ20_2, AR440_1,AS164_1,AX8_1,BD176_3,BD339_1,BD427_1,BL229_22, BV123_16, andCH377_l were deposited on November 15, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98261, from which each clone comprising a particular polynucleotide is obtainable.

Clones BD441_1, BD441_2, BG102_3, BK158_1, BP163_1, BZ16_3, CC182_1, CG109_1 and CJ397_1 were deposited on November 20, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98264, from which each clone comprising a particular polynucleotide is obtainable.

Clones AM795_4, AT340_1, BG132 , BG219_2, BG366_2, BV172_2, CC247 0, CI480_9, C0722_l, and CT748_2 were deposited on December 5, 1996 with the ATCC

(American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98271, from which each clone comprising a particular polynucleotide is obtainable.

Clones AJ1_1, AQ73_3, BG142_1, BV66_1, BV291_3, CK201_1, CQ331_2, CT550_1, CT585_1 and CT797_3 were deposited on December 13, 1996 with the ATCC (American Type

Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98278, from which each clone comprising a particular polynucleotide is obtainable.

Clones CB107 , CG300_3, CJ145_1, CJ160_11, CO20_l, C0223_l, CO310_2, CP258_3, CW1155_3 and CZ247_2 were deposited on December 17, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98279, from which each clone comprising a particular polynucleotide is obtainable. Clone C0223_3 was deposited on January 9, 1997 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U. S . A.) as an original deposit under the Budapest Treaty and was given the accession number 98291.

Clones AM666_1, BN387_3, BQ135_2, CR678_1, CW420_2, CW795_2, CW823_3, DF989_3, DL162_2, DL162_l, andEC172_l were deposited on January 10, 1997 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98292, from which each clone comprising a particular polynucleotide is obtainable.

All restrictions on the availability to the public of the deposited material will be iπevocably removed upon the granting ofthe patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806. Each clone has been transfected into separate bacterial cells (E. coli) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/Notl digestion (5' site, EcoRI; 3' site, Notl) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1 A and IB, respectively. The pED6dpc2 vector ("pED6") was derived from pEDόdpcl by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al, 1991, Nucleic Acids Res. 19: 4485- 4490); the pNOTs vector was derived from pMT2 (Kaufman et al, 1989, Mol. Cell. Biol. 9: 946- 958) by deletion ofthe DHFR sequences, insertion of a new polylinker, and insertion ofthe Ml 3 origin of replication in the Clal site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and Notl. However, Notl will then produce the 5' site and

EcoRI will produce the 3' site for placement ofthe cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

OO Λ iy3 t O Λ Λ ιV3 iy3 Λ (y3 &O C/2 &O CZ5 CΛ CΛ &α CΛ W

W W til W tTl t l tTl W W W W W W W W W O O O /O O O O O O O /O O O O

B p tό O

VO

CP258_3 SEQ ID NO:270

CW1155_3 SEQ ID NO:271

CZ247_2 SEQ ID NO:272

AM666_1 SEQ ID NO:273 BN387_3 SEQ ID NO:274

BQ135_2 SEQ ID NO:275

CR678_1 SEQ ID NO:276

CW420_2 SEQ ID NO:277

CW795_2 SEQ ID NO:278 CW823_3 SEQ ID NO:279

DF989_3 SEQ ID NO:280

DL162_1, DL162_2 SEQ ID NO:281

EC172_1 SEQ ID NO:282

In the sequences listed above which include an N at position 2, that position is occupied in prefeπed probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (l-dimethoxytrityloxy-2-(N- biotinyl-4-aminobutyl)-propyl-3-0-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramadite) (Glen Research, cat. no. 10-1953)). The design of the oligonucleotide probe should preferably follow these parameters:

(a) It should be designed to an area ofthe sequence which has the fewest ambiguous bases ("N's"), if any;

(b) It should be designed to have a T_m of approx. 80 ° C (assuming 2" for each A or T and 4 degrees for each G or C). The oligonucleotide should preferably be labeled with γ-³²P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity ofthe resulting probe should be approximately

4e+6 dpm/pmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μl ofthe stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μg/ml. The culture should preferably be grown to saturation at 37^°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicilhn at 100 μg/ml and agar at 1.5% in a 150 mmpefri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65 ^°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 gNaCl/hter, 88.2 g Na citrate/liter, adjusted to pH 7.0 withNaOH) containing 0.5% SDS, 100 μg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to le+6 dpm/mL. The filter is then preferably incubated at 65 °C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0. IX SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybndization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments ofthe protein may be in linear form or they may be cychzed using known methods, for example, as described in H.U. Saragovi, etal , Bio/Technology 10, 773-778 (1992) andinR.S. McDowell, etal, J. Amer. Chem.

Soc. 114. 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to caπier molecules such as lmmunoglobulms for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation ofthe nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with the ATCC) in a suitable mammalian cell or other host cell. The sequence(s) ofthe mature form(s) ofthe protein may also be determinable from the ammo acid sequence ofthe full- length form. The present invention also provides genes coπesponding to the polynucleotide sequences disclosed herein. "Coπesponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Coπesponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, mtrons, promoters, enhancers, and silencer or suppressor elements. The coπesponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated

The chromosomal location coπesponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes in situ. It may also be possible to determine the coπesponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address http://www.ncbi.nlm.nih.gov/UniGene/, in order to identify "UmGene clusters" of overlapping sequences. Many ofthe "UniGene clusters" so identified will already have been mapped to particular chromosomal sites. Organisms that have enhanced, reduced, or modified expression of the gene(s) coπesponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or nbozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Moms, 1994, Trends Pharmacol Sci 15(7): 250-254; Lavarosky et al , 1997, Biochem Mol. Med 62(1): 11-22; and Hampel, 1998, .Prog Nucleic Acid Res Mol Biol 58: 1-39, all of which are incorporated by reference herein). The desired change in gene expression can also be achieved through the use of double-stranded ribonucleotide molecules having some complementarity to the mRNA transcribed from the gene, and which interfere with the transcription, stability, or expression of the mRNA ("RNA intereference" or "RNAi"; Fire et al, 1998, Nature 391 (6669): 806-811; Montgomery et al, 1998, Proc. Natl. Acad. Sci. USA 95 (26): 15502-15507; and Sharp, 1999, Genes Dev. 13 (2): 139-141 ; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) coπesponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649464 Bl, incorporated by reference herein). In addition, organisms are provided in which the gene(s) coπesponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the coπesponding gene(s) or through deletion of all or part of the coπesponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, Bioessays 14(9): 629-633; Zwaal et al, 1993, Proc. Natl. Acad. Sci. USA 90(16): 7431-7435; Clark et al, 1994, Proc. Natl. Acad. Sci. USA 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al, 1988, Nature 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614, 396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the coπesponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the coπesponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all ofthe infracellular and transmembrane domains ofthe protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The infracellular and fransmembrane domains of proteins ofthe invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredll computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location ofthe center ofthe fransmsmbrane domain, with at least ten transmembrane amino acids on each side ofthe reported central residue(s).

Proteins and protein fragments ofthe present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle ed., Methods in Enzymology 266: 460-480; Altschul et al. , 1990, Basic local alignment search tool, Journal of Molecular Biology 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, Nature Genetics 3 : 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, Proc. Natl. Acad. Sci. USA 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from ftp://blast.wustl.edu/blast/executables. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent ofthe author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite — BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX - the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=l 0 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=l 0 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matnx is BLOSUM62, but other ammo acid comparison matrices such as PAM can be utilized. Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, Pan troglodytes, Gorilla gorilla, Pongo pygmaeus, Hylobates concolor, Macaca mulatta, Papiopapio, Papio hamadryas, Cercopithecus aethiops, Cebus capucinus, Aotus trivirgatus, Sanguinus oedψus, Microcebus murinus, Mus musculus, Rattus norvegicus, Cricetulus griseus, Felis catus, Mustela vison, Canis familiaris, Oryctolagus cumculus, Bos taurus, Ovis aries, Sus scrofa, and Equus caballus, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization ofthe related genes in another species (O'Brien and Seuanez, 1988, Ann Rev Genet 22: 323-351; O'Brien et al , 1993, Nature Genetics 3: 103-112; Johansson et al , 1995, Genomics 25: 682-690; Lyons et al, 1997, Nature Genetics 15: 47-56; O'Brien et al, 1997, Trends in Genetics 13(10): 393-399; Carver and Stubbs, 1997, Genome Research 7: 1123-1137; all of which are incorporated by reference herein). The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occuπing alternative forms ofthe isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

' The hybrid length is that anticipated for the hybπdized regιon(s) of the hybridizing polynucleotides When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that ofthe hybridizing polynucleotide When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences ofthe polynucleotides and identifying the region or regions of optimal sequence complementarity ^f SSPE (lxSSPE is 0 15M NaCl, lOmM NaH₂P0₄, and 1 25mM EDTA, pH 7 4) can be substituted for SSC (lxSSC is 0 15 M NaCl and 15mM sodium citrate) in the hybridization and wash buffers, washes are performed for 15 minutes after hybridization is complete *T_B - T_R The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) ofthe hybrid, where T_m is determined according to the following equations For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases) For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81 5 + 16 6(log₁₀[Na⁺]) + 0 41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for lxSSC = 0 165 M)

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11 , and Current Protocols in Molecular Biology , 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) ofthe length ofthe polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide endcoing the protein ofthe invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185. 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide ofthe invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence. A number of types of cells may act as suitable host cells for expression of the protein.

Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV- 1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods. The protein may also be produced by operably linking the isolated polynucleotide ofthe invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein ofthe invention may be prepared by cultuπng transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalm A-agarose, hepaπn- toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or lmmunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component ofthe milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein. The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by ammo acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another ammo acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and denvatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein Such modifications are believed to be encompassed by the present invention.

USES AND BIOLOGICAL ACTIVITY The polynucleotides and proteins ofthe present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the coπesponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract- out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris et al. , 1993, Cell 75: 791-803 and in Rossi etal, 1997, Proc. Natl. Acad. Sci. USA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the coπesponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate coπelative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products. Methods for performing the uses listed above are well known to those skilled in the art.

References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987. Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide ofthe invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide ofthe invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein ofthe present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein ofthe present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DAI, 123, T1165, HT2, CTLL2, TF- 1 , Mo7e and CMK. The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Cuπent Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in

Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145: 1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation,

Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ, Schreiber, R.D. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994. Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173: 1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenbergeretal., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83: 1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991 ; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Cuπent Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SOD)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g.,

HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein ofthe present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein ofthe present invention may also be useful where a boost to the immune system generally may be desirable, e , in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillam-Baπe syndrome, autoimmune thyroiditis, insulin dependent diabetes melhtis, myasthema gravis, graft- versus-host disease and autoimmune inflammatory eye disease. Such a protein ofthe present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins ofthe invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already m progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolenzmg agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence ofthe tolenzmg agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), e g , preventing high level lymphokme synthesis by activated T cells, will be useful in situations of tissue, skm and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural hgand(s) on immune cells (such as a soluble, monomenc foπn of a peptide having B7-2 activity alone or in conjunction with a monomenc form of a peptide having an activity of another B lymphocyte antigen (e g , B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural hgand(s) on the immune cells without transmitting the coπesponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blockmg reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the lmmunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al , Science 257:789-792 (1992) and Turkaetα/ , Proc. Natl. Acad. Sci USA, 89: 11102-11105 (1992). In addition, muπne models of GVHD (see Paul ed , Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor: ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include muπne experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, muπne autoimmune collagen arthritis, diabetes melhtus in NOD mice and BB rats, and muπne experimental myasthema gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide ofthe present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti -viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein ofthe present invention as described herein such that the cells express all or a portion of the protein on their surface, and reinfroduce the fransfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) fransfected with a nucleic acid encoding at least one peptide ofthe present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be fransfected to express a combination of peptides. For example, tumor cells obtained from a patient can be fransfected ex vivo with an expression vector directing the expression of a peptide having B7-2- like activity alone, or in conjunction with a peptide having B7-l-like activity and/or B7-3-like activity. The fransfected tumor cells are returned to the patient to result in expression of the peptides on the surface ofthe fransfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.

The presence ofthe peptide ofthe present invention having the activity of a B lymphocyte antigen(s) on the surface ofthe tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the fransfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I chain protein and β₂ microglobulin protein or an MHC class II CC chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Cuπent Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Heπmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Heπmann et al., J. Immunol. 128: 1968-1974, 1982; Handa et al., J. Immunol. 135: 1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Heπmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J. Virology 61 :1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Thl and CTL responses) include, without limitation, those described in: Cuπent Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine

173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169: 1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1 -639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84: 111-117, 1994; Fine et al., Cellular Immunology 155: 111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al, Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with lπadiation/chemofherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as tbrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all ofthe above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuna), as well as in repopulatmg the stem cell compartment post lπadiation chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone maπow fransplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods: Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15: 141-151, 1995; Keller et al. Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al. Blood 81 :2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described m: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, et al eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al, Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high prohferative potential, McNiece, I.K. and Bπddell, R.A. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al. Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone maπow cultures in the presence of stromal cells, Spooncer, E, Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R.I. Freshney, et al eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In Culture of Hematopoietic Cells. R.I. Freshney, et al eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers. A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone- forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes. Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligamentlike tissue formation induced by a composition ofthe present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions ofthe present invention may provide an environment to attract tendon- or ligament- forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament- forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the freatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a caπier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the freatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyofrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non- healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothehum), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothehum) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scaπmg to allow noπnal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and freatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothehum ). Assays for wound healing activity include, without limitation, those described in: Winter,

Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstem and Mertz, J. Invest. Dermatol 71:382-84 (1978).

Activm/Inhibin Activity

A protein of the present invention may also exhibit activm- or mhibin-related activities.

Inhibms are characterized by their ability to inhibit the release of follicle stimulating hormone

(FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein ofthe present invention, alone or in heterodimers with a member of the lnhibm CC family, may be useful as a contraceptive based on the ability of mhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other mhibins can induce infertility in these mammals. Alternatively, the protein ofthe invention, as a homodimer or as a heterodimer with other protein subumts ofthe mhibin-β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells ofthe anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement ofthe onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

Assays for activin/inhibm activity include, without limitation, those described in: Vale et al. Endocrinology 91 :562-572, 1972; Ling et al. Nature 321 -.119-182, 1986; Vale et al. Nature 321:776-779, 1986; Mason et al. Nature 318:659-663, 1985; Forage et al, Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

Chemotactic/Chemokmetic Activity

A protein ofthe present invention may have chemotactic or chemokinetic activity (e g, act as a chemokme) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothehal cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent. A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis. The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Cuπent Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95: 1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolvtic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein ofthe invention may also be useful for dissolving or inhibiting formation of thromboses and for freatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al, J. Clin. Pharmacol. 26: 131-140, 1986; Burdick et al, Thrombosis Res. 45:413-419, 1987; Humphreyet al, Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467- 474, 1988.

Receptor/Li gand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions. The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described m:Cuπent Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1 -7.28.22), Takai et al, Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al, J. Exp. Med. 168: 1145-1156, 1988; Rosenstem et al, J. Exp. Med. 169: 149-160 1989; Stoltenborg et al, J. Immunol. Methods 175:59-68, 1994; Stitt et al. Cell 80:661-670, 1995.

Anti-Inflammatory Activity

Proteins ofthe present invention may also exhibit anti-inflammatory activity. The anti- lnflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved m the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine- mduced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL- 1. Proteins ofthe invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Cadhenn/Tumor Invasion Suppressor Activity

Cadherms are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgans and pemphigus fohaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members ofthe superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherm domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophihc adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherms engage in heterophihc adhesion with other cadherms.

E-cadheπn, one member ofthe cadherin superfamily, is expressed m epithelial cell types. Pathologically, if E-cadheπn expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E- cadheπn has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reinfroducing E-cadheπn expression reverts carcinomas to a less advanced stage. It is likely that other cadherms have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherms of a different tissue type than their origin, thus allowing these cells to mvade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherms, restoring noπnal cell adhesive properties and reducing or eliminating the tendency ofthe cells to metastasize.

Additionally, proteins ofthe present invention with cadherin activity, and polynucleotides ofthe present invention encoding such proteins, can used to generate antibodies recognizing and binding to cadherms. Such antibodies can be used to block the adhesion of inappropπately expressed tumor-cell cadherms, preventing the cells from forming a tumor elsewhere. Such an anti-cadhenn antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadhenn-bindmg antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide ofthe cadherin recognition site, and poly-nucleotides ofthe present invention encoding such protein fragments, can also be used to block cadhenn function by binding to cadherms and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11 : 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein ofthe invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, coπecting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable caπier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness ofthe biological activity of the active ingredient(s). The characteristics of the caπier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL- 1 , IL-2, IL-3, IL- 4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity ofthe protein or compliment its activity or use in freatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations ofthe particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti- inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions ofthe invention may comprise a protein ofthe invention in such multimeric or complexed form.

The phaπnaceutical composition ofthe invention may be in the foπn of a complex ofthe protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a hposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable caπiers, with amphipafhic agents such as hpids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable hpids for hposomal formulation include, without limitation, monoglycendes, diglycendes, sulfatides, lysolecithin, phospholipids, saponm, bile acids, and the like. Preparation of such hposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No.4,501,728; U.S. Patent No.4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component ofthe pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein ofthe present invention may be administered in accordance with the method ofthe invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokme(s), lymphokme(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokme(s), lymphokme(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein ofthe present invention used in the pharmaceutical composition or to practice the method ofthe present invention can be earned out in a variety of conventional ways, such as oral mgestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is prefeπed.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the phaπnaceutical composition of the invention may additionally contain a solid caπier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein ofthe present invention, and preferably from about 25 to 90% protein ofthe present invention. When administered in liquid form, a liquid caπier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form ofthe phaπnaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein ofthe present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A prefeπed phaπnaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition ofthe present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein ofthe present invention in the pharmaceutical composition ofthe present invention will depend upon the nature and severity ofthe condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to freat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method ofthe present invention should contain about 0.01 μg to about 100 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 μg to about 1 mg) of protein ofthe present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition ofthe present invention will vary, depending on the severity ofthe disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application ofthe protein ofthe present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition ofthe present invention. Protein ofthe invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein. Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.

Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of antibody-producing hybridomas in accordance with known methods (see for example, Goding, 1983, Monoclonal antibodies: principles and practice, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in Current Protocols in Immunology, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons). Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the relevant protein or fragments thereof in accordance with known methods. Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection ofthe desired fragments in accordance with known methods (see for example, Goding, supra; and Andrew et al., 1992, "Fragmentation of Immunoglobulins" in Current Protocols in Immunology, Unit 2.8, Greene Publishing Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding murine antibodies in accordance with well known methods (see for example, U.S. Patent Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild et al, 1996, Nature Biotechnology 14: 845-851 ; Mendez et al, 1997, Nature Genetics 15: 146-156 (erratum Nαtwre Genetics 16: 410); and U.S. Patents 5,877,397 and 5,625,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteme residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyamn (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Meπifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, et al, FEBS Lett. 21! 10 (1987).

Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection ofthe protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also m the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions ofthe present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, m a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods ofthe invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protem-contaming composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such mafrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradabihty, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matnces for the compositions may be biodegradable and chemically defined calcium sulfate, fricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently prefeπed is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A prefeπed family of sequestering agents is cellulosic materials such as alkylcelluloses

(including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most prefeπed being cationic salts of carboxymethylcellulose (CMC). Other prefeπed sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling ofthe composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment ofthe bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-oc and TGF-β), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such freatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition ofthe damaged tissue, the size of a wound, type of damaged tissue (e.g, bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tefracycline labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides ofthe invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured ex vivo in the presence of proteins ofthe present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be infroduced in vivo for therapeutic purposes.

Patent and literature references cited herein are incorporated by reference as if fully set forth.

Claims

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:41;

(b) the nucleotide sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027;

(c) the nucleotide sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027;

(d) the nucleotide sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431 ;

(e) the nucleotide sequence of the full-length protein coding sequence of clone BG160_1 deposited with the ATCC under accession number 98232;

(f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone BGl 60_1 deposited with the ATCC under accession number 98232 ;

(g) the nucleotide sequence of a mature protein coding sequence of clone BG160_1 deposited with the ATCC under accession number 98232;

(h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232;

(i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:42;

(j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h); and

(1) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as sfringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:41.

2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

3. A host cell transformed with the polynucleotide of claim 2.

4. The host cell of claim 3, wherein said cell is a mammalian cell.

5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:

(a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with the polynucleotide of claim 2; and

(b) purifying said protein from the culture.

6. A protein produced according to the process of claim 5.

7. An isolated polynucleotide encoding the protein of claim 6.

8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232.

9. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:42;

(b) the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 110;

(c) a fragment ofthe amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and

(d) the amino acid sequence encoded by the cDNA insert of clone BG 160_1 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins.

10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO :42.

11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable caπier.

12. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO: 129; (b) the nucleotide sequence of SEQ ID NO: 129 from nucleotide 383 to nucleotide 3958;

(c) the nucleotide sequence of SEQ ID NO: 129 from nucleotide 470 to nucleotide 3958;

(d) the nucleotide sequence of SEQ ID NO: 129 from nucleotide 271 to nucleotide 488;

(e) the nucleotide sequence of the full-length protein coding sequence of clone C0722_l deposited with the ATCC under accession number 98271;

(f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone C0722_l deposited with the ATCC under accession number 98271 ;

(g) the nucleotide sequence of a mature protein coding sequence of clone C0722_l deposited with the ATCC under accession number 98271;

(h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone C0722_l deposited with the ATCC under accession number 98271;

(i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 130;

(j) a nucleotide sequence encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 130, the fragment comprising eight contiguous amino acids of SEQ ID NO: 130;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as sfringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h); and

(1) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one ofthe polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO: 129.

13. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NOT 30;

(b) the amino acid sequence of SEQ ID NO: 130 from amino acid 1 to amino acid 34;

(c) a fragment ofthe amino acid sequence of SEQ ID NO: 130, the fragment comprising eight contiguous amino acids of SEQ ID NO: 130; and (d) the amino acid sequence encoded by the cDNA insert of clone C0722_l deposited with the ATCC under accession number 98271 ; the protein being substantially free from other mammalian proteins.